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In type-2 diabetes mellitus (T2DM), insulin resistance and metabolic derangements reduce 
glucose transporter-4 (GLUT-4) expression to decrease glucose uptake, and hence the glucose 
oxidation in the diabetic heart. Further, the diabetic heart displays reduced basal myocardial 
energy status while diminished glucose oxidation further aggravates this condition in 
myocardial ischemia. Previous studies showed that normalization of glucose metabolism via 
increasing GLUT-4 expression attenuated diabetes-induced cardiac dysfunction. 
Cardiomyocytes possess a non-neuronal cholinergic system (NNCS) that consists of choline 
acetyltransferase (ChAT), choline transporter 1 (CHT1), vesicular acetylcholine transporter 
(VAChT), and acetylcholinesterase (AChE) to synthesize, release and degrade acetylcholine 
(ACh), respectively. The released ACh binds to type-2 muscarinic ACh receptor (M2AChR) 
and mediates pro-survival phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) 
/hypoxia-inducible factor1α (HIF1α) signaling cascade to promote glucose metabolism through 
increasing GLUT-4 expression in normoxic condition. However, the expression and function 
of cardiac NNCS are not known in the diabetic heart. Therefore, the main aim of this thesis was 
to examine the role of cardiac NNCS in the diabetic heart. 
The first aim was to investigate if the expression of cardiac NNCS (i.e., ChAT, CHT1, VAChT, 
AChE, and M2AChR) and glucose transporters (GLUT-1 and GLUT-4) are affected in the 
diabetic db/db mouse and the diabetic human heart. The novel findings showed that the 
expression of the components of cardiac NNCS were altered in the diabetic db/db mouse (i.e., 
increased AChE and decreased M2AChR expression) and diabetic human heart (i.e., decreased 
CHT1 expression). Besides, the findings also confirmed that T2DM decreased GLUT-4 
expression in the diabetic db/db mouse and the diabetic human heart. Interestingly, the 
alteration of cardiac NNCS preceded the decrease in GLUT-4 expression and diastolic 
dysfunction in the db/db mice. Also, the findings showed that the diabetic cardiomyocytes 
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altered cardiac NNCS (i.e., increased VAChT and CHT1 expression; decreased AChE and 
M2AChR expression) possibly to enrich the db/db mouse heart with ACh after developing 
diastolic dysfunction. 
The next aim was to examine if cardiac NNCS activation can increase GLUT-4 expression and 
enhance the LV function of the diabetic heart. In this case, this study used diabetic db/db mice 
with ventricular-specific overexpression of ChAT gene (db/db-ChAT-tg). The findings showed 
that cardiac NNCS activation significantly enhanced the LV systolic function and 
contractibility in the diabetic heart. Further, western blot analysis confirmed that the superior 
LV function was associated with increased GLUT-4 expression, which was activated by pro-
survival PI3K/Akt/HIF1α signaling cascade in the diabetic heart. As previous studies showed 
that cardiac NNCS plays a role in angiogenesis, I next investigated if activation of cardiac 
NNCS enhances the vascular function of the diabetic heart. The findings showed that activation 
of cardiac NNCS preserved the coronary macro- and micro-vasculature and endothelial 
function in the diabetic heart. Western blot analysis confirmed that the preserved vascular 
function was associated with increased VEGF-A expression in the diabetic heart.  
Having demonstrated the role of cardiac NNCS in the diabetic heart, I further investigated if 
cardiac NNCS activation increases GLUT-4 expression and in return, attenuates the hypoxic 
injury in the diabetic cardiomyocytes in-vitro. The in-vitro insulin resistance diabetic 
cardiomyocytes model showed impaired Akt phosphorylation induced by 400 μM palmitate 
and 30.5 mM glucose. The findings revealed that cardiac NNCS activation by overexpression 
of the ChAT gene did not alleviate hypoxia-induced apoptosis, although it preserved membrane 
GLUT-4 expression in the diabetic cardiomyocytes model. Further, the findings also revealed 
that palmitate and glucose treatment, as well as hypoxia, decreased cardiac NNCS activation, 
as indicated by reduced ChAT expression. On a side note, my results also showed that insulin 




In conclusion, this thesis provides the first evidence that cardiac NNCS is altered in diabetes 
heart. Such alteration may contribute to decreased GLUT-4 and glucose uptake, and eventually 
causing cardiac dysfunction in the diabetic heart. The thesis also shows the protective effect of 
cardiac NNCS on the cardiovascular function of diabetic heart. Taken together, targeting 
cardiac NNCS to increase GLUT-4 and VEGF-A can be a potential therapeutic intervention to 
enhance glucose metabolism and angiogenesis, respectively, can be a potential therapeutic 
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Chapter 1 : General Introduction 
1.1 Type-2 diabetes mellitus (T2DM) 
In the first part of the literature review, I introduce type-2 diabetes mellitus, which is the strong 
contributing factor of diabetic heart disease (DHD). Then, I will discuss the diabetes-induced 
alteration in cardiac metabolism and myocardial energy production and how such changes 
contribute to DHD. Also, the therapeutic options aiming to restore the cardiac metabolism are 
discussed.  
 
1.1.1 T2DM and diabetic heart disease  
Diabetes mellitus is a chronic metabolic disorder characterized by the inability to maintain 
blood glucose level (reviewed in [2]). The prevalence of DM is increasing at an alarming rate, 
affecting 425 million individuals (1 in 11 individuals) globally in 2017 [3]. This estimate is 
projected to further increase to 637 million in 2045 [3]. The standard classifications of DM 
include type-1 DM (T1DM), type-2 DM (T2DM) and gestational DM (reviewed in [2]). 
Notably, over 90% of diabetes cases are T2DM, which is characterized by insulin resistance 
(i.e., defective insulin action) [4]. The pathogenesis of T2DM is complex and entails different 
elements such as genetic factor, sedentary lifestyle, and dietary factor (reviewed in [5]).  
T2DM is associated with more than a two-fold greater risk of developing cardiovascular 
diseases, which is termed  diabetic heart disease (DHD) [6-9]. DHD includes coronary artery 
disease (CAD), diabetic cardiomyopathy, and heart failure (HF) (reviewed in [10]). The 
etiology of DHD is multifactorial as DM has different impacts on the cardiovascular system [6, 
9, 11-13]. This includes hypertension [14, 15], macro- and microvascular dysfunction [16, 17], 
impaired cardiac metabolism [18-24], cardiac autonomic neuropathy [25] and increased 




1.1.2 Cardiac metabolism in the healthy and diabetic heart 
1.1.2.1 The healthy heart 
The heart is an aerobic organ that relies on the oxidation of substrates such as free fatty acid 
(FFA), glucose, and lactate to produce ATP [28, 29]. Notably, the heart predominantly 
metabolizes FFA as it is an energy-dense substrate and contributes to 70% of ATP production 
in the heart (Figure 1.1A) [28, 29]. Conversely, glucose and lactate contribute to 20% and 10% 
of ATP production, respectively [28, 29]. As shown in Figure 1.1A, FFA is transported by fatty 
acid transporter CD36 and enters mitochondria to undergo β-oxidation, Krebs cycle, and 
oxidative phosphorylation to generate ATP (reviewed in [30, 31]). Further, a healthy heart can 
flexibly switch substrates to allows adaptation in different physiological [28, 29, 32-34] or 
pathological conditions [35-37] in response to altered hormones, substrates availability, 
myocardial oxygen supply, and cardiac workload. For examples, in normal physiological 
conditions, FFA utilization is predominant in fasted-state [38-40]; glucose utilization is 
predominant in fed-state [40]; and lactate utilization is predominant during exercise [38, 41].  
In a pathological condition such as acute ischemia, the heart prefers to metabolize glucose [42-
45] (Figure 1.1B). This preference is because glucose requires lesser oxygen molecules for 
oxidation (ATP/O2 ratio = 5-5.3) in comparison to FFA oxidation (ATP/O2 ratio = 4.6) to 
generate ATP  (reviewed in [46]). However, whether glucose is aerobically or anaerobically 
metabolized depends on the severity of ischemia. In mild-to-moderate ischemia such as a 60% 
reduction in left anterior descending (LAD) coronary artery blood flow, glucose oxidation, but 
not anaerobic glycolysis, is essential to maintain contractile function [45]. In this case, glucose 
transporter-4 (GLUT-4) transport glucose into the cells where it undergoes glycolysis to be 
converted into pyruvate, thereby leading to generation of ATPs (Figure 1.1B; reviewed in [31]). 
Pyruvate is further converted by pyruvate dehydrogenase (PDH) and enters the Krebs cycles, 
where it subsequently will be further processed and oxidized to generate ATPs (Figure 1.1B; 




Figure 1.1 Schematic illustration of the cardiac metabolism of a healthy heart under normoxic 
and ischemic condition. 
(A) A healthy heart predominantly metabolizes FFA to generate ATPs in normoxic condition. (B) In 
ischemic condition, the heart switches to glucose for ATP generation due to lower oxygen consumption 
required to complete oxidation in mitochondria.  
 
1.1.2.2 The diabetic heart 
In contrast, the diabetic heart is metabolically inflexible as it mainly relies on FFA to produce 
ATP (Figure 1.2A) [47-51]. The increase in FFA reliance is due to loss of insulin action, which 
leads to increased lipolysis from the adipose tissue, and thus increasing the release of FFA into 
circulation [52]. Hyperlipidemia promotes cardiac FFA uptake, storage, and oxidation in the 
diabetic heart [53-57]. Further, increased FFA oxidation and insulin resistance reduce 
expression and membrane translocation of GLUT-4 that is responsible for cardiac glucose 
uptake, thus suppressing glucose oxidation [56-64]. Therefore, this alteration indicates that the 
diabetic heart is unable to utilize glucose to generate ATP. Consequently, increased FFA 
oxidation increases basal myocardial oxygen consumption (MVO2), thereby reducing cardiac 
efficiency (a ratio between cardiac work/MVO2) [19, 20, 65-68]. However, whether reduced 
cardiac efficiency per se alters cardiac function remains inconclusive. This is because the 
diabetic individuals reported as having normal cardiac morphology and contractility [19, 68] 




1.1.3 Impaired ATP production in the diabetic heart  
Multiple studies showed the basal myocardial energy status was decreased in diabetic animal 
models [70, 71], diabetic patients with normal cardiac function [19] or with abnormal cardiac 
function [21, 72]. Further, Scheuermann-Freestone et al. [19] showed that decreased basal 
myocardial energy status was associated with increased plasma FFA in diabetic patients. In line 
with this, emerging evidence suggests that excessive FFA utilization decreased mitochondrial 
oxidative capacity, thereby reducing ATP production in the diabetic heart [35, 73-76]. Thus, 
these studies indicate that increased FFA utilization increased ATP concentrations before the 
onset of DHD (Figure 1.2A). 
As diabetes mellitus progresses, prolonged exposure to metabolic derangements contributes to 
endothelial dysfunction, contributing to CAD and coronary microvascular disease (CMVD) [16, 
17, 77, 78]. CAD and CMVD reduce coronary artery blood flow and myocardial perfusion, 
thereby reducing the availability of oxygen to the myocardium [68]. In this case, the 
combinational effects of defective glucose utilization [56-62, 79], decreased oxygen availability 
[68], excessive FFA utilization [19, 20, 65-68] and reduced mitochondrial oxidative capacity 
[35, 73-76] impair ATP production and contractile function of the diabetic heart, contributing 





Figure 1.2 Schematic illustration of the cardiac metabolism of a diabetic heart under normoxic 
and ischemic condition. 
(A) FFA oxidation is increased in the diabetic heart due to insulin resistance and metabolic 
derangement. Thus, elevated FFA oxidation increases MVO2 and decrease mitochondrial function, thus 
leading to decreased cardiac efficiency and ATP production in normoxic condition. (B) In ischemic 
condition, the availability of oxygen is insufficient for FFA oxidation, thus further impairing the 
production of ATP. Energy deficit affects the contractile function and subsequently leads to cardiac 
dysfunction. Red dashed lines indicate diminished FFA oxidation.  
 
1.1.4 Normalization of cardiac metabolism by pharmacological 
approaches 
As the occurrence of altered cardiac metabolism and energetics precedes the onset of DHD, 
early normalization of this derangement has been demonstrated to be effective in preventing 
the onset of DHD in T2DM animal models [19, 20, 23]. In this section, commercially available 
pharmacological agents that either promote glucose uptake and oxidation or suppress FFA 
uptake and oxidation are discussed (reviewed in [82]). However, as some of these drugs were 
developed in the setting of CAD or HF only [83-86], the effect of these drugs in the diabetic 
population is yet to be elucidated.  
 
1.1.4.1 Targeting the glucose uptake and oxidation 
Increased glucose uptake and oxidation can be targeted to normalize the altered cardiac 
metabolism in the diabetic heart (Table 1.1). For example, glucose-insulin potassium (GIK) 
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solution increases the insulin concentration in the circulation and stimulate the peripheral 
organs, including the heart to uptake glucose for oxidation, which in return, reduce the oxygen 
consumption in the ischemic heart [87, 88]. However, this may not apply to diabetic individuals 
as the plasma glucose level is already high and accompanied by insulin resistance. Besides, 
pyruvate dehydrogenase kinase (PDK), which inhibits PDH and prevents the conversion of 
pyruvate to acetyl-CoA for oxidation, can be inhibited by dichloroacetate, SDZ048-619, and 
PS10 [86, 89, 90]. However, the effect of these inhibitors was only tested in animal models, 
while the effect is unknown in diabetic individuals.  
 
Table 1.1 Examples of drugs promote glucose uptake and oxidation  
Therapeutic goal Treatment [Reference] 
Increase in glucose uptake from 
circulation 
Glucose-insulin potassium solution [87, 88] 
Increase in glucose oxidation PDK inhibitor – dichloroacetate, SDZ048-619 and PS10  [86, 89, 
90] 
 
1.1.4.2 Targeting the FFA uptake and oxidation 
Reduction of FFA oxidation can be another approach to prevent FFA uptake from circulation 
as well as by inhibition of mitochondrial FFA uptake and oxidation (Table 1.2). The β-
adrenoceptor antagonists (e.g., carvedilol and propranolol) reduce catecholamine-induced 
lipolysis and thus, the extraction of FFA from circulation [91, 92]. Also, it reduces sympathetic-
stimulated cardiac workload, thereby reducing oxygen consumption. Besides, peroxisome 
proliferator-activated receptor alpha (PPARα) agonists (e.g., ciprofibrate and fenofibrate) 
decrease circulating FFA availability by inducing hepatic enzymes that are involved in hepatic 
FFA breakdown [93, 94]. 
On the other hand, etomoxir [95] and perhexiline [85] have been developed to inhibit the 
activity of carnitine palmitoyltransferase-1 (CPT-1), which is responsible for mitochondrial 
FFA uptake. Trimetazidine directly inhibits the mitochondrial long-chain 3-ketoacyl CoA 
thiolase (LC 3-KA), which is the terminal enzyme of FFA β-oxidation [83, 84]. Nevertheless, 
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as the diabetic heart predominantly utilizes FFA for ATP production, suppression of FFA 
utilization and oxidation alone may further reduce the ATP production as the diabetic heart is 
unable to use other substrate fuels (i.e., glucose and lactate). Thus, it may seem reasonable to 
postulate that the suppression of FFA utilization may not be ideal for diabetic individuals. 
However, the effectiveness and potential side effects of these drugs are still yet to be studied in 
diabetic individuals. This suggests that more therapeutic interventions are required to be 
developed for the diabetic population.  
 
Table 1.2 Examples of drugs prevent FFA uptake and oxidation  
Therapeutic goal Treatment [Reference] 
Inhibition of FFA uptake from 
circulation 
β-adrenoceptor antagonists – carvedilol & propranolol [91, 92] 
PPARα agonists – ciprofibrate & fenofibrate [93, 94] 
Inhibition of mitochondrial FFA 
uptake 
CPT-1 inhibitors - etomoxir & perhexiline [85, 95]  
Inhibition of β-oxidation LC 3-KA inhibitor – trimetazidine [83, 84] 
 
1.2 The cardiac non-neuronal cholinergic system (NNCS) 
The cardiac NNCS is known as an intrinsic defensive mechanism to allow the heart to adapt to 
changes in physiological and pathological condition [96-101]. In this part of the introduction, I 
first provide an overview of cardiac NNCS and discuss its physiological role focusing on the 
regulation of glucose metabolism. Then, I discuss the signaling cascade mediated by cardiac 
NNCS in the heart. (a part of the literature presented in this section has been modified from the 
published literature review in the Journal of Molecular and Cellular Cardiology [102]) 
 
1.2.1 Discovery of NNCS in the heart 
The cholinergic neurons transmit electrical impulses from the brain to the heart through 
acetylcholine (ACh) to regulate cardiac function [103-107]. In the last decade, several 
researchers have provided evidence that the cardiomyocytes possess a functional intrinsic 
cholinergic machinery to synthesize, release, and degrade ACh [96, 99, 108]. Kakinuma et al. 
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[96] employed immunogold electron microscopy to demonstrate the presence of vesicle-like 
structure with positive vesicular ACh transporter (VAChT) immunoreactivity in the muscle 
fibers of the rat hearts, indicating ACh storage and release via vesicles. This finding is further 
supported by Rocha-Resende et al. [99] who showed co-localization of VAChT with recycling 
vesicles in the isolated adult mouse ventricular cardiomyocytes. Also, Rana et al. [108] used 
bromoacetylcholine, an inhibitor of choline acetyltransferase (ChAT), to treat isolated atrial 
and ventricular rat cardiomyocytes and found that ACh secretion from cardiomyocytes was 
significantly reduced, supporting that ChAT is the main ACh-synthesizing enzyme in the 
cardiomyocytes. Rocha-Resende et al. [99] identified the presence of choline transporter 1 
(CHT1) by treating the mouse cardiomyocytes with hemicholinium-3, a CHT1 inhibitor, to 
observe a reduced activity of cardiac NNCS. Moreover, the ACh derived from cardiomyocytes 
was detected intracellularly and extracellularly in the presence of acetylcholinesterase (AChE) 
inhibitors such as donepezil, physostigmine, and pyridostigmine [96, 97, 108]. In addition to 
rodent models, the presence of cardiac NNCS represented by VAChT and ChAT was detected 
in human LV [101]. Thus, all these findings indicate that cardiomyocytes do possess proteins 
for ACh synthesis (ChAT), reuptake of choline for synthesis (CHT1), storage and release 
(VAChT) and degradation (AChE). On a side note, the cardiac NNCS possess the same 
enzymes and transporters as the neuronal cholinergic system. A schematic illustration of the 
cardiac non-neuronal cholinergic system compared to the classical neuronal cholinergic system 





Figure 1.3 Schematic illustration of the comparison between the cardiac NNCS and the classical 
neuronal cholinergic system.   
In the cardiomyocytes and cholinergic neurons, ACh is synthesized by ChAT by combining acetyl-CoA 
and choline. ACh is stored and released by VAChT upon stimulation. The ACh released from cholinergic 
neurons binds to nicotinic or muscarinic ACh receptor present in the postsynaptic terminal. The non-
neuronal ACh released from cardiomyocytes binds to the muscarinic ACh receptor expressed on the 
membrane in an auto/paracrine manner to mediate signaling. AChE is present in the extracellular space 
and terminate the effect of ACh by hydrolysis. CHT1 is responsible for the reuptake of free choline from 
the extracellular space into the cholinergic neurons and cardiomyocytes for ACh synthesis.  
 
1.2.2 Type-2 muscarinic ACh receptor mediated signaling  
In the mammalian heart, the cholinergic system regulates the cardiac function via muscarinic 
receptors [109]. There are five subtypes of muscarinic ACh receptor (mAChR), and the 
quantitation of the mRNA expression of these receptors have revealed that type-2 muscarinic 
ACh receptor (M2AChR) is the major receptor while other subtypes are expressed at very low 
level in the rodent and human heart [110-112].  
M2AChR is a G protein-coupled receptors (GPCR) which is bound to a heterotrimeric G protein 
complex. Activation of this receptor leads to dissociation of the Gαi/o subunit from the complex 
and eventually changes in cardiac ion channel activity in two folds. First, Gβγ subunit interacts 
with G-protein coupled inward rectifying K+ (GIRK) channel that predominantly expressed in 
atrial, sinoatrial node and atrioventricular node cells, thus opening up an inwardly rectifying 
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potassium channel (KACh) [113]. This leads to hyperpolarization and therefore reducing the 
heart rate (HR). Second, Gαi/o subunit inhibits adenylyl cyclase activity and thereby reducing 
the generation of cyclic adenosine monophosphate (cAMP). A reduction in this cyclic 
nucleotide decreases the ion activity of the hyperpolarization-activated cyclic nucleotide-gated 
channels (HCN, also known as pacemaker channels) that solely expressed in the cardiac 
conduction system, hence reducing spontaneous depolarization in pacemaker action potentials 
and hence the HR [114]. Also, a reduction in cAMP decreases the ion activity of L-type Ca2+ 
channels (LCC), thereby decreasing the contraction force of cardiomyocytes [115-118].   
Apart from this, it has been reported that cardiomyocytes release ACh as a mediator to trigger 
autocrine/paracrine signaling independent of the abovementioned bradycardia mechanism. 
Upon ACh binding to M2AChR, the Gβγ subunit is released and binds directly to activate 
phosphatidylinositol-3-kinase (PI3K) [119]. PI3K is an upstream key player of a pro-survival 
signaling pathway, which subsequently activates protein kinase B (Akt) and hypoxia-inducible 
factor 1-alpha (HIF1α) [120, 121]. The effect of this signaling cascade is further discussed in 
Section 1.2.4. 
 
1.2.3 The physiological role of cardiac NNCS in glucose metabolism  
Previous studies showed that inactivation of cardiac NNCS decreased intracellular ATP level, 
increased oxygen consumption, and increased mitochondrial activity in the ChAT-KO HEK293, 
ChAT-KO HL-1 cardiomyocytes, and hemicholinium-3 treated H9c2 cells [96, 98, 122]. 
Conversely, activation of cardiac NNCS via overexpression of ChAT gene or exogenously 
added ACh to the HEK293 cells led to decreased mitochondrial function, increased intracellular 
ATP level and resistance to chronic serum deprivation [96, 122]. In line with this, 
overexpression of ChAT gene increased GLUT-1 and GLUT-4 protein expression, as well as 
the glucose content, in the left ventricle (LV) of ChAT-tg mice compared to the wild-type mice 
[100]. Further, immunohistochemistry analysis showed strong GLUT-4 immunoreactive signal, 
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but not GLUT-1, in the LV of ChAT-tg mice [100]. This evidence suggests that cardiac NNCS 
promotes glucose metabolism through enhancing GLUT-4 expression, therefore 
physiologically modulating cardiac metabolism and energetics in the heart. 
In addition to this, cardiac NNCS is involved in other physiological role such as  (1) production 
of pro-angiogenic factor vascular endothelial growth factor (VEGF) to maintain coronary 
vasculature [100, 123]; (2) maintaining action potential propagation through increasing 
connexin43 [98, 100]; (3) regulation of HR with the neuronal cholinergic system [97, 101]; (4) 
offsetting hypertrophic signals induced by hypersympathetic stimulation [97, 99, 101, 124]. 
ACh activates these effects through M2ACh receptor-mediating signaling (Figure 1.4). The 
ACh released from cardiomyocytes or cholinergic neurons stimulate the neighboring 
cardiomyocytes to synthesize ACh further to maintain or propagate the effects in the heart in 
an auto/paracrine manner [96]. 
 
 
Figure 1.4 Cardiac NNCS exerts its effect by an auto/paracrine amplification mechanism to 
initiate and propagate neuronal- and non-neuronal effects. 
(A) The ACh released from cardiomyocytes activates pro-survival signaling to promote glucose 
metabolism through GLUT-4 expression, as well as (B) to promote angiogenesis by increasing pro-
angiogenic factor VEGF-A expression in an auto/paracrine manner. (C) Besides, the ACh released from 
cardiomyocytes enhances the expression of connexin43 to preserve the gap-junction function and 
maintain action potential propagation. (D) Further, the ACh released from parasympathetic cholinergic 
neurons activates the NNCS in the cardiomyocytes to synthesize and release ACh. The ACh released 
from cardiomyocytes is thought to maintain and amplify the neuronal cholinergic effects to reduce heart 
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rate and possibly contraction force of the heart as well as (E) to counteract hypertrophic signals induced 
by hypersympathetic stimulation. The schematic purple bar represents the ACh concentrations being 
amplified through NNCS in the cardiomyocytes.  
 
1.2.4 Cardiac NNCS activates pro-survival signaling to regulate GLUT-4 
expression 
ACh-M2AChR interaction activates the pro-survival phosphatidylinositol-3-kinase 
(PI3K)/protein kinase B (Akt) signaling cascade, thereby increasing the availability of hypoxia-
inducible factor 1-alpha (HIF1α) under normoxic condition [100, 120, 125]. Activation of Akt 
prevents the binding of von Hipple-Lindau tumor suppressor (VHL) to the HIF1α protein [100, 
120, 125]. Thus, this prevents ubiquitin-mediated proteasomal degradation of the HIF1α protein, 
thus increasing its availability [126]. HIF1α and HIF1β dimerize to form HIF1, a master 
transcription factor, to transcriptionally activate a broad spectrum of hypoxia-responsive genes 
that eventually being translated to proteins to facilitate the adaption to ischemic stress, such as 
glycolysis to balance oxygen demand (Figure 1.5; reviewed in  [127]).  
The HIF1 transcription factor regulates glycolysis through transcriptionally activating GLUT-1 
and GLUT-4 genes to promote glucose uptake [128-131]. In particular, GLUT-4 is the major 
glucose transporter in the adult heart [132, 133]. An upregulation of GLUT-4 expression in the 
heart of ChAT-tg mice increased cardiac glucose content and ATP content [100]. Thus, these 
studies demonstrated that activation of cardiac NNCS increases ACh content, which in turn 
mediates PI3K/Akt/HIF1α signaling cascade to promote glucose metabolism through 





Figure 1.5 Cardiac NNCS activates pro-survival PI3K/Akt/HIF1α signaling cascade.  
Inhibition of ubiquitin-mediated proteasomal degradation by ACh increases HIF1α protein in normoxic 
condition. Subsequently, HIF1α and HIF1β dimerize to form a master transcription factor HIF1 to 
transcriptionally activate a broad spectrum of hypoxia-responsive genes which are eventually translated 
to proteins that are involved in glucose uptake (GLUT-1 & GLUT-4). P indicates phosphorylation; U 
indicates ubiquitination.  
 
1.3 Overview and outline of the Ph.D. thesis 
Before the onset of DHD, altered cardiac metabolism (i.e., increased FFA utilization and 
decreased glucose utilization) decreases the basal myocardial energy status and cardiac 
efficiency in the diabetic heart. Also, an ischemic condition induced by CAD or CMVD reduces 
oxygen availability to the myocardium, thus, limiting FFA oxidation and ATP production. In 
this case, the diabetic heart is unable to maintain its contractile function, thereby suffering 
extensive myocardial damage. Although there are guidelines and treatment in place for 
managing DHD [134], it remains the leading cause of death in the diabetic population 
worldwide [135]. The alarming increase in the incidence of DHD urges for alternative 
therapeutic options. However, the lack of understanding in the molecular mechanism involved 
in the disease progression hamper the progress in the development of new therapy.  
The heart consists of both neuronal and non-neuronal cholinergic system. It is now well 
established that cardiac NNCS physiologically modulates glucose and energy metabolism [96, 
98, 100, 122]. However, the role of cardiac NNCS in diabetic heart has yet to be elucidated. 
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Based on the current knowledge - (1) activation of cardiac NNCS results in an increase in 
GLUT-4 expression and (2) the diabetic heart displays reduced GLUT-4 expression and glucose 
utilization before the onset of DHD [58, 60, 64]. Therefore, it seems logical to postulate that 
T2DM could decrease cardiac NNCS before the onset of DHD. 
Therefore, it is essential to examine (1) whether the expression of various components (i.e., 
ChAT, CHT1, VAChT, AChE, and M2AChR) that are involved in the cardiac cholinergic 
machinery are altered in diabetes mellitus and (2) if activation of cardiac NNCS could prevent 
or attenuate the detrimental effect of diabetes on the heart. 
 
1.3.1 Aims and hypotheses 
The aim of my thesis is to examine the role of cardiac NNCS in the diabetic heart. Thus, I 
divided this project into five specific objectives. 
 
i. Examining the temporal expression changes in the components of cardiac NNCS 
and glucose transporters in the diabetic db/db heart. 
I hypothesized that the expression changes in the components of cardiac NNCS (ChAT, CHT1, 
VAChT, AChE, and M2AChR) and GLUTs (GLUT-1 and GLUT-4) would be dysregulated in 
the diabetic db/db heart. Also, I hypothesized that dysregulation of the components of cardiac 
NNCS would precede the decrease in GLUT-4 expression in the db/db mice. To test this 
hypothesis, I measured gene and protein expression of the components of cardiac NNCS and 
GLUTs in the ventricular tissues of type-2 diabetic db/db mice at different ages (i.e. 8-, 12-, 
16-, 20-, 24-, 28- and 32-weeks of age). 
 
ii. Examining the expression changes in the components of cardiac NNCS and glucose 
transporters in the diabetic human heart 
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I hypothesized that the expression changes in the components of cardiac NNCS (ChAT, CHT1, 
VAChT, AChE, and M2AChR) and GLUTs (GLUT-1 and GLUT-4) would be dysregulated in 
the diabetic human heart. To test this hypothesis, I measured the protein expression of the 
components of cardiac NNCS and GLUTs in the ventricular tissues of type-2 diabetic human 
who underwent coronary artery bypass surgery (CABG). 
 
iii. Investigating the beneficial effect of cardiac NNCS activation via overexpression of 
the ChAT gene on the cardiovascular function of the diabetic heart 
I hypothesized that ventricular-overexpression of ChAT gene would lead to activation of 
PI3K/Akt/HIF1α/GLUT-4 signaling pathway to promote glucose metabolism, thus improving 
the cardiac function of the diabetic heart. To test this hypothesis, the blood glucose level, LV 
function, protein expression of targets (ChAT, M2AChR, Akt, HIF1α, GLUT-4, AMPKα) were 
assessed in the diabetic db/db mice with ventricular-overexpression of ChAT gene at 8-, 12-, 
16- and 20-weeks of age. Also, I hypothesized that the ventricular-overexpression of ChAT 
gene would lead to an increase in VEGF-A expression and promote angiogenesis, thus 
improving vascular function of the diabetic heart. To test this hypothesis, the coronary 
circulation, microvascular density, protein expression of VEGF-A were assessed in the diabetic 
db/db mice with ventricular-overexpression of ChAT gene at 12- and 24-weeks of age. 
 
iv. Establishing an in-vitro diabetic cardiomyocytes model using AC16 cells  
I hypothesized that palmitate and glucose treatment would impair insulin signaling and lead to 
insulin resistance in the AC16 cells. To test this hypothesis, I treated the AC16 cells with 
palmitate and glucose for 48 hours and followed by insulin stimulation for 30- and 60-minutes 
to test the insulin responsiveness. The cytosolic and membrane proteins were isolated and 




v. Investigating the protective effect of cardiac NNCS in the diabetic AC16 cells under 
the hypoxic condition 
I hypothesized that activation of cardiac NNCS via overexpression of the ChAT gene would 
lead to an increase GLUT-4 expression, thus sustaining energy production and reducing 
apoptosis under hypoxic condition. To test this hypothesis, I first overexpressed ChAT gene in 
the AC16 cells for 24 hours, followed by palmitate and glucose treatment for 48 hours, and 
finally exposing the cells to 24 hours of hypoxic conditions. The cytosolic and membrane 
proteins were isolated and assessed the expression changes in GLUT-4, ChAT, AMPKα, and 





Chapter 2 : General materials and methods 
This chapter outlines the general materials and methods for the techniques applied in this Ph.D. 




The Animal Ethics Committee from the University of Otago (AEC25/12) and Nippon Medical 
School approved the animal studies conducted in this Ph.D. study (section 2.2.2 and 2.2.4). 
Health and Disability Ethics Committee in New Zealand approved the use of human LV tissues 
(LRS/12/01/001/AM13; section 2.2.1). The human tissues samples of patients with or without 
type-2 diabetes with CAD who underwent CABG in Dunedin hospital were collected following 
their informed consents. 
 
2.2 The study models and experimental design 
This Ph.D. study included animal and human ventricular tissues as well as a cardiomyocyte cell 
line for investigation (Figure 2.1). The ventricular tissues from type-2 diabetic db/db mouse 
model (C57BL/KsJ-Leprdb/db) and type-2 diabetic human with CAD were used to investigate 
the expression changes of cardiac NNCS (ChAT, VAChT, CHT1, AChE, and M2AChR) as 
well as GLUTs (GLUT-1 and -4). Next, the type-2 diabetic db/db mice with ventricle-specific 
overexpression of ChAT gene (C57BL/KsJ-Leprdb/db-ChAT-tg) and AC16 cells were used to 






Figure 2.1 A brief overview of the use of animal and human ventricular tissues as well as AC16 
cells in this thesis. 
The use of ventricular tissues from type-2 diabetic db/db mice and type-2 diabetic human with CAD was 
used to investigate the expression changes of cardiac NNCS and GLUTs. Then, I validated the function 
of cardiac NNCS using type-2 diabetic db/db mice with ventricle-specific overexpression of ChAT gene 
and AC16 cells to NNCS in the in-vivo and in-vitro condition. 
 
2.2.1 Type-2 diabetic db/db (C57BL/KsJ-Leprdb/db) mouse model 
The db/db mouse model served as the model of type-2 diabetes mellitus [1, 136, 137]. This 
mouse model develops spontaneous diabetes due to homozygous transverse point mutation 
(G→T) in the intron 18 of the leptin receptor (Lepr) [138, 139]. Before termination, these mice 
had free access to the food pellets. The tissue collection was performed between 3 pm to 4 pm 
by Dr. Shrtui Rawal as part of her Ph.D. study. The atrial tissues were removed, and the 
ventricular tissues were equally cut into three parts (Figure 2.2). These ventricular tissues were 
available (8-, 12-, 16-, 20-, 24-, 28- and 32-weeks of age; mixed gender) and used in my study 
[1]. Immunofluorescence analysis performed on the upper part of the ventricular tissues. RT-
qPCR analysis and western blot analysis performed on the middle and lower parts of the 





Figure 2.2 An overview of ventricular tissue collection and analytic techniques performed on type-
2 diabetic db/db mice. 
The ventricular tissues were cut into three parts after removal of the atrial tissues. The upper part of 
the ventricular tissue was harvested and fixed in 4% formaldehyde for immunofluorescence analysis. 
The middle and lower parts were collected for RNA and protein analysis, respectively. 
 
2.2.2 Type-2 diabetic human with CAD 
Through the HeartOtago research network, I had access to human left ventricular (LV) samples 
from type-2 diabetic and non-diabetic patients with CAD. These patients were admitted to 
Dunedin Hospital to undergo coronary artery bypass graft (CABG) surgery. The selection 
criteria of diabetic patients were hemoglobin A1C (HbA1C) level ≥ 50nmol/mol and diabetic 
duration of more than one year [140]. Besides, the samples were restricted from those aged 
between 60-84 years old. The LV samples were used for the western blotting experiment. The 
information about the cardiac functions of the recruited participants was retrieved from the 
database maintained by HeartOtago. 
 
2.2.3 Type-2 diabetic db/db mouse with ventricular-specific 
overexpression of ChAT gene 
Prof. Yoshihiko Kakinuma (Nippon Medical School, Japan) generated and provided this unique 
model. As shown in Figure 2.3, the generation of this model was performed by crossing the 
heterozygous db/+ mouse (Leprdb/+) with the mouse model of cardiac NNCS (i.e., ventricular-
specific overexpression of ChAT gene; ChAT-tg) [100]. The heterozygous db/+ littermates with 
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ChAT-transgene (db/+-ChAT-tg mice) were further crossbred to generate homozygous db/db 
littermates with ChAT-transgene (db/db-ChAT-tg mice).  
 
 
Figure 2.3 Type-2 diabetic db/db mouse with ventricular-specific overexpression of ChAT 
gene. 
The mouse model of cardiac NNCS and heterozygous Leprdb/+ mouse was crossbred. Heterogenous 
littermates with ventricle-specific ChAT transgene were further crossbred to obtain homogenous 
littermates with ventricle-specific ChAT transgene. 
 
The body weight, blood glucose level, LV function of the db/db-ChAT-tg mice were assessed. 
The age-matched diabetic db/db mice were used as control. After the measurement, the hearts 
from db/db and db/db-ChAT-tg mice (8-, 12-, 16-, and 20-weeks of age; mixed gender) were 
retrieved. This procedure was performed between 9.00 am to 10.30 am. The atrial tissues were 
removed and the ventricular tissues were equally cut into three parts (i.e. upper, middle and 
lower) and collected by Prof. Yoshihiko Kakinuma as described in Figure 2.2. The lower part 
of the ventricular tissues was used for western blot analysis to measure the protein expression 
of the selected targets in my study (Figure 2.4). The wild type non-diabetic (ND) mice were 
included for western blot analysis only to allow comparison with db/db and db/db-ChAT-tg 
mice.   
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Also, the coronary vascular function was performed on db/db and db/db-ChAT-tg mice (12- and 
24-weeks of age) in the SPring-8 facility in Japan. After Synchrotron radiation 
microangiography, the hearts were retrieved. The atrial tissues were removed and the 
ventricular tissues were equally cut into three-part (i.e. upper, middle and lower) and collected 
(Figure 2.2). The upper part of the ventricular tissue was used to assess the density of arterioles 
and capillaries in ex-vivo while the lower part of the ventricular tissues was used for western 
blot analysis (i.e., VEGF-A). 
 
 
Figure 2.4 An overview of the experimental setup and analytical techniques to assess the 
cardiovascular function and molecular alterations initiated by cardiac NNCS in the db/db-
ChAT-tg mice. 
The body weight and blood glucose level were examined. The LV function was examined by admitting 
the pressure-volume catheter to the cardiac apex. The coronary vascular function was examined by 
microangiography as well as immunofluorescence to measure the capillary and arteriole density. 
Finally, western blot was performed to assess the expression changes in the proteins involved in the 
cardiac NNCS-mediated signaling.   
 
2.2.3 Human ventricular cardiomyocyte cell line – AC16 cells 
AC16 cells were purchased from Dr. Mercy M. Davidson from Columbia University. This cell 
line was generated by fusing SV40 transformed, uridine auxotroph human fibroblasts, devoid 
of mitochondrial DNA, with the primary cells from human ventricular tissues [141]. This model 
was used to overexpress human ChAT gene, followed by the induction of insulin resistance and 
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hypoxic treatment (Figure 2.5). At the end of the experimental time point, the cytosolic and 
membrane proteins were separated and collected. Western blot analysis was performed to 
measure the protein expression of selected targets (Figure 2.5). 
 
 
Figure 2.5 An overview of the experimental setup and analytical techniques used to study 
the function of cardiac NNCS in AC16 cells. 
The experiment was designed to demonstrate the protective effect of cardiac NNCS in diabetic AC16 
cells under hypoxic condition. The function of cardiac NNCS was assessed by protein targets that 
involved in glucose uptake, energy homeostasis and apoptosis.  
 
2.3 Molecular analyses of gene and protein expression 
2.3.1 Determination of gene expression from mouse ventricular tissues 
2.3.1.1 Isolation of ribonucleic acid (RNA) 
RNA was isolated using Trizol reagent (Invitrogen, 15596026) according to the manufacturer’s 
instruction. Briefly, mouse ventricular tissues were lysed and homogenized in Trizol reagent 
using 2.0 mm stainless steel beads (Next Advance, SSB14B-RNA) in a homogenizer (Next 
Advance, BBX24). The lysate was cleared by centrifugation at 12,000 g at 4°C and followed 
by phase separation using chloroform (in the ratio of 1:5, chloroform: Trizol). The aqueous 
phase containing RNA was then transferred to a fresh tube and precipitated by isopropanol (in 
the ratio of 1:2, isopropanol: Trizol). The precipitated RNA was washed using 75% ethanol (in 
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the ratio of 1:1, 75% ethanol: Trizol) and solubilized by RNA-free water. The concentration of 
RNA was measured using a NanoDrop-1000 spectrophotometer (NanoDrop Technologies, 
USA). The purity of the RNA was evaluated by the absorbance ratio of 260 over 280 and 260 
over 230 nm. A 260/280 ratio between 1.8 and 2.1 and 260/230 ratio of above 2 indicate pure 
RNA quality and no protein and organic solvent contamination. All RNA samples in my study 
had 260/280 and 260/230 ratio of 1.8 and above.  
  
2.3.1.2 Synthesis of complementary deoxyribonucleic acid (cDNA) by reverse 
transcription 
Before reverse transcription, isolated RNA was treated with recombinant DNase (rDNase) to 
remove genomic DNA. In brief, 3.5 μg of RNA was treated with rDNase at 37⁰C for 30 minutes, 
followed by incubation at 75⁰C for 10 minutes to inactivate rDNase. Then, the concentration of 
DNase-treated RNA was measured as described above. One microgram of the rDNase-treated 
RNA was mixed with PrimeScript™ buffer, oligo dT primer, random hexamers and 
PrimeScript™ RT enzyme mix 1 (Takara, RR037A; Table 2.1) to reverse transcribe the RNA 
to cDNA. The reaction mixture was incubated at 37⁰C for 15 minutes to synthesize cDNA, and 
85⁰C for five seconds to inactivate the reverse transcriptase in a thermal cycler (BioRad, T100).  
 
Table 2.1 The concentration and volume of components required for reverse transcription 
Reagent Initial concentration Final concentration/volume 
PrimeScript™ buffer 5X 1X 
Oligo dT primer  50 μM 5 μM 
Random hexamers  100 μM 10 μM 
PrimeScript™ enzyme mix I  
(0.5 μl per 500 ng RNA) 
- 2 μl 
rDNase-treated RNA - 1 μg 
 
2.3.1.3 Quantitative polymerase chain reaction (qPCR) 
After reverse transcription, PCR amplification was performed to measure the gene expression 
of selected targets. Briefly, the synthesized cDNA was mixed with SYBR Premix Ex Taq™ 
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(Takara, RR420L), KiCqStart forward and reverse primer (Sigma-Aldrich), nuclease-free water 
and then plated in a 96-well plate in triplicates (Table 2.2). Then, the reaction was initiated by 
incubating the reaction mixture at 95⁰C for two minutes for to activate the enzyme, followed by 
40 cycles of denaturation at 95⁰C for five seconds and primer annealing at 54-60⁰C for 30 
seconds in StepOnePlus Real-time PCR system (ThermoFisher Scientific; 4376600). The 
primer sequences, optimized concentrations, and annealing temperature of each primer are 
listed in Chapter 3. After amplification, the PCR amplicons were subjected to the gradual 
increment of temperature to measure the melting temperature. Such measurement provides an 
indication of the specificity of amplification.  
 
Table 2.2 The concentration and volume of components required for qPCR amplification 
*Primer sequences, optimized concentrations, and annealing temperature of each primer are listed in 
Chapter 3. 
 
2.3.1.4 qPCR data analysis  
The qPCR experiment was performed one time for each sample as this analysis was to detect 
the presence of selected targets in the mouse ventricular tissues. The gene expression of selected 
targets was normalized to ribosomal RNA 18S by the 2-ddCt method [142] and any samples 
showing a CT value of >35 were excluded from the analysis. 
 
2.3.2 Determination of protein expression from mouse, human ventricular 
tissues and AC16 cells 
2.3.2.1 Total protein isolation  
Total proteins were isolated using RIPA buffer (150 mM NaCl, 0.1% SDS solution, 1% Triton 
X-100, 1% sodium deoxycholate in 50 mM Tris-HCl, pH 8.0), supplemented with 1X 
Reagent Initial concentration Final concentration/volume 
SYBR Premix Ex Taq™ 2X 1X 
Forward primer* 10 μM 0.2 – 1 μM 
Reverse primer* 10 μM 0.2- 1 μM 
Synthesized cDNA - 2 μl 
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cOmplete™ protease inhibitor cocktail (Roche, 4693159001) and 100 mM phenylmethane 
sulfonyl fluoride (PMSF; Sigma-Aldrich, 10837091001) [137]. Mouse and human ventricular 
tissues were lysed and homogenized in RIPA buffer by 2.0 mm stainless steel beads (Next 
Advance, SSB14B-RNA) in a homogenizer (Next Advance). For AC16 cells, RIPA buffer was 
added to the culture dish to lyse the cells. Then, the protein lysates were collected and cleared 
by centrifugation at 13,400 rpm at 4⁰C for 30 minutes.  Purified protein lysates were then 
transferred to a fresh tube and quantified by Bradford assay described in the following section.  
 
2.3.2.2 Membrane and cytosolic protein isolation from AC16 cells  
The fraction of membrane and cytosolic protein from AC16 cells was isolated using the Mem-
PER™ Plus Membrane Protein extraction kit (Thermo Scientific, 89842). Briefly, 5 x 106 cells 
were washed once with cell wash solution supplied from kit followed by scraping the cells with 
0.75 mL of permeabilization buffer supplemented with 1X cOmplete™ protease inhibitor 
cocktail, 1X PhosSTOP™ phosphatase inhibitor cocktail (Roche, 4906845001) and 100 mM 
PMSF. The cell lysates were collected in a microcentrifuge tube and incubated for 10 minutes 
at 4⁰C with constant mixing. After centrifugation at 16,000 g for 15 minutes, the supernatant 
containing cytosolic proteins was collected, and the pellet was resuspended in 0.5 mL of 
solubilization buffer with the addition of 1X cOmplete™ protease inhibitor cocktail, 1X 
PhosSTOP™ phosphatase inhibitor cocktail and 100 mM PMSF. The cell lysates were then 
incubated for 30 minutes at 4⁰C with constant mixing. After centrifugation at 16,000 g for 15 
minutes, the supernatant containing solubilized membrane and membrane-associated proteins 
was transferred to a new microcentrifuge tube and quantified by Bradford assay described in 
the following section. The protein expression of pan-cadherin (a membrane protein) was 





2.3.2.3 Determination of protein concentration by Bradford assay 
Bradford assay was performed to determine protein concentration by extrapolating against 
bovine serum albumin (BSA) standard. First, BSA powder (Sigma-Aldrich, A7906) was 
dissolved in PBS to make 2 mg/mL stock solution. Serial dilutions of this stock solution were 
made according to Table 2.3.  Then, five microlitres of BSA standards or purified protein lysates 
from test samples were added to wells containing 250 μL of Bradford dye reagent in a 96-well 
plate (BioRad, 5000205). The absorbance of BSA standards and test samples were measured at 
595 nm by SpectraMax i3x microplate reader (Molecular Device, USA). A standard graph was 
plotted by using the absorbance of BSA standards versus the final concentration, thus allowing 
determination of the protein concentration of test samples. 
 
Table 2.3 Preparation of BSA standards for Bradford assay 
Tube # BSA volume 
(μL) 




Final BSA concentration 
(μg/mL) 
1 20 2 mg/mL stock 0 2,000 
2 30 2 mg/mL stock 10 1,500 
3 20 2 mg/mL stock 20 1,000 
4 20 Tube 2 20 750 
5 20 Tube 3 20 500 
6 20 Tube 5 20 250 
7 20 Tube 6 20 125 
8 - - 20 0 
 
 
2.3.2.4 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and immunoblotting 
Following the quantification, the protein lysates were mixed with 6X Laemmli samples buffer 
(12% SDS, 60% glycerol, 30% β-mercaptoethanol, 0.012% bromophenol blue, 0.375 M Tris-
HCl, pH 6.8) and incubated at 95⁰C for five minutes to denature the proteins. Then, an equal 
amount of denatured protein lysates was loaded to discontinuous polyacrylamide gel (Table 2.4) 
and subjected to electrophoresis in Tris-glycine buffer (25 mM Tris base, 192 mM glycine and 
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0.1% SDS, pH 8.3). Precision plus Kaleidoscope prestained protein ladder (BioRad, 1610375) 
was used to determine the molecular weight of the proteins. 
 
Table 2.4 Composition of discontinuous polyacrylamide gel 
Component Stacking gel Resolving gel 
0.5 M Tris-HCl, pH 6.8 0.0625 M - 
1.5 M Tris-HCl, pH 8.8 - 0.4 M 
30% Acrylamide/Bis solution 5% 7.5% - 12% 
10% SDS 0.1% 0.1% 
10% APS 0.1% 0.1% 
TEMED 0.1% 0.1% 
 
After separation, the proteins were transferred onto polyvinylidene difluoride (PVDF) 
membrane (BioRad, 1620264) in Tris-glycine transfer buffer (25 mM Tris base, 192 mM 
glycine and 20% (v/v) methanol, pH 8.3) at 110 voltage for 90 minutes. Successful transfer of 
total proteins was confirmed by staining the PVDF membrane with Ponceau S solution (0.1% 
(w/v) Ponceau S in 5% (v/v) acetic acid), and the image was captured using Syngene Pxi 
imaging system (USA). Next, the PVDF membrane was washed with TBST buffer (20 mM 
Tris base, 137 mM NaCl, 2.7 mM KCl, and 0.1% (v/v) Tween-20) to remove the Ponceau S 
dyes. The membrane was blocked with 5% (w/v) of BSA/TBST solution for one hour at room 
temperature, followed by incubation of primary antibody at 4⁰C overnight. Following day, the 
membrane was washed with TBST buffer and incubated with horseradish peroxidase (HRP)-
conjugated secondary antibody for one hour at room temperature. Finally, the membrane was 
washed with TBST buffer to remove any unbound secondary antibody, followed by incubation 
with enhanced chemiluminescence (ECL) substrate reagent (BioRad, 1705060). The 
chemiluminescence signal was captured by Syngene Pxi imaging system (USA) to visualize 




2.3.2.5 Western blot data analysis 
The western blot experiment was performed two to four times for each sample. The band 
intensity was quantified using ImageJ analysis software (https://imagej.nih.gov/ij/index.html). 
The band intensity of protein of interest was normalized to the band intensity of a prominent 
band between 37 kDa and 50 kDa from Ponceau S stained blot (total protein expression level) 
[143, 144] and expressed as fold changes towards the control group [145]. This particular 
approach was taken because the protein expression of housekeeping genes such as α-tubulin 
and β-actin showed a decreasing trend in the db/db mice while the selected band between 37 
kDa and 50 kDa (from Ponceau S stained blot) showed consistent expression in the ND, db/db 
and db/db-ChAT-tg mice (Appendix 2, Figure S2.1). Although it is unknown why α-tubulin and 
β-actin expression showed a decreasing trend, this could be due to enhanced protein degradation 
that is associated with diabetes mellitus [146-150]. 
 
2.4 Immunofluorescence   
2.4.1 Processing of mouse ventricular tissues 
2.4.1.1 Tissues fixation and cryosection 
Mouse ventricular tissues were excised and fixed in 4% paraformaldehyde (PFA) solution 
overnight. The tissues were then washed with PBS and dehydrated by immersing it in a 30% 
sucrose solution until it sank to the bottom of the tube. After dehydration, the tissues were 
washed in PBS, embedded in optimum cutting temperature (OCT) medium (Thermo Scientific, 
6769006) and stored at -80⁰C. OCT-coated ventricular tissues were cut into 7 µm section on the 
short axis using cryostat-microtome (Leica, CM1950) at -20⁰C. The sectioned tissues were 
adhered onto the superfrost plus microscope glass slides (LabServ, LBS4951plus) and stored 




2.4.1.2 Pre-staining treatment 
The tissues were treated with ice-cold acetone for five minutes in -20⁰C, followed by air-drying 
for 30 minutes in the room temperature. The use of acetone is to remove lipids and dehydrate 
the cells. Next, permeabilization was performed by treating the tissue sections with PBS 
solution containing 0.1% Triton-X 100 for 30 minutes in the room temperature. Tissues were 
washed thrice by PBS containing 0.03% Triton X-100 for five minutes in between each step. 
After permeabilization, tissue sections were incubated with 5% goat serum for one hour in the 
room temperature to block non-specific antigens.  
 
2.4.2 Processing of AC16 cells 
2.4.2.1 Fixation 
AC16 cells were cultured in 8-well chamber slide. Upon reaching 70% confluency or after 24 
hours of transfection, the culture medium was removed and washed with PBS. The cells were 
then incubated in 4% PFA solution for 15 minutes at room temperature, after which the cells 
were washed with PBS thrice and left in PBS and ready for the following treatment.  
 
2.4.2.2 Pre-staining treatment 
Permeabilization was performed by treating the cells with PBS solution containing 0.1% Triton-
X 100 for 30 minutes in the room temperature. Cells were washed thrice by PBS containing 
0.03% Triton X-100 for five minutes in between each step. After permeabilization, the cells 
were incubated with 5% goat serum for one hour in the room temperature to block non-specific 
antigens.  
 
2.4.3 Immunostaining of ventricular tissue section and cells 
This section describes the general protocol of single immunostaining or multicolor 
immunostaining (double or triple staining of multiple targets in a sequential manner) in the 
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same sample (original protocol provided by Abcam). The specific antibody, concentration, and 
methods are described in the corresponding chapter.  
Briefly, the tissue sections/cells were incubated with primary antibody diluted in 0.1% goat 
serum in PBS in a humidified chamber at 4⁰C overnight. Next day, the tissue sections/cells were 
incubated with secondary antibody conjugated with a fluorophore for two hours in the room 
temperature protected from light. If multicolor immunostaining was performed, the second 
blocking step was required and followed by incubation with second primary antibody diluted 
in 0.1% goat serum in PBS in a humidified chamber at 4⁰C overnight. On the following day, 
the tissue sections/cells were incubated with second secondary antibody conjugated with a 
fluorophore that was different from the one used for the first antibody for two hours. For triple 
staining, a third blocking step followed by the third primary and secondary antibody was 
performed.  
After immunostaining, tissue sections/ cells were counterstained with DAPI (Santa Cruz, 
SC3598; 1:1,000) to stain the nucleus for one minute. The tissue section/cells were washed with 
PBS containing 0.03% Triton X-100 three times in between each step. Finally, slides were 
mounted on the coverslip with fluorescent mounting medium (Invitrogen, 00495802) and dried 
overnight.  
 
2.4.4 Secondary antibody-only control for immunofluorescence 
Tissue sections or cells used as secondary antibody-only control underwent the same steps 
described above except the addition of primary antibody. 
 
2.4.5 Microscopic imaging  
Nikon A1 confocal laser microscope or Olympus BX51 fluorescent microscope was used to 
visualize and capture fluorescent images. The images were captured in four or ten random areas 




2.4.6 Immunofluorescence data analysis 
ImageJ software was used to process and quantify the fluorescent images. No analysis was 
performed for fluorescent images captured to identify the localization and confirm the 
expression of selected targets. 
 
2.5 Cell culture 
AC16 cells were maintained and grown in cell culture media composed of Dulbecco’s modified 
Eagle’s medium (DMEM; Gibco, 31600034), 5% fetal bovine serum (FBS; Hyclone, 
SH30406.02) and 1X antibiotic-antimycotic solution (Gibco, 15240062) in 75cm2 flask, under 
37⁰C and 5% CO2. The complete DMEM medium was changed every two days.  
 
2.5.1 Subculture 
Upon reaching 90-100% confluency, AC16 cells were passaged and subcultured at 1:5 ratio. 
Briefly, the cells were dissociated from the surface of the flask using TrypLE (Gibco, 12604021) 
for one minute at 37⁰C, followed by centrifugation at 300 g for five minutes. The cell pellet was 
resuspended in fresh complete DMEM medium and seeded in a new 75cm2 flask or 60mm dish. 
 
2.5.2 Cryopreservation 
In brief, cells were dissociated from the surface of the flask using TrypLE for one minute at 
37⁰C, followed by centrifugation at 300 g for five minutes. Next, the cell culture medium was 
removed, and the cell pellet was resuspended in freezing medium (10% dimethyl sulfoxide 
(DMSO; Sigma-Aldrich, D8418) in complete DMEM medium) and transferred to a cryovial. 
The cryovial was frozen in cell freezing container (Biocision, BCS405) at -80°C overnight 




2.6 Overexpression of human ChAT gene in AC16 cells 
2.6.1 Mammalian expression plasmid 
The pReceiver-M83 expression plasmid with the insertion of human ChAT gene 
(NM_001142929) was purchased from GeneCopoeia™ (Figure 2.6). The same plasmid without 
open reading frame served as the negative control. This plasmid is bicistronic as it contains an 
internal ribosome entry site (IRES) to allow simultaneous expression of the mCherry 
fluorescent protein as well as ChAT. The mCherry fluorescent protein was used as a reporter to 
determine transfection efficiency. 
 
 
Figure 2.6 The construct of the pReceiver-M83 plasmid 
The promoter for cytomegalovirus (CMV) was used to overexpress human ChAT gene. The presence of 
IRES allows the gene expression of mCherry, which eventually translated to a fluorescent protein. The 
image was adapted from GeneCopoeia™ and modified with permission (source: 
https://www.genecopoeia.com/wp-content/uploads/oldpdfs/tech/omicslink/pReceiver-M83.pdf). 
 
2.6.2 Amplification of expression plasmid 
2.6.2.1 Bacterial transformation 
DH5-α competent E. coli (Invitrogen, 18265017) were used to amplify the pReceiver-M83 
plasmid to generate a sufficient amount of plasmid that is required for the downstream 
experiment. Briefly, the bacteria were pre-incubated with 200 ng of the plasmid on ice for 30 
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minutes. Then, the bacteria were heat-shocked at 42⁰C for 45 seconds to induce uptake of 
plasmid, followed by two minutes incubation on ice. A pre-heated super optimal broth (SOC) 
medium (Invitrogen, 15544034) was added to the bacteria and incubated at 37⁰C for an hour in 
a shaking incubator at 235 rpm.  
After incubation, 100 μL of the bacterial suspension was streaked on LB-ampicillin agar plates 
(Table 2.9), which was incubated at 37⁰C overnight (>16 hours). On the following day, a single 
bacterial colony was picked and incubated in 100 mL of LB-ampicillin medium (Table 2.9) to 
further culture the colony at 37⁰C overnight (>16 hours) in a shaking incubator at 235 rpm.  
 
2.6.2.2 Extraction and purification of plasmid 
A large scale extraction of plasmid from bacteria grown overnight was performed using 
NucleoBond Xtra Midi plus kit (Macherey-Nagel, 740412) as per manufacturer’s instruction. 
After overnight culture, the bacterial cells were harvested and pelleted at 6,000 g for 10 minutes 
at 4⁰C. Next, the pellet was vigorously resuspended in 8mL of RES buffer in the presence of 
RNase, followed by addition of 8 mL LYS buffer to lyse the cells with gentle mixing. The 
mixture was incubated at room temperature for five minutes. While incubating, NucleoBond 
Xtra column together with inserted column filter was set up and equilibrated with 12 mL of 
EQU buffer. Next, 8mL of NEU buffer was added to neutralize the mixture with gentle mixing, 
followed by loading the mixture to the equilibrated column filter. The NucleoBond Xtra column 
and the column filter was washed with 5 mL of EQU buffer. After the buffer entirely flowed 
through the column, the column filter was removed. Next, the column was washed with 8 mL 
of WASH buffer, followed by elution using 5 mL of ELU buffer and collected in a fresh 50 mL 
falcon tube.  
Next, the plasmid present in the eluted buffer was precipitated using 3.5 mL of room-
temperature isopropanol and centrifuged at 15,000 g for 30 minutes at 4⁰C. The supernatant 
was discarded, and the pellet was washed with 2 mL of room-temperature 70% ethanol at 
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15,000 g for five minutes at 4⁰C. The supernatant was discarded, and the pellet was dry at room 
temperature for 15 minutes. Finally, the plasmid was reconstituted in DNase-free water. The 
concentration of plasmid was measured by using a NanoDrop-1000 spectrophotometer 
(NanoDrop Technologies, USA). The purity of the plasmid was evaluated by the absorbance 
ratio of 260 over 280 and 260 over 230 nm. 
 
2.6.3 Lipofectamine-mediated transfection of pReceiver-M83 expression 
plasmid 
Lipofectamine-mediated transfection was performed to overexpress the human ChAT gene in 
the AC16 cells. The cell seeding density was optimized at 0.75x105 cells/cm2, which resulted 
in approximately 90% confluency after overnight attachment. Lipofectamine™ 3000 kit 
(Invitrogen, L3000015) was used to transfect AC16 cells with pReceiver-M83 expression 
plasmid with human ChAT gene (M83-hChAT) or without an open reading frame (M83-neg) 
as a negative control. Briefly, for each well of the 24-well culture dish, 1 µg of M83-hChAT or 
M83-neg plasmid was mixed with 1.5 μL of Lipofectamine™ 3000 reagent and 2 μL of 
P3000™ reagent and incubated for 15 minutes to form DNA-lipid complex. The mixture was 
then added to the cells and incubated for 24 hours.  
 
2.6.3.1 Transfection efficiency analysis  
After 24 hours of transfection, AC16 cells were fixed with 4% PFA solution for 15 minutes. 
Images were captured at random areas (four images per sample) using an Olympus BX51 
fluorescent microscope under a 40X objective lens. The results were expressed as the mean 
values of the two independent experiments. The transfection efficiency was determined using 




𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑚𝐶ℎ𝑒𝑟𝑟𝑦 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
 𝑥 100% 
 
2.7 Induction of insulin resistance in AC16 cells  
An in-vitro diabetic cardiomyocyte model was established using AC16 cells to investigate the 
role of cardiac NNCS in regulating GLUT-4 in diabetic condition . 
 
2.7.1 Preparation of palmitate/BSA complex solution  
Palmitate was used to induce insulin resistance in AC16 cells. Palmitate is a saturated fatty acid 
which is insoluble in the cell culture medium. Thus, conjugation of palmitate to FFA-free BSA 
solution (Sigma-Aldrich, A8806) is required to create an aqueous solution that can be absorbed 
and utilized by cells. Briefly, a 100 mM of sodium palmitate solution (Sigma-Aldrich, P9767) 
was prepared in 0.1 M NaOH (BDH, 10252) at 70⁰C. A 10% (w/v) FFA-free BSA solution was 
prepared in H2O and filtered using 0.2 μM syringe filter. Next, 100 mM of palmitate was 
conjugated to 10% FFA-free BSA solution in the ratio of 1:9 at 55⁰C to obtain the final 
concentration 10 mM palmitate/ 10% BSA complex solution [151].  
 
2.7.2 Preparation of cell culture medium for induction of insulin resistance  
The cell seeding density was optimized at 0.6x105 cells/cm2, which resulted in approximately 
70% confluency after overnight attachment. Then, the cells were cultured in DMEM serum-
free medium containing 30.5 mM glucose, 400 μM palmitate/4% BSA complex, 1X antibiotic-
antimycotic solution to induce insulin resistance. The cells cultured in DMEM serum-free 
medium containing 5.5 mM glucose, 25 mM mannitol (osmotic control), non-conjugated BSA 




2.8 Oil Red O staining of AC16 cells 
Oil Red O (ORO) staining was performed to confirm the uptake of palmitate in the cells. 0.35% 
(w/v) ORO/isopropanol stock solution was prepared and filtered using 0.2 μM syringe filter 
[152]. The ORO working solution was prepared by mixing six part of the stock solution and 
four-part of distilled water, which was then filtered using 0.2 μM syringe filter. After 48 hours 
of palmitate incubation in the cells, AC16 cells were harvested and fixed with 4% PFA solution 
for 15 minutes and washed with PBS for 5 minutes thrice. Next, the cells were treated with 60% 
isopropanol thrice and incubated with 250 μL of ORO working solution for one hour in room 
temperature. After incubation, the cells were rinsed with 60% isopropanol for five minutes and 
distilled water for one minute. Next, the cells were incubated with Mayer’s hematoxylin 
solution (Sigma-Aldrich, MHS-16) for 10 minutes to stain the nucleus followed by washing 
with distilled water for three minutes thrice to remove unbound hematoxylin solution. Slides 
were mounted on the coverslip with mounting medium and dried overnight.  
 
2.8.1 ORO staining analysis 
Five images were captured at random areas from each sample using an Olympus BX61 
Montaging light microscope under a 40X objective lens. The results were expressed as the mean 
values of the two independent experiments. The palmitate uptake was determined using the 
following formula:  
 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑂𝑅𝑂 𝑠𝑡𝑎𝑖𝑛𝑖𝑛𝑔
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
 𝑥 100% 
 
2.9 Statistical analyses 
This section describes the general workflow to carry out statistical analyses. The use of the 
specific statistical test is described in each chapter. All data were tabulated in Microsoft Excel™ 
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and statistically analyzed using GraphPad Prism software (version 7). The type of analysis 
performed was consulted with biostatistician Dr. Claire Cameron and Mr. Andrew Gray from 
the Centre for Biostatistics (University of Otago). 
D’Agostino-Pearson and Shapiro-Wilk tests tested the assumption of the normal distribution of 
the data. Parametric tests (unpaired T-test, One-way, and Two-way ANOVA) were used if the 
data were normally distributed. Non-parametric tests (Mann-Whitney and Kruskal-Wallis test) 
were used if the data were not normally distributed. Then, a post-hoc analysis (such as Tukey’s 
and Sidak’s test) was performed for multiple’s group comparisons. The data are expressed as 
mean ± standard error of the mean (SEM), and the numbers of samples are presented as n.  A 




Chapter 3 : Characterization of cardiac NNCS and glucose 
transporters in the diabetic heart 
 
3.1 Introduction 
As described in chapter 1, cardiac NNCS regulates glucose metabolism by inducing GLUT-4 
expression [100, 122]. However, if this regulation is impaired in diabetes mellitus is unknown. 
Since glucose metabolism is diminished in the diabetic heart [48, 58, 61-63, 153, 154], this 
chapter investigated the hypothesis that cardiac NNCS could be dysregulated in the diabetic 
heart, and such dysregulation could occur in the early stage of diabetes. 
 
3.1.1 Cardiac dysfunction in the diabetic heart 
A reduction in diastolic function (i.e., myocardial relaxation) is one of the early diabetes-
induced alterations, which may later progress to systolic dysfunction and ultimately HF [20, 65, 
69, 155-159]. The incidence of diastolic dysfunction is usually high in the diabetic population 
with preserved systolic function [156, 160-162]. This prevalence is because the myocardial 
relaxation is a high ATP-consuming process while the myocardial energy status in the diabetic 
heart is reduced and unable to provide enough ATP to relax the chamber [21, 72, 163]. In 
addition, Gopal et al. [164] showed that impaired myocardial glucose oxidation was associated 
to the development of  diastolic dysfunction in a mouse model. Moreover, it has also been 
reported that increased circulating AGEs promotes cardiac fibrosis as well as LV stiffness, 
subsequently impairing the diastolic function [165-169]. Further, altered cardiac metabolism 
and energetics decreases cardiac efficiency and progressively decreases the contractile function 
of the diabetic heart [20, 65, 69, 159, 170]. Also, diabetes adversely alters the cardiac structure, 




3.1.2 Cardiac glucose transporters in the diabetic heart 
Glucose is the dominant fuel substrate for ATP production in the postprandial condition. The 
uptake of glucose is facilitated by glucose transporters (GLUTs) in an ATP-independent 
mechanism (reviewed in [175]). In the human heart, GLUT-4 is the most abundantly expressed 
GLUT in the LV, followed by GLUT-1 [132]. GLUT-4 is responsible for insulin-stimulated 
glucose uptake [176] while GLUT-1 is responsible for the basal glucose uptake [177]. In a 
pathological condition such as diabetes, GLUT-4 expression is reduced [58, 63, 153], thereby 
decreasing glucose uptake and oxidation [48, 61, 62, 154]. Such a reduction is caused by insulin 
resistance and elevated FFA oxidation [56-61, 79].  
 
3.1.3 Cardiac NNCS 
3.1.3.1 Bioavailability of ACh  
As outlined in Chapter 1, the cardiomyocytes possess an intrinsic cholinergic machinery. The 
functionality of this machinery can be categorized into three aspects – synthesis, release, and 
degradation of ACh. There are two components involved in ACh synthesis – namely ChAT and 
CHT1. ChAT is an enzyme involved in ACh synthesis by combining acetyl-CoA and choline 
[108]. CHT1 is a transporter that engages in the uptake of choline from extracellular space for 
ACh synthesis [99]. As choline is the precursor of ACh, the uptake of choline is the rate-limiting 
step for ACh synthesis (reviewed in [178]). ACh is stored and released from VAChT [96, 99]. 
Lastly, AChE is an enzyme present in extracellular space to hydrolyze ACh [96, 97, 108]. These 
components collectively maintain the homeostasis of ACh in cardiomyocytes.  
 
3.1.3.2 ACh mediated signaling through muscarinic ACh receptors (mAChR)  
ACh released from the cardiomyocytes mediates signaling via binding to the muscarinic ACh 
receptor (mAChR) expressed on the plasma membrane of cardiomyocytes. Thus far, five 
subtypes of mAChR (M1-5AChR) have been identified. In the human atrium and ventricle, the 
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gene expression of these five subtypes is readily detectable; however, the protein expression of 
M4AChR cannot be detected [112]. Furthermore, gene expression studies revealed that 
M2AChR is the predominant subtype in both the atrium and ventricle of the mouse and rat, 
however, the expression of other subtypes is relatively low [111, 179].  
The initiation of ACh-mAChR mediated signaling in the heart can be a result of both neuronal 
and non-neuronal ACh origin. The neuronal effect is initiated in the atrial region by ACh 
released from cholinergic neurons that decrease heart rate (HR) and cardiac contraction by 
modulating the activity ion channels [113, 180]. It is suggested that this neuronal effect is 
further amplified and propagated by the intrinsic cardiac NNCS [96, 97]. This could help in 
transmitting neuronal cholinergic signals in the sparsely innervated ventricular myocardium 
[181-185]. Besides, it is well established that M2AChR mediates this neuronal effect [113, 180], 
but emerging evidence suggests that M1- and M3AChR also play a role in regulating the HR 
and contraction [186, 187]. 
On the other hand, the non-neuronal effects induced by the cardiac NNCS include increased 
ACh synthesis through increased cardiomyocytes ChAT expression [96]; and activation of pro-
survival PI3K/Akt/HIF1α signaling cascade in the cardiomyocytes via auto/paracrine manner 
[96, 100]. It is still unknown which subtype of mAChR is responsible for the non-neuronal 
effect. However, it is reasonable to postulate that M2AChR is likely the main receptor 





3.2 Study aim 
The aims of this chapter are (1) to investigate the expression changes in cardiac NNCS (ChAT, 
CHT1, VAChT, AChE and M2AChR) and glucose transporters (GLUT-1 and GLUT-4) in the 
ventricles of type-2 diabetic db/db mouse and human, and (2) to investigate if the expression 
changes in cardiac NNCS precedes the expression changes in GLUT-4 in the ventricles of type-
2 diabetic db/db mouse of different ages.  
I hypothesized that the components of cardiac NNCS and GLUTs would be dysregulated - 
particularly (1) ChAT, CHT1, and VAChT expression would be decreased; (2) AChE 
expression would be increased, (3) M2AChR expression, as well as (4) GLUT-1 and GLUT-4 
expressions, would be decreased in the ventricles of diabetic db/db mouse and diabetic human. 
Further, I hypothesized that dysregulation of cardiac NNCS would precede the downregulation 
of GLUT-4 in the ventricles of diabetic db/db mice. 
 
3.3 Materials and methods 
This section only outlines the specific reagents, concentration, and conditions used for each of 
the general methodologies. Detailed experimental procedures for general methods are described 
in ‘Chapter 2: General materials and methods’. 
 
3.3.1 Type-2 diabetic db/db mouse  
The ventricular tissues from type-2 diabetic db/db mice of 8-, 12-, 16-, 20-, 24-, 28-, and 32-
weeks old were available [1] and used in this study to investigate the gene and protein 
expression changes in cardiac NNCS and GLUTs. These aged-matched non-diabetic db/+ mice 
(ND) were used as a control (see Section 2.2.2). The echocardiographic data of these ND and 




3.3.2 Type-2 diabetic human LV tissues 
The LV tissues taken from non-diabetic (ND-CAD) and type-2 diabetic (D-CAD) human 
patients who underwent coronary artery bypass graft were used in this study to investigate the 
protein expression changes in cardiac NNCS and glucose transporters (see Section 2.2.1). The 
corresponding echocardiographic data from ND-CAD and D-CAD patients were retrieved from 
the patient database of HeartOtago. 
 
3.3.3 Immunofluorescence analysis 
Triplet-labelling immunofluorescence of ChAT, GLUT-4 and CTNI was performed on ND 
mouse ventricular tissues, and followed by counterstained with DAPI (1:1,000) to stain nuclei 
(described in Chapter 2, Section 2.4). The purpose of performing multicolor 
immunofluorescence was to identify if ChAT and GLUT-4 are localized in the mouse 
ventricular cardiomyocytes. The specificity of anti-ChAT antibody was tested on the ventricular 
tissue of db/db-ChAT-tg mice (served as positive control; Appendix 3, Figure S3.1) while anti-
CTNI antibody was tested on the skeletal muscle of ND mouse (served as negative control; 
Appendix 3, Figure S3.2). Unfortunately, there was no appropriate control to test the specificity 
of anti-GLUT-4 antibody, hence, this is one of the limitations of the study.  
Besides, as anti-ChAT and anti-GLUT-4 primary antibodies were produced in rabbit (Table 
3.1), an additional blocking step is required to prevent the second secondary antibody from 
binding to the first primary antibody. In this case, after labeling ChAT with secondary antibody 
(Figure 3.1, step 2), the sections were incubated with 10% rabbit serum (Sigma-Aldrich, R9133; 
Figure 3.1, step 3) for two hours and followed by AffiniPure anti-rabbit Fab fragment (Jackson 
ImmunoResearch, 111-007-003; Figure 3.1, step 4) at 1:15 for two hours. In Appendix 3, Figure 
S3.3 shows the fluorescent images of co-labelling ChAT and GLUT-4 in the same ventricular 
tissue with and without AffiniPure anti-rabbit Fab fragment to demonstrate successful blocking. 
Besides, single staining of ChAT, GLUT-4 and CTNI on mouse ventricular tissues was 
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individually performed to serve as a control to compare with the images obtained from triple-
labelling staining (Appendix 3, Figure S3.4).  
 
 
Figure 3.1 Double labeling of primary antibodies produced from the same host species  
Immunostaining of ChAT was first performed (1-2) and followed by blocking with rabbit serum and Fab 
fragments (3-4). Then, immunostaining of GLUT4 was performed (5-6). The image was taken from 




Table 3.1 Information on antibodies for triplet-labelling immunofluorescence  
Antigen Source Dilution 
Manufacturer/Catalogue 
number 
Primary antibodies  
ChAT Rabbit 1:100 Abcam, AB181023 
GLUT-4 Rabbit 1:100 NovusBio, NBP1-49533 
CTNI (antibody is biotinylated) Mouse 1:100 NovusBio, NB110-2546B 
Secondary reagents 
AlexaFluor® 488 conjugated anti-rabbit IgG Goat 1:100 Invitrogen, A32731 
AlexaFluor® 633 conjugated anti-rabbit IgG Goat 1:200 Invitrogen, A21070 
Streptavidin-AlexaFluor® 568 - 1:200 Invitrogen, S11226 
 
3.3.4 Quantitative polymerase chain reaction (qPCR) analysis 
Total RNA extraction from the middle part of the mouse ventricular tissues was performed as 
described in Section 2.3.1.1. The isolated RNAs were treated with rDNase to remove genomic 
DNA and followed by reverse transcription (Section 2.3.1.2) and real-time amplification 
(Section 2.3.1.3) were performed to detect gene expression of ChAT, CHT1, VAChT, AChE, 
M2AChR, GLUT-1, and GLUT-4. The successful rDNase treatment was confirmed by directly 
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subjecting the rDNase-treated RNA to real-time amplification and ensuring no amplification 
(Appendix 1, Figure S1.1B). Also, gradient PCR was performed at annealing temperature of 
50⁰C, 54⁰C and 58.4⁰C (CHT1, AChE, M2AChR, GLUT-1, and GLUT-4) or 50⁰C, 55⁰C and 
60⁰C (ChAT and VAChT) to determine the optimal annealing temperature of each primer 
(Appendix 1, Figure S1.1A). Besides, the melt curve analysis showed the melting temperature 
of each PCR amplicons, which was used as an indicator to examine the specificity of PCR 
amplification (Appendix 1, Figure S1.1C). Table 3.2 summarizes the primer sequences, the 
primer binding exon-exon junction/exon, optimal annealing temperature, concentration and 
amplicon size. The gene expression of the selected target was normalized to the expression of 
reference gene RN18S and expressed as 2-ΔΔCt [142].  
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Table 3.2 Predesigned KiCqStart mouse primers used for qPCR amplification 










F= GGACAGCCAATCCATTCCCAC 6-7 55 0.2 
194 
R= CAAAGAACTGGTTGCAGCAGG 7-8 55 0.2 
CHT1 NM_022025 
F= TCAGACAAAATGCATCAGAC 8-9 54 1.0 
145 
R= ATGATGTAGACAAGGTCAGAG 9 54 1.0 
VAChT NM_021712 
F= ATGGCTGTGAGGACGACTAC NA 60 0.2 
149 
R= ACTCATTAGAGGAGGTGGGC NA 60 0.2 
M2AChR NM_203491 
F= AGTCAGTGACAGGTTTAAATG 2-3 54 0.2 
102 
R= GGACTGGTAATAGCCAAAC 3 54 0.2 
AChE NM_009599 
F= GTATCTTCCGATTTTCCTTCG 2 54 0.2 
99 
R= CCTGCAGGTCTTGAAAATC 2-3 54 0.2 
GLUT-1 NM_011400 
F= AAGTCCAGGAGGATATTCAG 10 54 0.2 
163 
R= CTACAGTGTGGAGATAGGAG 10 54 0.2 
GLUT-4 NM_009204 
F= CAATGGTTGGGAAGGAAAAG 3-4 54 0.2 
108 
R= AATGAGTATCTCATAGGAGGC 4 54 0.2 
RN18S NR_003278 
F= CAGTTATGGTTCCTTTGGTC NA 54-60 0.2 
198 
R= TTATCTAGAGTCACCAAGCC NA 54-60 0.2 
bp, basepair; Conc., Concentration; NA, Not applicable; Temp, Temperature
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3.3.5 Western blot analysis 
Total protein extraction from mouse (lower part) and human ventricular tissues was performed 
as described in Section 2.3.2.1. Ten micrograms of mouse and human protein samples were 
separated using SDS gel electrophoresis following which the membrane was probed for 
antibodies against ChAT, CHT1, VAChT, AChE, M2AChR, GLUT-1, and GLUT-4. The 
specificity of anti-AChE, anti-ChAT, anti-CHT1, anti-M2AChR and anti-VAChT antibodies 
were examined on a full blot with the use of positive control (i.e. mouse brain) and compared 
to the predicted molecular weight recommended by manufacturer and UniProt (Appendix 2, 
Figure S2.2-2.5). Unfortunately, there was no positive control to test anti-GLUT-1 and anti-
GLUT-4 antibodies, hence, this is one of the limitations of the study. The band intensity of the 
target protein was normalized to a prominent band between 37 kDa and 50 kDa on the Ponceau 
S stained blot as described in Chapter 2 (section 2.3.2.5) [143, 144] and expressed as fold 
changes towards the control group [145]. The information of antibodies are listed in Table 3.3. 
The full blot for each antibody is shown in Appendix 2. 
 











AChE  Rabbit/polyclonal 1:1,000 68 Bioss, BS-2511R 
ChAT Goat/polyclonal 1:1,000 70/74 
Chemicon, 
AB144P 
CHT1 Rabbit/polyclonal 1:1,000 70-75 
Merck Millipore, 
ABN458 
GLUT-1 Rabbit/polyclonal 1:1,000 54 
Merck Millipore, 
07-1401 
GLUT-4 Rabbit/polyclonal 1:1,000 55 
NovusBio, NBP1-
49533 
M2AChR Rabbit/monoclonal 1:1,000 52 Abcam, AB109226 




Anti-goat IgG, HRP 
conjugated 
Mouse 1:3,000 - 
Santa Cruz, 
SC2354 
Anti-rabbit IgG, HRP 
conjugated 





Recombinant mouse IgGҡ 
light chain binding 
protein, HRP conjugated 
- 1:3,000 - 
Santa Cruz, 
SC516102 
Note: the predicted molecular weight of protein is recommended by the manufacturer 
 
3.3.6 Statistical analyses 
All statistical analyses were performed using GraphPad Prism (version 7) in consultation with 
biostatistician Mr. Andrew Grey and Dr. Claire Cameron (Centre for Biostatistics, University 
of Otago). Data are expressed as the mean ± SEM. For the gene expression and protein 
expression data from the ND and db/db mice, there were data from some specific age groups 
that failed the normality test. However, there is no single non-parametric test equivalent to Two-
way ANOVA. In this case, a non-parametric Mann-Whitney U test was used. This particular 
approach was consulted with biostatistician Dr. Claire Cameron and Mr. Andrew Gray. Besides, 
unpaired T-test was used to analyze all the parameters of patient characteristics and western 





3.4.1 Characterization of cardiac NNCS and glucose transporters in the 
ventricles of type-2 diabetic db/db mice   
3.4.1.1 Cardiac function and structures 
The echocardiographic results of db/db mice have already been published [1]. The results 
shown here is for referencing purposes. The db/db mice showed a progressive deterioration of 
cardiac function with marked ventricular remodeling. The early diastolic dysfunction was 
observed at 20-weeks of age (i.e. E/A ratio and deceleration time; Figure 3.2A&B) and severely 
impaired at 28-weeks of age. The systolic function (i.e. EF and FS; Figure 3.2C&D) began to 
deteriorate at 20-weeks of age and gradually progress to systolic dysfunction at 28-weeks of 
age (EF<50%). In terms of the cardiac structure, cardiac hypertrophy as evidenced by an 
increase in LV mass developed at 16-weeks of age (Figure 3.2E). Subsequently, increased LV 
internal diameter at systole and diastole as well as increased relative wall thickness was 
observed at 20- and 24-weeks of age, respectively (Figure 3.2F-H). Changes in these indices 
indicate cardiac remodeling.  
 
 
Figure 3.2 Diabetes-induced progressive cardiac dysfunction and remodeling in the type-2 
diabetic db/db mice 
Line graphs showing the temporal changes of diastolic function indicated by (A) E/A ratio and (B) 
deceleration time; systolic function indicated by (C) ejection fraction (EF) and (D) fractional shortening 
(FS) as well as the temporal changes in LV structure indicated by (E) LV mass, (F) relative wall 




old db/db mice. Data are presented as mean ± SEM and are from eight animals in each group. Two-
way ANOVA with Tukey’s multiple comparisons test was performed.  *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001 VS age-matched ND (Non-diabetic) group. These results were collected and analyzed 
by Rawal et al. [1].  
 
3.4.1.2 Localization of ChAT and GLUT-4 in the ventricular tissue 
Triplet-labeling immunofluorescence was performed to co-stain the ventricular tissues with 
antibodies against ChAT and GLUT-4 together with cardiomyocyte-specific marker cardiac 
troponin-I (CTNI) and counterstained with DAPI (nuclear marker). The confocal image showed 
positive staining of CTNI in the mouse ventricular tissues (Figure 3.3A). Further, positive 
staining of ChAT was detected in the ventricular tissues, confirming that ChAT was expressed 
by the ventricular cardiomyocytes (Figure 3.3B, white arrows). The localization of GLUT-4 
was observed in two regions. First, intracellular GLUT-4 vesicles were close to the nucleus in 
the ventricular cardiomyocytes (Figure 3.3B, red arrows). Second, membrane GLUT-4 was on 
the surface of the ventricular cardiomyocytes (Figure 3.3B, yellow arrows). The representative 
images for secondary-antibody only controls for CTNI, ChAT, and GLUT-4 staining are in 
Appendix 3 (Figure S3.5). These findings confirm that ChAT and GLUT-4 were expressed and 
localized in the mouse ventricular cardiomyocytes.  
 
 
Figure 3.3 Localization of ChAT, GLUT-4, and CTNI in the mouse ventricular tissue 
The representative confocal images showing (A) the staining of CTNI as a cardiac marker and (B) the 
staining and localization of ChAT (white arrows), intracellular GLUT-4 (red arrows) and membrane 




3.4.1.3 Cardiac NNCS in the ventricles of type-2 diabetic db/db mice 
The next aim was to investigate if the cardiac NNCS is altered in diabetes mellitus. The gene 
and protein expression of the components of cardiac NNCS (i.e., ChAT, CHT1, VAChT, AChE, 
and M2AChR) were examined. The gene expression was measured by quantitative PCR 
analysis, while protein expression was measured by western blot analysis.  
 
3.4.1.3.1 ACh synthesis - ChAT  
Gene expression 
The expression changes in ChAT gene was not statistically different between the ND and db/db 
mice at 8- to 32-weeks of age (Figure 3.4A).  
 
Protein expression 
The goat anti-ChAT antibody resulted in multiple bands (Appendix 2, Figure S2.2). As the 
manufacturer recommends the ChAT-positive bands to be 70/74 kDa, and overexpression of 
ChAT gene in the ventricles (Chapter 4) and AC16 cells (Chapter 5) resulted in a strong band 
at 70 kDa. Thus, I quantified the band intensity from the area between 70 to 74 kDa. One 
possible reason why there were multiple bands could be due to post-translational modification.   
ChAT protein expression was not statistically different between the ND and db/db mice at 8-, 
12-, 16-, 20-weeks of age (Figure 3.4B). At 24-weeks of age, there was an increasing trend in 
ChAT expression (p=0.09). At 28-weeks of age, the expression was significantly decreased in 
the db/db mice, indicating a reduction in ACh synthesis and bioavailability. At 32-weeks of age, 






Figure 3.4 Decreased ChAT protein expression in the db/db mice at 28-weeks of age. 
(A) Quantitative bar graphs with scatter plot showing the gene expression of ChAT in the ND and db/db 
mice at 8- to 32-weeks of age. (B) Representative blots and quantitative bar graphs with scatter plot 
showing the protein expression of ChAT in the ND and db/db mice at 8- to 32-weeks of age. Data are 
presented as mean ± SEM. A non-parametric Mann-Whitney U test was performed. **p<0.01 VS age-




3.4.1.3.2 Reuptake of choline for ACh synthesis - CHT1  
Gene expression 
The expression changes in CHT1 gene was not statistically different between the ND and db/db 
mice at 8- and 12-weeks of age (Figure 3.5A). The expression was significantly increased in 
the db/db mice at 16-weeks of age. Subsequently, CHT1 gene expression was decreased in the 
db/db mice at 24-weeks of age. However, the gene expression was increased in the db/db mice 
at 32-weeks of age.  
 
Protein expression 
The anti-CHT1 antibody resulted in two bands between 70 to 75 kDa (Appendix 2, Figure S2.3). 
The manufacturer specified that the CHT1-positive bands can be 70 and 75 kDa. This is because 
one N-linked glycosylation site has been reported (https://www.uniprot.org/uniprot/Q9GZV3), 
thus, resulting in molecular weight of 75 kDa. In this case, I quantified the band intensity from 
the area between 70 to 75 kDa.  
CHT1 protein expression was not statistically different between the ND and db/db mice at 8-, 
12-, 16- and 20-weeks of age (Figure 3.5B). At 24-weeks of age, the expression was 
significantly increased in the db/db mice. An increase in CHT1 protein expression suggests 
increased uptake of choline for ACh synthesis, hence increasing the ACh bioavailability. At 28- 






Figure 3.5 Altered CHT1 gene and protein expression in the db/db mice at 16-, 24- and 32-weeks 
of age. 
(A) Quantitative bar graphs with scatter plot showing the gene expression of CHT1 in the ND and db/db 
mice at 8- to 32-weeks of age. (B) Representative blots and quantitative bar graphs with scatter plots 
showing the protein expression of CHT1 in the ND and db/db mice at 8- to 32-weeks of age. Data are 
presented as mean ± SEM. A non-parametric Mann-Whitney U test was performed. *p<0.05, **p<0.01 







3.4.1.3.3 ACh release - VAChT 
Gene expression 
The expression changes in VAChT gene was not statistically different between the ND and 
db/db mice at 8-, 12-, 16-, 20-, 24- and 32-weeks of age (Figure 3.6A). However, the gene 
expression was significantly increased in the db/db mice at 28-weeks of age. 
 
Protein expression 
The polyclonal anti-VAChT antibody resulted in multiple bands on blot (Appendix 2, Figure 
S2.3). The manufacturer recommends that the VAChT-positive band is approximately 70 kDa. 
Further, this particular antibody was used by Guzman et al. [188] and they did not detect a band 
in the striatum-specific VAChT knockout mice.  
VAChT expression was not statistically different between the ND and db/db mice at 8-, 12-, 
16- and 20-weeks of age (Figure 3.6B). However, the expression was significantly increased in 
db/db mice in comparison to the ND mice at 24- and 28-weeks of age. An increase in VAChT 
expression suggests increased ACh release, thus, increasing the ACh bioavailability in the 
extracellular space. At 32-weeks of age, the expression was significantly decreased, suggesting 





Figure 3.6 Altered VAChT gene and protein expression in the db/db mice at 24-, 28- and 32-weeks 
of age. 
(A) Quantitative bar graphs with scatter plot showing the gene expression of VAChT in the ND and 
db/db mice at 8- to 32-weeks of age. (B) Representative blots and quantitative bar graphs with scatter 
plots showing the protein expression of VAChT in the ND and db/db mice at 8- to 32-weeks of age. Data 
are presented as mean ± SEM. A non-parametric Mann-Whitney U test was. *p<0.05, **p<0.01 VS 
age-matched ND mice. The number of samples per group is indicated in the figure. 
 
3.4.1.3.4 ACh degradation - AChE 
Gene expression 
The expression changes in AChE gene was not statistically different between the ND and db/db 




namely AChE-S (synaptic variant), AChE-R (readthrough variant) and AChE-E (erythrocytic 
variant) (reviewed in [189]). The primers used in this study is unable to differentiate these 
variants as the primers anneal to exon 2 (forward primer) and exon 2-3 junction (reverse primer) 
that are commonly present in all variants (reviewed in [189]). However, it has previously been 
reported that AChE-S is present in the heart [190]. 
 
Protein expression 
Although the polyclonal anti-AChE antibody resulted in multiple bands, I observed only one 
band around 75 kDa on the blot (Appendix 2, Figure S2.4). I identified this band as AChE-
positive as the predicted molecular weight is approximately 68 kDa.  
AChE protein expression was significantly increased in the db/db mice at 8-weeks of age 
(Figure 3.7B). This result indicates an increase in ACh degradation, and hence the ACh 
bioavailability was possibly decreased. At 12-, 16- and 24-weeks of age, the expression was 
not statistically different between the ND and db/db mice. However, at 20-, 28- and 32-weeks 
of age, AChE expression was significantly decreased in the db/db mice compared to the age-
matched ND mice. This result indicates a reduction in ACh degradation, and thus the ACh 






Figure 3.7 Altered AChE protein expression in the db/db mice at 8-, 20-, 28- and 32-weeks of age. 
(A) Quantitative bar graphs with scatter plot showing the gene expression of AChE in the ND and db/db 
mice at 8- to 32-weeks of age. (B) Representative blots and quantitative bar graphs with scatter plots 
showing the protein expression of AChE in the ND and db/db mice at 8- to 32-weeks of age. Data are 
presented as mean ± SEM. A non-parametric Mann-Whitney U test was performed. *p<0.05, **p<0.01 




3.4.1.3.5 ACh binding receptor - M2AChR 
Gene expression 
The expression changes in M2AChR gene was not statistically different between the ND and 
db/db mice at 8- to 32-weeks of age (Figure 3.8A).  
 
Protein expression 
The monoclonal anti- M2AChR antibody detected only one band that was close to 50 kDa on 
the blot (Appendix 2, Figure S2.2). I identified this band as M2AChR-positive as the predicted 
molecular weight is approximately 52 kDa. 
M2AChR protein expression was significantly decreased in the 8- to 32-weeks old db/db mice 
(Figure 3.8B). This result suggests reduced receptor density for ACh binding, and thus ACh 






Figure 3.8 Decreased M2AChR protein expression in the db/db mice at 8- to 32-weeks of age. 
(A) Quantitative bar graphs with scatter plot showing the gene expression of M2AChR in the ND and 
db/db mice at 8- to 32-weeks of age. (B) Representative blots and quantitative bar graphs with scatter 
plots showing the protein expression of M2AChR in the ND and db/db mice at 8- to 32-weeks of age. 
Data are presented as mean ± SEM. A non-parametric Mann-Whitney U test was performed. *p<0.05, 
**p<0.01 VS age-matched ND mice. The number of samples per group is indicated in the figure. 
 
In summary, the findings from this section show that (1) CHT1 and VAChT gene expression 
and (2) ChAT, CHT1, VAChT, AChE, and M2AChR protein expression were altered in the 





3.4.1.4 GLUTs in the ventricles of type-2 diabetic db/db mice 
Since insulin resistance decreases cardiac glucose utilization, the next aim was to investigate if 
T2DM affects GLUT-1 and GLUT-4 expressions in the ventricles of diabetic db/db mice. 
Quantitative PCR and western blot analyses were carried to measure the gene and protein 
expression of GLUT-1 and GLUT-4.  
 
3.4.1.4.1 Basal glucose uptake - GLUT-1 
Gene expression 
The expression changes in GLUT-1 gene was not statistically different between the ND and 
db/db mice at 8- to 32-weeks of age (Figure 3.9A).  
 
Protein expression 
The polyclonal ani-GLUT1 antibody detected multiple bands, however, there was only one 
band between 50 kDa and 75 kDa (Appendix 2, Figure S2.5). Thus, I identified this band as 
GLUT-1 positive based on the predicted molecular weight indicated by the manufacturer and 
UniProt. Further, Linz et al [191] used the same antibody and reported the same result.  
There was an increasing trend in the GLUT-1 protein expression (p=0.09) in the db/db mice at 
8-weeks of age (Figure 3.9B). At the 12-weeks of age, the expression was not statistically 
different between the ND and db/db mice. At 16- to 32-weeks of age, GLUT-1 expression was 
significantly decreased in the db/db mice in comparison to the age-matched ND mice. This 





Figure 3.9 Decreased GLUT-1 protein expression in the db/db mice at 16- to 32-weeks of age. 
(A) Quantitative bar graphs with scatter plot showing the gene expression of GLUT-1 in the ND and 
db/db mice at 8- to 32-weeks of age. (B) Representative blots and quantitative bar graphs with scatter 
plots showing the protein expression of GLUT-1 in the ND and db/db mice at 8- to 32-weeks of age. 
Data are presented as mean ± SEM. A non-parametric Mann-Whitney U test was performed. **p<0.01 




3.4.1.4.2 Insulin-stimulated glucose uptake - GLUT-4 
Gene expression 
The expression changes in GLUT-4 gene were not statistically different between the ND and 
db/db mice at 8- to 32-weeks of age (Figure 3.10A).  
 
Protein expression 
The polyclonal anti-GLUT-4 antibody detected multiple bands on the blot (Appendix 2, Figure 
S2.5). As the predicted molecular weight is 55 kDa, I identified the band that was closest to 50 
kDa as GLUT-4-positive.  
GLUT-4 protein expression was significantly increased in the db/db mice at 8-weeks of age 
(Figure 3.10B). At 12- and 16-weeks of age, the expression was not statistically different 
between the ND and db/db mice. However, GLUT-4 expression was significantly decreased in 
the db/db mice at 20-weeks of age, indicating decreased insulin-stimulated glucose uptake. 
Interestingly, there was an increasing trend in GLUT-4 expression in the db/db mice at 24-
weeks of age. Subsequently, the expression was significantly decreased in the db/db mice at 






Figure 3.10 Altered GLUT-4 protein expression in the db/db mice at 8-, 20-, 28- and 32-weeks of 
age. 
(A) Quantitative bar graphs with scatter plot showing the gene expression of GLUT-4 in the ND and 
db/db mice at 8- to 32-weeks of age. (B) Representative blots and quantitative bar graphs with scatter 
plots showing the protein expression of GLUT-4 in the ND and db/db mice at 8- to 32-weeks of age. 
Data are presented as mean ± SEM. A non-parametric Mann-Whitney U test was performed. *p<0.05, 





In summary, the findings from this section show that GLUT-1 and GLUT-4 gene expression 
were not altered in the ventricles of db/db mice. However, GLUT-1 and GLUT-4 protein 
expression were altered in the ventricles of db/db mice.  
 
3.4.2 Characterization of cardiac NNCS and glucose transporters in the 
ventricles of type-2 diabetic human patients 
3.4.2.1 Clinical characteristic of type-2 diabetic human patients 
Table 3.4 lists the metabolic, hemodynamic, cardiac function, and left ventricular (LV) 
structural profile of ND-CAD and D-CAD patients used in this study. D-CAD patients had 
increased BMI (p=0.006) and high level of glycated hemoglobin level (HbA1C, p>0.0001) 
compared to ND-CAD patients. The functional profile based on LV end-diastolic volume 
(LVEDV), LV end-systolic volume (LVESV), heart rate (HR), stroke volume (SV), cardiac 
output (CO), the diastolic function (i.e. E/A ratio, E/e’ ratio and deceleration time (decT)) and 
systolic function (i.e. ejection fraction and fractional shortening) were comparable between 
ND-CAD and D-CAD patients. Interestingly, the D-CAD patients exhibited diabetes-induced 
ventricular remodeling, as evidenced by significantly increased LV internal diameter at diastole 
(LVIDd, p=0.006). It is noteworthy that most of the patients in this study were treated with 
statins, beta-blockers, ACE inhibitors, calcium channel blockers. Additionally, D-CAD patients 







Table 3.4 Patient characteristic 
 ND-CAD (n=21) D-CAD (n=16) p-value 
Age (year) 71.2 ± 1.6 70.7 ± 2.1 0.8 
Gender (male/female) 15/6 12/4  
Metabolic profile 
BMI (kg/m2) 28.0 ± 0.9 33.2 ± 1.7 <0.01** 
Diabetic duration (years) - 12.2 ± 1.5  
HbA1C (mmol/mol) 38.1 ± 0.7 55.1 ± 2.7 <0.0001***** 
Hemodynamic profile 
LVEDV (mL) 91.3 ± 7.3 107.9 ± 10.6 0.22 
LVESV (mL) 41.1 ± 4.7 49.2 ± 4.2 0.3 
HR (beats/min) 69.7 ± 2.3 68.1 ± 2.3 0.63 
SV (mL) 50.2 ± 3.4 58.7 ± 7.8 0.25 
CO (L/min) 3.5 ± 0.2 3.9 ± 0.5 0.35 
Diastolic profile 
E/A 1.0 ± 0.1 0.8 ± 0.1 0.43 
E/e’ 11.8 ± 0.9 12.2 ± 1.8 0.84 
decT (msec) 251.1 ± 13.4 273.3 ± 22.8 0.38 
Systolic profile 
Ejection fraction (%) 56.4 ± 2.1 51.1 ± 2.0 0.08 
Fractional shortening (%) 32.9 ± 1.8 32.4 ± 2.1 0.86 
Ventricular structure 
IVSd (cm) 1.2 ± 0.1 1.3 ± 0.1 0.44 
LVPWd (cm) 1.0 ± 0.05 1.0 ± 0.1 0.92 
LVIDd (cm) 4.2 ± 0.1 4.9 ± 0.2 <0.001** 
LVIDs (cm) 2.9 ± 0.1 3.3 ± 0.2 0.059 
Medications 
Statins 15/21 (71%) 15/16 (94%)  
Beta-blockers 17/21 (81%) 14/16 (88%)  
ACE inhibitors 11/21 (52%) 13/16 (81%)  
Calcium channel blocker 5/21 (24%) 9/16 (56%)  
Anti-diabetic agents  0/21 (0%) 11/16 (69%)  
BMI, Body mass index; HbAIC, Glycated hemoglobin; LVEDV, Left ventricular end-diastolic volume; 
LVESV, Left ventricular end-systolic volume; HR, Heart rate; SV, Stroke volume; CO, Cardiac output; 
E, Early ventricular filling velocity; A, Late ventricular filling velocity; e’, Early ventricular 
myocardium relaxation velocity; decT, Early ventricular deceleration time; IVSd, Interventricular 
septal diameter diastole; LVPWd, Left ventricular posterior wall thickness at diastole; LVIDd, Left 
ventricular internal diameter at diastole; LVIDs, Left ventricular internal diameter at systole. Unpaired 
T-test was performed. **p<0.01; *****p<0.00001 VS ND-CAD patients. 
 
3.4.2.2 Cardiac NNCS in the ventricles of type-2 diabetic human patients 
Having confirmed that the cardiac NNCS was altered in the type-2 diabetic db/db mice, the next 
aim was to assess the protein expression of ChAT, CHT1, VAChT, AChE, and M2AChR in the 




detect these targets in human LV tissues and the specificity of these antibodies and the reason 
to quantify multiple bands (i.e. ChAT and CHT1) have been discussed in previous section.  
 
3.4.2.2.1 ACh synthesis - ChAT  
There was a decreasing trend in ChAT protein expression (p=0.058) in D-CAD patients. 
However, it was not statistically significant (Figure 3.11).  
 
 
Figure 3.11 Unaltered ChAT protein expression in the LV tissues of D-CAD patients.   
Representative blots and quantitative bar graphs with scatter plots showing the protein expression of 
ChAT. Data are presented as mean ± SEM. Unpaired T-test was performed. The number of samples per 
group is indicated in the figure. 
 
3.4.2.2.2 Reuptake of choline for ACh synthesis - CHT1 
CHT1 protein expression was significantly decreased in D-CAD patients (Figure 3.12). This 
result suggests a reduction in reuptake of choline for ACh synthesis. Hence the ACh 
bioavailability was reduced.  
 
     
Figure 3.12 Decreased CHT1 protein expression in the LV tissues of D-CAD patients.   
Representative blots and quantitative bar graphs with scatter plots showing the protein expression of 
CHT1. Data are presented as mean ± SEM. Unpaired T-test was performed. *p<0.05 VS ND-CAD 





3.4.2.2.3 ACh release - VAChT 
The VAChT protein expression was not altered in the D-CAD patients in comparison to the 
ND-CAD patients (Figure 3.13).  
 
 
Figure 3.13 Unaltered VAChT protein expression in the LV tissues of D-CAD patients. 
Representative blots and quantitative bar graphs with scatter plots showing the protein expression of 
VAChT. Data are presented as mean ± SEM. Unpaired T-test was performed. The number of samples 
per group is indicated in the figure. 
 
3.4.2.2.4 ACh degradation - AChE 
The AChE protein expression was not altered in the D-CAD patients in comparison to the ND-
CAD patients (Figure 3.14).  
 
 
Figure 3.14 Unaltered AChE protein expression in the LV tissues of D-CAD patients. 
Representative blots and quantitative bar graphs with scatter plots showing the protein expression of 
AChE. Data are presented as mean ± SEM. Unpaired T-test was performed. The number of samples per 






3.4.2.2.5 ACh binding receptor - M2AChR 
The M2AChR protein expression was not altered in the D-CAD patients in comparison to the 
ND-CAD patients (Figure 3.15).  
 
 
Figure 3.15 Unaltered M2AChR protein expression in the LV tissues of D-CAD patients. 
Representative blots and quantitative bar graphs with scatter plots showing the protein expression of 
M2AChR. Data are presented as mean ± SEM. Unpaired T-test was performed. The number of samples 
per group is indicated in the figure. 
 
In summary, the findings from this section show that CHT1 protein expression was decreased 
in the D-CAD human LV tissues, while the protein expression changes in ChAT, VAChT, 
AChE, and M2AChR were not statistically different.  
 
3.4.2.3 GLUTs in the ventricles of type-2 diabetic human patients  
Having confirmed that GLUT-1 and GLUT-4 protein expression were decreased in the db/db 
mice, the next aim was to examine the protein expression of these GLUTs in the ventricles of 
diabetic human patients by western blot analysis. Note: I used the same antibodies to detect 
these targets in human LV tissues and the specificity of these antibodies have been discussed in 
previous section 
 
3.4.2.3.1 Basal glucose uptake - GLUT-1 
The GLUT-1 protein expression was not altered in the D-CAD patients in comparison to the 






Figure 3.16 Unaltered GLUT-1 protein expression in the LV tissues of D-CAD patients. 
Representative blots and quantitative bar graphs with scatter plots showing the protein expression of 
GLUT-1. Data are presented as mean ± SEM. Unpaired T-test was performed. The number of samples 
per group is indicated in the figure. 
 
3.4.2.3.2 Insulin-stimulated glucose uptake - GLUT-4 
The GLUT-4 protein expression was significantly decreased in the D-CAD patients, suggesting 
a reduction in insulin-stimulated glucose uptake (Figure 3.17). 
 
 
Figure 3.17 Decreased GLUT-4 protein expression in the LV tissues of D-CAD patients. 
Representative blots and quantitative bar graphs with scatter plots showing the protein expression of 
GLUT-4. Data are presented as mean ± SEM. Unpaired T-test was performed. **p<0.01 VS ND-CAD 
patients. The number of samples per group is indicated in the figure. 
 
In summary, the findings from this section show that GLUT-4 protein expression, but not 






In this chapter, the expression changes in the components of cardiac NNCS (i.e., ChAT, CHT1, 
VAChT, AChE, and M2AChR), GLUT-1 and GLUT-4 were examined in the mouse model for 
type-2 diabetes represented by the db/db mouse. A recent publication from Katare laboratory 
showed that these db/db mice developed cardiac structural remodeling accompanied with 
activation of fetal genes, diastolic dysfunction, and systolic dysfunction at 16-, 20- and 28-
weeks of age, respectively [1]. In another part of the study, human LV tissues from diabetic 
patients were investigated. The cardiac function and LV structural parameters measured by 
echocardiography were obtained from HeartOtago. One key reason of using both db/db mice 
and human LV tissues in this study is that the db/db mice of different ages allowed me to 
examine the expression changes in the components of cardiac NNCS over the progression of 
T2DM, which is not feasible in a human study. The young db/db mice (8- to 12-weeks of age) 
could represent the individuals with asymptomatic diabetes and remains undiagnosed for years, 
while the db/db mice at 16- to 24-weeks of age could represent the diabetic individuals with 
clinical symptoms such as marked hyperglycemia, polyuria, polydipsia, weight loss and 
potential complications such as diastolic dysfunction and diabetic cardiomyopathy [192]. Lastly, 
the db/db mice at 28- to 32-weeks of age could represent the diabetic individuals with end-stage 
complications such as heart failure (reviewed in [193]). However, the development of end-stage 
complications is often delayed/prevented in most of the diabetic individuals due to anti-diabetic 
therapy such as metformin (reviewed in [194]).  
I hypothesized that cardiac NNCS, particularly (1) ChAT, CHT1, VAChT, and M2AChR 
expression would be decreased while (2) AChE expression would be increased; as well as (4) 
GLUT-1 and GLUT-4 expressions would be reduced in the ventricles of both diabetic mouse 
and human patients. Apart from this, I hypothesized that dysregulation of cardiac NNCS would 
precede the decrease in GLUT-4 expression in the ventricles of db/db mice. The main findings 





1. db/db mice:  
• Cardiac function profile: 
o Diastolic and systolic dysfunction was remarkably evident at 20- and 28-weeks 
of age, respectively 
• Gene expression:  
o Cardiac NNCS: 
▪ At 16-weeks of age, CHT1 expression was increased 
▪ At 24-weeks of age, CHT1 expression was decrased 
▪ At 28-weeks of age, VAChT expression was increased 
▪ At 32-weeks of age, CHT1 expression was increased  
o GLUTs: 
▪ No changes in GLUT-1 and GLUT-4 
• Protein expression: 
o Cardiac NNCS:  
▪ At 8-weeks of age, AChE expression was increased while M2AChR 
expression was decreased 
▪ At 12- and 16-weeks of age, M2AChR expression was decreased 
▪ At 20-weeks of age, AChE and M2AChR expression were decreased 
▪ At 24-weeks of age, CHT1 and VAChT expression were increased while 
M2AChR expression was decreased 
▪ At 28-weeks of age, ChAT, AChE and M2AChR expression were 
decreased while VAChT expression was increased 






▪ At 8-weeks of age, GLUT-4 expression was increased 
▪ At 16-weeks of age, GLUT-1 expression was decreased 
▪ At 20-weeks of age, GLUT-1 and GLUT-4 expression were decreased 
▪ At 24-weeks of age, GLUT-1 expression was decreased 
▪ At 28- and 32-weeks of age, GLUT-1 and GLUT-4 expression were 
decreased 
 
2. Diabetic human patients: 
• Significant increase in BMI and HbA1C level 
• No sigificant changes in cardiac function 
• LV remodelling was evident by increased LVIDd  
• CHT1 expression was decreased 
• GLUT-4 expression was decreased 
 
The findings from gene and protein expression are not well correlated (e.g. Table 3.5: CHT1 
expression at 24-weeks of age; or increased CHT1 gene expression but no change in protein 
expression at 16-weeks of age), suggesting that regulation of gene and protein expression of 
cardiac NNCS and GLUTs could be independent in the ventricles of diabetic heart. Another 
possible reason could be because of the different region of ventricles used for RT-qPCR and 
western blot analysis (Section 2.2.1, Figure 2.2). However, the underlying reason for this is not 
exactly clear. Considering that ACh released from cholinergic neurons can stimulate the 
cholinergic machinery in the cardiomyocytes [96], the presence and extend of cholinergic 
innervation in the epicardium and endocardium of ventricles could contribute to the difference 
in expression changes of RNA and protein [195-201]. In line with this, previous study showed 
that the thickness of epicardial AChE-positive nerves (i.e. parasympathetic nerves) decreases 




thoroughly examine the correlationship between the changes in parasympathetic nerve 
thickness and expression of cardiac NNCS. Additionally, Rana et al. [108] showed that there is 
not difference in the gene and protein expression of ChAT, VAChT and CHT1 between the left 
and right ventricles, thus ruling out the possible contribution from the left and right ventricles. 
Nonetheless, due to the divergent expression changes between the gene and protein, the 




Table 3.5 Summary of gene and protein expression changes in the components of cardiac NNCS and GLUTs in the ventricles of diabetic mouse and  human 
patients.  
T2DM progression 
in db/db mice 




Diastolic dysfunction [1] Systolic dysfunction [1] D-CAD 
patients 
8W 12W 16W 20W 24W 28W 32W 
Cardiac NNCS 
ChAT         
CHT1                     
VAChT                     
AChE         
M2AChR         
GLUTs 
GLUT-1         
GLUT-4         





3.5.1 Dysregulation of cardiac NNCS expression in DM 
As outlined in Chapter 1, altered cardiac metabolism is indicated by a reduction in glucose 
uptake and oxidation with a concomitant increase in FFA uptake and oxidation in the diabetic 
heart [20, 48-51, 65, 159]. Further, the reduction in glucose uptake is associated with decreased 
GLUT-4 expression in the diabetic heart [58, 61, 63, 153]. Besides, elevated FFA oxidation 
decreases cardiac efficiency (a ratio between cardiac work/MVO2) and basal myocardial energy 
status, thus contributing to cardiac dysfunction in the diabetic heart [19-21, 65-68, 70-72]. 
Notably, Kakinuma et al. [100] demonstrated that increased ACh bioavailability through 
activation of cardiac NNCS promoted glucose metabolism by increasing GLUT-4 expression 
in the ChAT-tg mice. Importantly, the shift of fuel substrate to glucose increased ATP 
production, decreased oxygen consumption, and mitochondrial activity in the in-vitro and in-
vivo model of cardiac NNCS [96, 100, 122]. 
In my study, the cardiac NNCS was dysregulated at 8- to 16-weeks of age, as evidenced by 
increased AChE expression (8-weeks of age; Figure 3.7B) and decreased M2AChR expression 
(8- to 16-weeks of age; Figure 3.8B). Further, GLUT-4 expression was significantly reduced in 
the db/db mice at 20-weeks of age (Figure 3.10B). In addition, the db/db mice progressively 
developed diastolic and systolic dysfunction at 20- and 28-weeks of age, respectively [1]. In 
line with this, ChAT (Figure 3.11, p=0.058), CHT1 (Figure 3.12), GLUT-4 expression (Figure 
3.17) were decreased in the D-CAD patients, suggesting that reduced ACh bioavailability from 
cardiac NNCS could be related to the reduction of GLUT-4 expression in the diabetic heart. 
However, the diastolic and systolic functions of D-CAD patients were not different from that 
of the ND-CAD patients, which may be due to the prescribed medications masking the effect 
of DM on cardiovascular function (Table 3.4). Also, the changes in the components of cardiac 
NNCS were different in diabetic human patients and db/db mice. This discrepancy could be 
species-specific, but the reduced ACh bioavailability could possibly be the common outcome 




demonstrated the causal relationship between cardiac NNCS and GLUT-4 and based on the 
expression profiles obtained from my study, it is logical to postulate that early dysregulation of 
cardiac NNCS, together with insulin resistance, could contribute to reduced GLUT-4 
expression and glucose uptake in the diabetic heart.  
Apart from this, the db/db mice used in my study displayed a significant increase in LV mass 
at 16-weeks of age (Figure 3.1;[1]). The hypertrophied heart of these db/db mice showed a 
significant decreased α-myosin heavy chain (α-MHC) and increased β-myosin heavy chain (β-
MHC) expression, indicating the development of cardiac remodeling in the diabetic heart [1]. 
Further, the D-CAD patients showed increased LVIDd (Table 3.4), which is an indication of 
ventricular dilation [202]. Other parameters such as IVSd, LVPWd, and LVIDs were 
comparable between the ND-CAD and D-CAD patients. However, as the ND-CAD and D-
CAD patients had already had coronary artery disease, the extent of the altered cardiac structure 
may be similar in both groups. Also, medications such as ACE inhibitors or beta-blockers that 
was prescribed to most of the patients could have prevented diabetes-induced cardiac 
remodeling [203, 204]. Thus, the diabetes-induced LV structural changes may not be obvious.  
Although metabolic derangements and insulin resistance are the known contributing factors to 
cardiac remodeling in diabetes [171-174, 205, 206], the underlying mechanism of how diabetes 
leads to cardiac remodeling is yet to be elucidated. Previous studies showed that a reduction of 
ACh bioavailability through inactivation of cardiac NNCS resulted in hypersympathetic-
induced cardiac hypertrophy and molecular remodeling (i.e., increased β-MHC expression) in 
the rodent models [97, 99, 101, 124]. Conversely, increased ACh bioavailability through 
activation of cardiac NNCS prevented cardiac hypertrophy induced by MI in the ChAT-tg mice 
[100], suggesting that cardiac NNCS plays a role in offsetting hypertrophic signals. 
Interestingly, in my study, dysregulation of cardiac NNCS (increased AChE and decreased 
M2AChR expression at 8- to 16-weeks of age) preceded the LV hypertrophy and molecular 




NNCS could contribute to the development of LV hypertrophy and remodeling in the diabetic 
heart. However, further investigation is certainly needed to examine the role of cardiac NNCS 
in cardiac remodeling in the diabetic heart.  
 
3.5.2 The compensatory effect of cardiac NNCS in the diabetic heart 
In the diabetic db/db mice, decreased AChE expression (20-weeks of age; Figure 3.7B) and 
increased CHT1 and VAChT expression (24-weeks of age; Figure 3.5B and 3.6B) coincided 
with diastolic dysfunction [1]. Although M2AChR expression remained decreased at 20- and 
24-weeks of age (Figure 3.8B), the modulation of AChE, CHT1, and VAChT expression was 
likely able to boost the ACh bioavailability collectively. These changes would, in turn, activate 
M2AChR-mediated signaling and result in non-neuronal effects (i.e., increased ChAT 
expression for ACh synthesis and PI3K/Akt/HIF1α pathway for survival) to compensate the 
diabetic heart with diastolic dysfunction. 
The non-neuronal effects were observed in the db/db mice at 24-weeks of age. The effect was 
evidenced by an increasing trend in the ChAT (Figure 3.4B) and GLUT-4 expression (Figure 
3.10B). In line with this, Kakinuma et al. [100] showed that overexpression of the ChAT gene 
in the ventricles increased ACh bioavailability and in turn, shifted the cardiac metabolism to 
glucose-dependent by increasing GLUT-4 expression. Thus, this suggests that the diabetic 
cardiomyocytes modulated cardiac NNCS, possibly to increase ACh bioavailability, which in 
turn promoted glucose uptake and oxidation for ATP production to sustain the contractile 
function. However, the measurement of cardiac ACh, glucose, and ATP content is undoubtedly 
required to confirm this postulation. Additionally, these findings also suggest that cardiac 
NNCS-mediated signaling remained intact and functional in the diabetic heart.  
Apart from this, such compensatory effect through increasing ACh bioavailability has been 
reported previously [101, 207]. Roy et al. [101] showed that cardiac VAChT expression was 




Kanazawa et al. [207] showed that cardiac sympathetic neurons transdifferentiated into 
cholinergic neurons in the LV of chronic HF patients and rat model. The cholinergic 
transdifferentiation suggests a compensatory mechanism to enhance ACh bioavailability in the 
failing heart. Thus, these findings underscore the vital role of ACh in the diseased heart. 
Modulation of cardiac NNCS is one of the mechanisms to increase the ACh bioavailability in 
the heart.  
Importantly, the compensatory effect of cardiac NNCS is likely to be transient in the diabetic 
heart. The decline in cardiac NNCS machinery was evidenced by decreased ChAT expression 
in parallel with decreased AChE and increased VAChT expression in the db/db mice at 28-
weeks of age. Further, decreased VAChT and AChE expression was observed in the db/db mice 
at 32-weeks of age. Gavioli et al. [124] showed that cardiomyocytes decreased ChAT, VAChT, 
and M2AChR gene expression after subjecting to AChE inhibitor to increase ACh content. Thus, 
it is logical to postulate that the diabetic cardiomyocytes decreased ChAT and VAChT 
expression to prevent excessive ACh production, thus maintaining ACh homeostasis. Figure 
3.18 summarizes the expression changes of ChAT, CHT1, VAChT, and AChE that are involved 






Figure 3.18 Summary of expression changes in the components of cardiac NNCS that are 
associated with the ACh bioavailability in the db/db mice. 
The cardiomyocytes can synthesize, release, and degrade ACh. In early DM, the AChE expression was 
increased. In response to diastolic dysfunction, CHT1 and VAChT expression were increased to enrich 
the diabetic heart with ACh for protective effects. In late DM, the diabetic cardiomyocytes decreased 
ChAT and VAChT expression to reduce ACh bioavailability to maintain ACh homeostasis while AChE 
expression remained decreased.  
 
 
Although the advantage of using db/db mice of different ages allowed me to examine the 
temporal expression changes in the components of cardiac NNCS, the results require careful 
interpretation. As there was an interval of 4-weeks between the mice of different age group and 
it is also logical that protein expression would take less than 4-weeks to change in the 
cardiomyocytes [208], this raises the question that whether the temporal changes represent the 
genuine biological changes in the db/db mice. Thus, future study should consider examining 
the temporal expression changes in a shorter age interval (e.g. difference of 1-week) and this 
would better represent the biological changes in cardiac NNCS and allow precise data 
interpretation. 
Besides, the underlying mechanism of such temporal expression changes in the diabetic db/db 
mouse heart is not entirely clear. Whether T2DM per se alters the expression of these 
component at different stages of disease or the expression changes in one component lead to 
the expression changes of other components, this requires further investigation. Since AChE 
expression was first increased in the db/db mice at 8-weeks of age (Figure 3.18), one possible 
experiment to clarify the effect of T2DM could be achieved by injecting the AChE inhibitor 
such as physostigmine to inhibit the activity of AChE. If such inhibition does not prevent the 
expression changes of other components in later time point, this suggests that T2DM alone 
possibly influences the different components of cardiac NNCS as the disease progresses.  
On a side note, Oikawa et al. [209] reported that cardiac NNCS possess a circadian rhythm that 
is similar to the neuronal cholinergic system (i.e. increased ChAT expression and ACh 




mice). However, the db/db mice and the age-matched ND mice were culled together between 3 
pm to 4 pm (described in Section 2.2.1), hence, the influence of circadian rhythm in altering 
the expression of cardiac NNCS can be ruled out.  
 
3.5.3 Altered glucose transporters expression in the diabetic heart 
My findings showed a time-dependent increase and decrease in GLUTs in the diabetic mouse 
heart. The GLUT-4 expression was significantly increased in the db/db mice at 8-weeks of age 
(Figure 3.10B). Also, there was an increasing trend in GLUT-1 expression (not statistically 
significant, Figure 3.9B). Considering that glucose uptake and oxidation are reduced in the 
diabetic heart [20, 55, 210-214], the increase in GLUT-1 and GLUT-4 expression could be a 
compensatory effect to restore glucose uptake in the diabetic heart.  
Progressively, GLUT-1 and GLUT-4 expression were significantly decreased in the db/db mice 
at 16- and 20-weeks of age, respectively, suggesting decreased basal and insulin-stimulated 
glucose uptake in the diabetic heart (Figure 3.9B and 3.10B). A reduction of GLUT-1 has 
previously been reported in a T1DM mouse model [215], while my study showed the reduction 
of GLUT-1 expression in a T2DM mouse model. However, GLUT-1 expression did not change 
in the diabetic human heart (Figure 3.16). Thus, whether GLUT-1 plays a role in the 
pathophysiology of T2DM is yet to be elucidated. Besides, previous studies showed that GLUT-
4 expression was decreased in the diabetic animal models [20, 58, 63, 153] and diabetic human 
[61]. These are in agreement with my study that GLUT-4 expression was indeed decreased in 
the diabetic db/db mouse and the diabetic human heart.  
Although the cardiac glucose content and glucose oxidation were not measured in this study, 
the reduction in GLUT-1 and GLUT-4 expression is likely to reduce glucose uptake and 
oxidation [20, 48, 59, 61, 154, 159]. Notably, GLUT-4 expression was normalized in the db/db 








Figure 3.19 The association of cardiac NNCS with GLUT-4 expression in the diabetic heart.  
The cardiac NNCS activity was decreased in the db/db mice at 8- to 16-weeks of age, while GLUT-4 
expression was decreased at 20-weeks of age. The increase in cardiac NNCS activity started from 20-
week of age while the rise in GLUT-4 protein expression was detected in 24-weeks of age. This may 
indicate a compensatory role of cardiac NNCS by promoting glucose metabolism through regulating 
GLUT-4 expression to protect the diabetic heart against diastolic dysfunction.  
 
3.6 Limitations 
3.6.1 Assessing other possible components of cardiac NNCS 
Although the cardiac cholinergic machinery has been completely established, it is still 
worthwhile to explore other proteins that could be involved in this machinery. Electrogenic 
cation transporters (OCTs) are engaged in ACh release in placental cells [216], urothelial cells 
[217], and airway epithelial cells [218]. However, OCTs have not been explored and studied in 
the cardiomyocytes. Similarly, AChE and butyrylcholinesterase (BChE) are reported to be 
complementary to each other (reviewed in [219]). Nonetheless, it would be interesting to 
investigate the presence and function of these proteins in cardiomyocytes. However, these are 





3.6.2 Measurement of cardiac ACh level 
Measurement of ACh level should have performed to support the western blot analysis of 
cardiac NNCS expression in the diabetic human patients and db/db mouse heart. However, the 
measure of ACh requires fresh myocardial tissues. Hence this was not possible in my study. 
This is because all the mouse and human ventricular tissues were previously snap-frozen and 
stored in the freezer.  
 
3.6.3 Measurement of cardiac glucose level 
Measurement of glucose level should have performed to support the western blot analysis of 
GLUT-1 and -4 in the diabetic mouse and human heart. However, due to limited availability of 
ventricular tissues, the tissues were prioritized for western blot analysis.  
 
3.6.4 Aging effect in the diabetic db/db mouse model 
To effectively compare the expression changes of cardiac NNCS and glucose transporters 
between db/db and age-matched ND mice, six protein samples isolated from ND and db/db 
mice of the same age group were loaded on the same gel and processed. By doing this, 
comparison of expression changes of the same protein target between different age groups had 
to be omitted as the experimental condition could vary from time to time. However, it is 
undeniable that aging is one of the factors that could alter the expression changes.  
 
3.6.5 Assessing membrane GLUT-4 expression 
The present study measured the total GLUT-4 expression (i.e. cytosolic and membrane GLUT-
4) from the ventricular tissues of ND and db/db mice. The measurement of membrane GLUT-
4 expression could have provided further insight on the function of GLUT-4 in transporting 




not initially planned. Thus, this is one of the limitations of the study. Future study should 
carefully design the experimental layout considering this factor.   
 
3.6.6 Specificity of antibodies  
For immunofluorescence analysis, anti-ChAT and anti-CTNI antibodies were tested on positive 
and negative control, respectively. As GLUT-4 is commonly expressed even in the non-insulin 
sensitive tissues (e.g. liver and kidney), I was not able to identify an appropriate control to test 
the specificity of anti-GLUT-4 antibody. Also, due to limited resources and time, I was not able 
to test the antibody on purified antigen or obtain GLUT-4 knockout/overexpressing tissues/cells. 
However, the specificity of anti-GLUT-4 antibody has been validated by the manufacturer via 
biological strategy (i.e. positive and negative expressing cells; 
https://www.novusbio.com/products/glut4-antibody_nbp1-49533). Further, this particular 
antibody was also used in western blot analysis in Chapter 4 and Chapter 5, and the molecular 
weight of the GLUT-4 positive band was similar to predicted molecular weight. Particularly, in 
response to insulin stimulation in in-vitro model (Chapter 5), the intensity of the GLUT-4 
positive band increased. Nevertheless, this is the limitation of the study. Future study should 
thoroughly examine the specificity of antibody and consider including absorption, positive and 
negative control to strengthen the outcome of the experimentation.  
For western blot analysis, except anti-M2AChR antibody, all the antibodies used for western 
blot analysis resulted in multiple bands on the full blot. I was able to identify the positive band(s) 
of ChAT, CHT1, VAChT and AChE based on the predicted molecular weight indicated by the 
respective manufacturer and UniProt as well as with the use of positive control such as mouse 
brain. There was no appropriate control to test anti-GLUT-1 and anti-GLUT-4 antibodies (same 
antibody used for immunofluorescence analysis) due to abovementioned reasons, thus, this is 
the limitation of the study. Future study should consider testing the antibody on purified antigen, 




3.6.7 Different region of ventricular tissues used for qPCR and western 
blot analyses 
As discussed earlier, the gene and protein expression changes of the components of cardiac 
NNCS and GLUTs were divergent. Whether T2DM regulates the gene and protein expression 
differently or the divergent results are caused by the different region of ventricular tissues, this 
is not clear. As the present study used different part of the ventricular tissues for qPCR and 
western blot analysis, this is one of the limitations of the study. Thus, future study should 
consider using the same part of tissues for examining the gene and protein expression.  
 
 
3.6.8 Sample size 
In the present study, I often observed an increasing or decreasing trend in protein expression, 
while these changes were not statistically significant. This could be due to the number of 
samples (i.e. 6 mice and 9-16 human LV tissues) was not powerful enough to detect the 
differences. For example, in order to detect the significant changes in ChAT expression in the 
db/db mice at 24-weeks of age (Figure 3.4) or diabetic patients (Figure 3.11), power analysis 
revealed that 14 mice per group and 24 human LV tissues per group are required (80% power), 
respectively (https://clincalc.com/stats/samplesize.aspx). Thus, future study should consider 




In summary, the diabetic db/db heart exhibited decreased M2AChR, GLUT-1, and -4 as well as 
increased AChE expression while the diabetic human heart exhibited decreased CHT1 and 
GLUT-4 protein expression. Thus, I partially confirm the hypothesis that cardiac NNCS and 




NNCS (i.e., increased AChE and decreased M2AChR expression) occurred in the db/db mice 
at 8- to 16-weeks of age, before the decrease in GLUT-4 expression at 20-weeks of age. Thus, 
I confirm the second hypothesis that dysregulation of cardiac NNCS would precede the 
decrease in GLUT-4 expression in the diabetic db/db heart. Therefore, this suggests that 
changes in cardiac NNCS, together with insulin resistance, contribute to decreased GLUT-4 
expression in the diabetic heart. On the other hand, this study also provides evidence that 
cardiac NNCS exerted a compensatory effect against diastolic dysfunction in the db/db mice. 
This effect was evident by normalized ChAT and GLUT-4 expression at 24-weeks of age after 
an increase in cardiac NNCS activity (i.e., CHT1 and VAChT expression) at 20- and 24-weeks 
of age, suggesting an attempt to utilize glucose for ATP production in response to diastolic 
dysfunction (Figure 3.18).  
The overall findings from this chapter suggest the potential for modulating cardiac NNCS as a 
therapeutic intervention to rectify cardiac metabolism and, hence preventing cardiac 
dysfunction. Thus, the next step is to demonstrate the effect of activating cardiac NNCS using 
an in-vivo model (Chapter 4). Activation of cardiac NNCS can be directly achieved by 
overexpressing ChAT gene, thereby increasing the ACh synthesis. The in-vivo study will 
provide evidence that cardiac NNCS prevents cardiovascular dysfunction and examine the 





Chapter 4 : The effect of cardiac NNCS activation on 
cardiovascular function in the diabetic db/db mice 
 
4.1 Introduction 
The findings from Chapter 3 showed that the expression of the components of cardiac NNCS 
(i.e., ChAT, CHT1, VAChT, AChE, and M2AChR) and GLUT-4 were dysregulated in the 
diabetic mouse and human heart. Further, the early dysregulation of cardiac NNCS preceded 
the decreased GLUT-4 expression in the diabetic db/db heart. These findings suggest that 
altered cardiac NNCS could be an additional mechanism to reduce GLUT-4 expression in 
T2DM. Thus, it may be possible that restoration of cardiac NNCS by increasing ACh synthesis 
or release could normalize the GLUT-4 expression in the diabetic heart. Therefore, in this 
chapter, I investigated if overexpression of the ChAT gene has beneficial effects on the 
cardiovascular function of the diabetic heart.  
 
4.1.1 Inactivation of 5’-AMP-activated protein kinase (AMPK) in the 
diabetic heart 
Flexibility in fuel substrate selection is essential for the heart to sustain ATP production and 
contractile function. This process is tightly regulated by 5’-AMP-activated protein kinase 
(AMPK), which is the energy sensor in the cardiomyocytes (reviewed in [220, 221]). AMPK is 
inactivated when the AMP/ATP ratio is low while it is activated when the AMP/ATP ratio is 
high [222]. Activation of the AMPK signaling cascade leads to the ATP-generating process by 
promoting FFA β-oxidation [223], glucose uptake [224], and glycolysis [225].  
Apart from impaired insulin-stimulated glucose uptake [48, 61, 62, 154], AMPK inactivation 
is related to decreased glucose utilization in the diabetic heart [226, 227]. Viollet et al. [226] 




reduced insulin-stimulated glucose utilization, and increased circulating FFA in a mouse model 
[226]. Further, AMPK activators such as pterostilbene [228], metformin [229], and 
trimetazidine [227] have been shown to preserve the contractile function of the diabetic heart 
by activating AMPK signaling. Thus, these studies suggest the critical role of AMPK in 
regulating glucose metabolism in the diabetic heart. 
 
4.1.2 Impaired coronary vascular function in the diabetic heart 
Diabetic individuals present chest pain due to obstructive CAD [230] or CMVD without the 
presence of atherosclerotic plaques [231]. Such conditions are caused by endothelial 
dysfunction and atherosclerosis that impairs the function of epicardial coronary arteries and 
microvessels, restricting the blood delivery to the myocardium and myocardial perfusion, 
respectively [16, 232-236]. In this case, the availability of oxygen molecules for FFA oxidation 
is reduced, thereby halting ATP production and affecting the contractile function of the diabetic 
heart [21].  
The underlying mechanism for endothelial dysfunction is multifactorial but remains unresolved. 
It has been demonstrated that increased reactive oxygen species (ROS) as a result of 
hyperglycemia or reduced nitric oxide (NO) bioavailability affects the endothelial function in 
diabetes [237-240]. Besides, the crosstalk between cardiomyocytes and endothelial cells 
mediated by paracrine factors is affected by diabetes. The cardiac-derived pro-angiogenic 
VEGF-A protein expression was found to be decreased in the diabetic human and diabetic db/db 
mouse model [137]. In line with this, Giordano et al. [241] demonstrated dilated and thin 
ventricular walls, hypovascularity, and contractile dysfunction in the mice with cardiac-specific 
knockout of VEGF-A protein. This evidence suggests that VEGF-A is crucial in maintaining 





4.1.3 Targeting cardiac NNCS in the diabetic heart  
4.1.3.1 Glucose metabolism  
Previous studies showed that rectification of cardiac metabolism by increasing GLUT-4 
expression prevented the development of cardiac dysfunction in diabetic animal models [20, 
69]. The findings from Chapter 3 suggests that dysregulation of cardiac NNCS could contribute 
to the decreased GLUT-4 expression in the diabetic heart. In this case, activation of cardiac 
NNCS to increase ACh bioavailability could be an approach to normalize GLUT-4 expression. 
The underlying mechanisms to increase GLUT-4 expression requires the ACh released from 
the cardiomyocytes to bind to the mAChR and mediate pro-survival PI3K/Akt/HIF1α signaling 
cascade [100, 120, 125]. Initiation of this signaling cascade increases the availability of HIF1α 
and allows it to dimerize with HIF1β to form HIF1 transcription factor [120]. HIF1 activates 
the transcription of GLUT-4 gene, which subsequently increases GLUT-4 protein expression.  
 
4.1.3.2 Angiogenesis  
Kakinuma et al. [100] showed that activation of cardiac NNCS increased the number of 
endothelial cells in the ChAT-tg mice. These endothelial cells are either from the capillaries or 
arterioles, which suggest that the density of these microvessels was increased in the ventricular 
region [100]. Although the angiogenic factor was not identified in this study [100], VEGF-A 
could be related to this angiogenic effect since VEGF-A gene is a direct downstream target of 
HIF1 transcription factor (reviewed in [127]). The previous study from Katare laboratory 
showed that microvascular rarefaction, which was associated with decreased VEGF expression, 
was observed in the diabetic human and db/db mouse heart [137]. Interestingly, alteration of 
cardiac NNCS (8- to 16-weeks of age; from Chapter 3) preceded the decrease in VEGF 
expression (12-weeks of age) and microvascular rarefaction (20-weeks of age) in the db/db 
mice [137]. This result suggests that targeting cardiac NNCS could be an attractive approach to 




artery blood flow and oxygen perfusion, in return, prevent contractile dysfunction of the 
diabetic heart.  
 
4.2 Study aim 
This chapter aims to determine the effect of overexpression of the ChAT gene on the 
cardiovascular function of the diabetic heart. Therefore, I hypothesized that ventricular-specific 
overexpression of ChAT gene would lead to activation of PI3K/Akt/HIF1α/GLUT-4 signaling 
pathway to promote glucose metabolism, thus improving cardiac function of the diabetic heart. 
Also, I hypothesized that overexpression of ChAT gene would in turn increase VEGF-A 
expression and promote angiogenesis, thus improving vascular function and in turn, enhance 
the cardiac function of the diabetic heart.  
 
4.3 Materials and methods 
This section only outlines the specific reagents, concentration, and conditions used for each of 
the general methodology as well as the specific methods applied to the study in this chapter 
(i.e., Section 4.3.2 - 4.3.4). Detailed experimental procedures for general methods are described 
in ‘Chapter 2: General materials and methods’. 
 
4.3.1 Type-2 diabetic db/db mouse with ventricular-specific 
overexpression of ChAT gene 
Type-2 diabetic db/db mice with ventricular-specific overexpression of the ChAT gene (db/db-
ChAT-tg) were used in this study to investigate the effect of cardiac NNCS activation on the 
diabetic heart. The body weight, blood glucose level, and LV function of db/db and db/db-
ChAT-tg mice at 8-, 12-, 16- and 20-weeks of age were measured by Prof. Yoshihiko Kakinuma 




Chapter 2 (Figure 2.2). The lower part of the ventricular tissues were used for western blot 
analysis (i.e., ChAT, M2AChR, Akt, HIF1α, GLUT-4, and AMPKα). The wild type non-
diabetic (ND) mice were included for western blot analysis to allow comparison with db/db and 
db/db-ChAT-tg mice.  
The assessment of in-vivo coronary vascular function was performed on db/db and db/db-ChAT-
tg mice at 12- and 24-weeks of age in Super Photon ring-8 GeV (SPring-8) facility, Japan. The 
mice at 24-weeks of age were used in my study because a recent publication from Katare 
laboratory showed that the db/db mice exhibited vascular dysfunction and rarefaction at this 
age [16]. The 12-weeks old mice served as control as these mice had not developed cardiac and 
vascular dysfunction at this age. After Synchrotron radiation microangiography, the ventricular 
tissues were collected as described in Chapter 2 (Figure 2.2). The upper part of the ventricular 
tissues were used to assess the density of arterioles and capillaries in ex-vivo while the lower 
part of the ventricular tissues were used for western blot analysis (i.e., ChAT and VEGF-A). 
These mice, especially the 24-weeks old mice, were prepared for the experiments in SPring-8 
facility, hence, the measurement of body weight, blood glucose level, and LV function were 
not possible to be performed in the facility. Although the lower part of ventricular tissues were 
collected for western blot analysis, the measurement of M2AChR, Akt, HIF1α, GLUT-4, and 
AMPKα protein expression was not performed as there was no age-matched ND mice available 
for comparison.  
 
4.3.2 Synchrotron radiation coronary microangiography 
Synchrotron radiation microangiography was performed to evaluate the potential angiogenic 
effect of cardiac NNCS in the type-2 diabetic db/db mice. This method allows one to visualize 
the coronary circulation in-vivo and to assess vascular responsiveness. This experiment was 




protocols from the Katare laboratory [16]. The study was blinded to me by generating a unique 
ID to each mouse to avoid bias on sample type during the analysis.  
 
4.3.2.1 Catheterization of the jugular vein and carotid artery 
For this approach, db/db-ChAT-tg and db/db mice at the age of 12- and 24-weeks were used. 
Following anesthesia using isoflurane/oxygen (1.5-5%/1 L.min-1), the mouse was positioned on 
a heating pad to maintain its body temperature at 37°C. The trachea was cannulated to ventilate 
the mouse mechanically. The jugular vein was cannulated with PE20 catheter for administration 
of fluid or drugs. The right common carotid artery was cannulated with a fine PE10 catheter for 
injection of iodinated contrast medium (Iomeron 350, Bracco-Eisai Co., Ltd.).  
The carotid catheter was positioned close to the aortic valve to inject the contrast medium to 
the coronary vessels efficiently. Also, the carotid catheter was used to measure the arterial blood 
pressure intermittently. Following surgical preparation, the mouse was positioned supine in 
front of, and perpendicular to the SATICON X-ray detector (Hitachi Denshi Techno-system) 
to image the thorax in an alignment of 9.5 mm x 9.5 mm imaging field [16]. A 50 μm-thick 
tungsten filament was placed across the corner of the detector’s window to be captured in all 
images and used as a reference to determine the size of the coronary vessels. 
 
4.3.2.2 Infusion of drugs and imaging 
A baseline angiogram of the coronary circulation was first recorded before the infusion of drugs. 
Then, the mouse was infused with the endothelium-dependent vasodilator ACh (10 μg/kg/min) 
for five minutes, followed by injecting the contrast medium to record the coronary circulation. 
Next, the mouse was infused with sodium nitroprusside (SNP, 10 μg/kg/min), an endothelium-
independent vasodilator, for five minutes, and the same procedure was repeated to record the 





4.3.2.3 Angiogram data analysis 
All analyses were performed using ImageJ software. The first analysis was performed to count 
the number of coronary vessel branches. The second analysis was done to measure the diameter 
of 2-4 vessels of each branch generation (i.e., first, second, and third-order vessels). The 50 μm-
thick tungsten filament was used as a reference to measure the diameter of vessels. Finally, as 
the diameter of the first, second and third-order vessels may vary from mouse to mouse, the 
third analysis was performed to sort the vessels according to their diameter (0-100, 100-150, 
150-200, and 200-350 μm). All the data are expressed as mean ± standard error of the mean, 
except the diameter of coronary vessels were expressed as the median in box and whisker to 
present the minimum and maximum distribution of data.  
 
4.3.3 Western blot analysis 
Western blot analysis was performed in Kakinuma laboratory in Nippon Medical School, Japan. 
Total protein extraction from the lower part of the mouse ventricular tissues was performed as 
described in Section 2.3.2.1. An equal amount of protein was loaded and electrophoresed and 
blotted for following protein targets, processed as described in Section 2.3.2.4. The band 
intensity of the target protein was normalized to a prominent band between 37 kDa and 50 kDa 
on the Ponceau S stained blot as described in Chapter 2 (section 2.3.2.5) [143, 144] and 
expressed as fold changes towards the control group [145]. As for the quantification of the 
phosphorylation of Akt and AMPKα, the band intensity of the phosphorylated protein was 
normalized to its respective total protein as well as to a prominent band between 37 kDa and 
50 kDa on the Ponceau S stained blot. The rationale for the latter approach is that (1) total Akt 
and  AMPKα expression were significantly decreased in the db/db mice (Section 4.4.2.2 & 
4.4.2.3); (2) to further examine the phosphorylation status in a condition when the expression 
of normalizer is consistent among the ND, db/db and db/db-ChAT-tg mice. This particular 




normalizer such as β-actin or GAPDH that showed consistent expression in their study [242, 
243]. Besides, the reason why total Akt and AMPKα expression were decreased in the db/db 
mice is not clear, however, this could be due to enhanced protein degradation that is associated 
with diabetes mellitus [146-150]. The information of each antibody are listed in Table 4.1. The 
full blot for each antibody is shown in Appendix 2.  
 











ChAT Goat/polyclonal 1:1,000 70/74 Chemicon, AB144P 
M2AChR Rabbit/monoclonal 1:2,000 52 Abcam, AB109226 
GLUT-4 Rabbit/polyclonal 1:2,000 55 
NovusBio, NBP1-
49533 
HIF1α Mouse/monoclonal 1:500 93 
NovusBio, NBP100-
123 
pAkt (Ser473) Rabbit/polyclonal 1:1,000 60 Cell Signaling, 9271 
Akt Rabbit/polyclonal 1:2,000 60 Cell Signaling, 9272 
pAMPKα (Thr172) Rabbit/polyclonal 1:1,000 62 Cell Signaling, 2535 
AMPKα Rabbit/polyclonal 1:2,000 62 Cell Signaling, 2532 
VEGF-A Rabbit/polyclonal 1:1,000 21 Santa Cruz, SC-152 
Secondary antibodies 
Anti-goat IgG, HRP 
conjugated 
Donkey 1:2,000 - Santa Cruz, SC2354 
Anti-rabbit IgG, HRP 
conjugated 
Goat 1:2,000 - Cell Signaling, 7074 
Anti-mouse IgG, HRP 
conjugated 
Goat 1:1,000 - Promega, W402B 
Note: the predicted molecular weight of protein is recommended by the manufacturer 
 
4.3.4 Immunofluorescence analysis 
Double-labelling immunofluorescence staining was performed to detect the density of total 
capillaries and arterioles using the upper part of the mouse ventricular tissues, as described in 
Section 2.4. As there is a distinct structural difference between capillary and arteriole (i.e., a 
single endothelial layer in capillary versus endothelial and a smooth muscle cell layer in 
arteriole), specific antibody and lectin were used to differentiate capillaries and arterioles. The 




B4 while the smooth muscle cell layer was detected by Cy3™-conjugated α-smooth muscle 
actin antibody. DAPI was used to stain the nuclei. The density of capillaries was expressed as 
the number of Isolectin+ cells/mm2 of ventricular tissue. The density of small or large arterioles 
was expressed as the number of αSMA+Isolectin+ cells/mm2 of ventricular tissue. Table 4.2 
summarizes the dilution factor and the pairing of primary and secondary antibodies used in the 
experiment. 
 
Table 4.2 Information on antibodies/lectin for double-labelling immunofluorescence  










α-smooth muscle actin (antibody is 
conjugated with Cy3™) 
Mouse 1:800 Sigma-Aldrich, C6198) 
Secondary reagent 
Streptavidin-AlexaFluor® 488  - 1:200 Invitrogen, S32354 
 
4.3.5 Statistical analyses 
All statistical analyses were performed using GraphPad Prism (version 7) in consultation with 
biostatistician Mr. Andrew Grey and Dr. Claire Cameron (Centre for Biostatistics, University 
of Otago). Data are expressed as the mean ± standard error of the mean. Two-way ANOVA 
followed by Sidak’s test for multiple comparison test was performed to analyze body weight, 
blood glucose level, and all the cardiac functions. For the western blot data, as data from some 
specific age groups of the same protein target failed the normality test, a non-parametric 
Kruskal-Wallis test with Bunn’s test (three groups comparison) or Mann-Whitney U test (two-
group comparison) was used. The number of different order coronary vessels of two age groups 
failed the normality test. However, there is no single non-parametric test equivalent to Two-
way ANOVA. Therefore, a non-parametric Mann-Whitney U test was used. The data for 
diameter, % changes of diameter in response to ACh and SNP, the density of small, large 




Whitney U test was used. This particular approach was consulted with biostatistician Dr. Claire 





4.4.1 Body weight and blood glucose level of db/db-ChAT-tg mice 
The body weight of db/db-ChAT-tg mice at 12-weeks of age was significantly reduced in 
comparison to db/db mice (Figure 4.1A). However, there was no significant difference in the 
body weight of db/db-ChAT-tg mice at 8-, 16- and 20-weeks of age compared to the age-
matched db/db mice. On the other hand, the 8- to 16-weeks old db/db-ChAT-tg mice showed a 
significant decrease in blood glucose levels in comparison to the db/db mice (Figure 4.1B). 
However, the decline in blood glucose level of 20-weeks old db/db-ChAT-tg mice was not 
statistically significant. The protocol for measuring blood glucose is described in Appendix 4.   
 
 
Figure 4.1 The body weight and blood glucose level in db/db and db/db-ChAT-tg mice. 
Bar graphs with scatter plots showing the change of (A) body weight and (B) blood glucose level in the 
db/db-ChAT-tg mice in comparison to the control age-matched db/db mice (DM). Data are expressed 
as mean ± SEM. Two-way ANOVA with Sidak’s test for multiple comparison was performed. *p<0.05; 
**p<0.01; ***p<0.001 vs age-matched db/db mice. The number of samples per group is indicated in 
the figure. 
 
4.4.2 LV function of db/db-ChAT-tg mice  
4.4.2.1 LV diastolic, systolic function and contractility  
The overexpression of the ChAT gene in the ventricles of db/db-ChAT-tg mice improved the 
LV function. The indices of diastolic function such as end-diastolic pressure (EDP) and volume 
(EDV) were not statistically different in the db/db-ChAT-tg mice at 8- to 20-weeks of age 




showed better systolic function as demonstrated by a significant increase in the end-systolic 
pressure (ESP) at 8- to 20-weeks of age (Figure 4.2C) and a considerable decrease in the end-
systolic volume (ESV) at 12- and 16-weeks of age compared to db/db mice (Figure 4.2D).  
 
  
Figure 4.2 Activation of cardiac NNCS improved the systolic function of db/db-ChAT-tg mice.  
Bar graphs with scatter plots showing the diastolic function as indicated by (A) end-diastolic pressure 
and (B) end-diastolic volume as well as systolic function as indicated by (C) end-systolic pressure and 
(D) end-systolic volume of the db/db-ChAT-tg mice in comparison to the control age-matched db/db 
mice. Data are expressed as mean ± SEM. Two-way ANOVA with Sidak’s test for multiple comparison 
was performed. *p<0.05; ***p<0.001; ****p<0.0001 VS age-matched db/db mice. The number of 
samples per group is indicated in figure A.  
 
The heart rate (HR) of db/db-ChAT-tg mice was unaltered at 8- to 20-weeks of age (Figure 
4.3A). However, the stroke volume (SV) was significantly increased in the db/db-ChAT-tg mice 
at 16-weeks of age (Figure 4.3B). Further, the cardiac output (CO) and ejection fraction (EF) 
were considerably improved in the db/db-ChAT-tg mice at 12- to 20-weeks of age (Figure 
4.3C&D). In summary, the overall findings indicate that the db/db-ChAT-tg mice exhibited 
superior LV systolic function and contractibility in comparison to the age-matched db/db mice. 





   
Figure 4.3 Activation of cardiac NNCS improved LV contractibility without altering heart rate in 
the db/db-ChAT-tg mice. 
Bar graphs with scatter plots showing the (A) heart rate, (B) stroke volume, (C) cardiac output and, (D) 
ejection fraction of the db/db-ChAT-tg mice in comparison to the control age-matched db/db mice. Data 
are expressed as mean ± SEM. Two-way ANOVA with Sidak’s test for multiple comparisons was 
performed. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 VS age-matched db/db mice. The number 
of samples per group is indicated in figure A. 
 
4.4.2.2 Molecular alterations associated with improved LV function 
Since it is well established that ACh-mediated signaling promotes glucose metabolism and 
decrease energy demand [100], western blot analysis was performed to determine the protein 
expression of key targets involved in ACh signaling (ChAT and M2AChR), ACh-mediated pro-
survival PI3K/Akt/HIF1α/GLUT-4 signaling pathway (Akt, HIF1α and GLUT-4) as well as 
ATP homeostasis (AMPKα).  
 
4.4.2.2.1 ChAT and M2AChR 
In comparison to age-matched ND mice, the ChAT protein expression in the db/db mice was 




db/db-ChAT-tg mice resulted in 1.7±0.2 to 2.0±0.1-fold increase in ChAT protein expression 
at 8-, 12-, 16- and 20-week of age (Figure 4.4). 
 
 
Figure 4.4 Increased ChAT protein expression in the db/db-ChAT-tg mice. 
Bar graphs with scatter plots showing the protein expression of ChAT in the ND, db/db, and db/db-
ChAT-tg mice at 8-, 12-, 16- and 20-weeks of age. Data are presented as mean ± SEM. A non-parametric 
Kruskal-Wallis test with Bunn’s test was performed. *p<0.05, **p<0.01, ***p<0.001 VS age-matched 
ND mice; ##p<0.01, ###p<0.001, ####p<0.0001 VS age-matched db/db mice. The number of samples per 
group is indicated in the figure. 
 
In comparison to the age-matched ND mice, the M2AChR protein expression was significantly 
decreased in the heart of db/db mice at 8-weeks of age while the expression change in db/db-
ChAT-tg mice was not statistically significant compared to ND mice (Figure 4.5). At 12-weeks 
of age, the M2AChR protein expression was significantly decreased in the db/db-ChAT-tg mice 
while the expression was not statistically different in the db/db mice in spite of a downward 
trend as compared to the ND mice. At 16-weeks of age, the M2AChR protein expression was 
unaltered in the db/db and db/db-ChAT-tg mice in comparison to the ND mice. At 20-weeks of 
age, the M2AChR protein expression was significantly decreased in the db/db mice in 
comparison to the ND mice. However, this was prevented in the db/db-ChAT-tg mice, showing 






Figure 4.5 Prevention of decreased M2AChR protein expression in the db/db-ChAT-tg mice. 
Representative blots and bar graphs with scatter plots showing the protein expression of M2AChR in the 
ND, db/db, and db/db-ChAT-tg mice at 8-, 12-, 16- and 20-weeks of age. Data are expressed as mean ± 
SEM. A non-parametric Kruskal-Wallis test with Bunn’s test was performed.  *p<0.05, **p<0.01, 
***p<0.001 VS age-matched ND mice; #p<0.05 VS age-matched db/db mice. The number of samples 
per group is indicated in the figure. 
 
4.4.2.2.2 Activation of pro-survival PI3K/Akt/HIF1α/GLUT-4 signaling pathway  
To determine if cardiac NNCS-mediated PI3K/Akt/HIF1α/GLUT-4 signaling pathway plays a 
role in improved LV systolic function and contractility of the db/db-ChAT-tg heart, protein 
expression of Akt and its phosphorylated form (Ser473), HIF1α and GLUT-4 were investigated.  
Both anti-pAkt and anti-Akt antibodies are polyclonal, but it detected only one band at 
molecular weight of 60 kDa (Appendix 2, Figure S2.6). Based on the predicted molecular 
weight by manufacturer and UniProt, I identified this band as pAkt/Akt-positive. Besides, as 
two approaches were taken to quantify the phosphorylation level of Akt, the outcome was 
different in the mice at 8-weeks of age. By normalizing to the selected band between 37 kDa 
and 50 kDa on the Ponceau S stained blot, the phosphorylation level of Akt was unaltered in 
the db/db and db/db-ChAT-tg mice in comparison to the ND mice at 8-weeks of age (Figure 




level of Akt was significantly increased in the db/db and db/db-ChAT-tg mice in comparison to 
the ND mice at 8-weeks of age. This difference is caused by a significant reduction in total Akt 
expression in the db/db and db/db-ChAT-tg mice. Further, the phosphorylation level of Akt 
showed similar trend in the db/db and db/db-ChAT-tg mice at 12- to 20-weeks after normalizing 
to total Akt expression or Ponceau S stained blot. In general, the phosphorylation level of Akt 
was significantly increased in db/db-ChAT-tg mice as compared to age-matched ND mice at 
12- to 20-weeks of age. While db/db mice showed an increasing trend (normalized to Ponceau 
S stained blot) or significant increase (normalized to total Akt expression) in phosphorylated 
Akt expression in comparison to age-matched ND mice at 12- to 20-weeks of age.  
The total Akt protein expression was significantly decreased in the db/db mice compared with 
the ND mice at 8- to 20-weeks of age. The db/db-ChAT-tg mice showed a similar decrease in 
total Akt protein expression at 8- and 12-weeks of age. However, at 16- and 20-weeks of age, 
the total Akt protein expression was significantly increased in the db/db-ChAT-tg compared 
with the db/db mice and was comparable to the ND mice.   
 
 
Figure 4.6 Modulation of total Akt protein expression and phosphorylated Akt at Ser473. 
Representative blots and bar graphs with scatter plots showing the protein expression of total Akt and 
its phosphorylated form (Ser473) in the ND, db/db and db/db-ChAT-tg mice at 8-, 12-, 16- and 20-weeks 




performed. *p<0.05, **p<0.01, ***p<0.001 VS age-matched ND mice; ##p<0.01 VS age-matched 
db/db mice. The number of samples per group is indicated in the figure. 
 
Another pro-survival protein I investigated was HIF1α. The anti- HIF1α antibody is monoclonal, 
however, it detected multiple bands (Appendix 2, Figure S2.6). This could be partly due to the 
presence of isoforms ranged from 82 kDa to 96 kDa as well as post-translation modifications 
(https://www.uniprot.org/uniprot/Q16665). In my study, I observed a band with strong intensity 
above the 75 kDa. In line with this, Jablonska et al. [244] used the same antibody and reported 
HIF1α-positive band to be approximately 80 kDa. Therefore, I identified the band with strong 
intensity above 75 kDa as HIF1α-positive. Western blot analysis revealed that HIF1α 
expression was significantly increased in the db/db-ChAT-tg mice in comparison to the ND and 
db/db mice at 8-weeks of age (Figure 4.7). At 12- to 20-weeks of age, no significant changes in 
the HIF1α protein expression in the db/db-ChAT-tg mice in comparison to the age-matched ND 
and db/db mice.  
 
 
Figure 4.7 Modulation of HIF1α protein expression by activating cardiac NNCS.  
Representative blots and bar graphs with scatter plots showing the protein expression of HIF1α in the 
ND, db/db, and db/db-ChAT-tg mice at 8-, 12-, 16- and 20-weeks of age. Data are presented as mean ± 




age-matched ND mice; #p<0.05 VS age-matched db/db mice. The number of samples per group is 
indicated in the figure. 
 
Next, GLUT-4 expression was tested to determine if the activation of PI3K/Akt/HIFα signaling 
cascade shifted the cardiac metabolism to glucose oxidation. At the 8-weeks of age, the GLUT-
4 protein expression was significantly increased in the db/db and db/db-ChAT-tg mice 
compared with ND mice (Figure 4.8). At 12- and 16-weeks of age, the GLUT-4 protein 
expression remained significantly higher in the db/db-ChAT-tg mice while the expression in the 
db/db mice was comparable to that of the age-matched ND mice. At the 20-weeks of age, there 
was a decreasing trend in GLUT-4 protein expression in the db/db mice (p=0.07) compared to 
the ND mice. Additionally, the GLUT-4 protein expression was unaltered in the db/db-ChAT-
tg mice compared to ND mice, but the expression was significantly increased compared to the 
db/db mice. The overall findings indicate that overexpression of the ChAT gene activated 
PI3K/Akt/HIF1α/GLUT-4 signaling cascade in the ventricles of db/db-ChAT-tg mice. Initiation 
of this signaling cascade is likely to promote glucose uptake and oxidation in the ventricles of 






Figure 4.8 Normalization of GLUT-4 protein expression in the db/db-ChAT-tg mice. 
Representative blots and bar graphs with scatter plots showing the protein expression of GLUT-4 in the 
ND, db/db, and db/db-ChAT-tg mice at 8-, 12-, 16- and 20-weeks of age. Data are expressed as mean ± 
SEM. A non-parametric Kruskal-Wallis test with Bunn’s test was performed. *p<0.05, **p<0.01 VS 
age-matched ND mice; #p<0.05, ####p<0.0001 VS age-matched db/db mice. The number of samples per 
group is indicated in the figure. 
 
4.4.2.2.3 ATP homeostasis - AMPKα  
After confirming that PI3K/Akt/HIF1α/GLUT-4 signaling cascade was activated in the db/db-
ChAT-tg mice’s heart, the next aim was to examine if glucose oxidation increased the energy 
status in the ventricles. For this, the phosphorylation level and total protein expression of 
AMPKα, which is the catalytic subunit of energy regulator AMPK, was measured to reflect the 
energy status in the heart. The anti-pAMPKα and anti-AMPKα antibodies are polyclonal and 
resulted in multiple bands, however, a band with strong intensity with molecular weight of 60 
kDa was detected (Appendix 2, Figure S2.7). Based on the predicted molecular weight indicated 
by manufacturer and UniProt, I identified this band as pAMPKα/AMPKα-positive.  
Besides, the two approaches to quantify the phosphorylation of AMPKα generally resulted in 
similar trend in the mice at 8- to 16-weeks of age. In the db/db-ChAT-tg mice at 8- and 12-
weeks of age, there was a decreasing trend in the phosphorylation level of AMPKα compared 
to ND mice (Figure 4.9). At 16-weeks of age, the phosphorylation level of AMPKα was 
significantly decreased in the heart of db/db-ChAT-tg mice compared to ND mice. As for the 
db/db mice, there was a decreasing trend in the phosphorylation level of AMPKα in at 8- and 
16-weeks of age; however, the changes were not statistically significant.  
At 20-weeks of age, by normalizing to Ponceau S stained blot, the phosphorylation level of 
AMPKα in the db/db showed an increasing trend while the phosphorylation level in the db/db-
ChAT-tg mice was comparable to the ND mice. By normalizing to total AMPKα expression, 
the phosphorylation level of AMPKα in the db/db showed a decreasing trend (p=0.06) while 
the phosphorylation level in the db/db-ChAT-tg mice was comparable to the ND mice. In terms 




significant in both the db/db and db/db-ChAT-tg mice compared to the ND mice at 8- to 20-
weeks of age. However, AMPKα protein expression was significantly increased in the db/db-
ChAT-tg mice compared to that of db/db mice at 20-weeks of age. The overall findings suggest 
that AMPK was possibly inactivated in the db/db and db/db-ChAT-tg mice at 8- to 16-weeks of 
age, which may occur due to low AMP/ATP ratio. While in the db/db mice at 20-weeks of age, 
the result is not conclusive as the two different normalization methods resulted in opposite result.  
 
 
Figure 4.9 Modulation of total AMPKα protein expression and phosphorylated AMPKα at Thr172. 
Representative blots and bar graphs with scatter plots showing the protein expression of total AMPKα 
and its phosphorylated form (Thr172) in the ND, db/db and db/db-ChAT-tg mice at 8-, 12-, 16- and 20-
weeks of age. Data are presented as mean ± SEM. A non-parametric Kruskal-Wallis test with Bunn’s 
test was performed. **p<0.01 VS age-matched ND mice; #p<0.05 VS age-matched db/db mice. The 
number of samples per group is indicated in the figure. 
  
4.4.3 Vascular function of db/db-ChAT-tg mice  
4.4.3.1 In-vivo coronary circulation 
Having demonstrated that in-vivo activation of cardiac NNCS improved the LV systolic 
function and contractility in the db/db-ChAT-tg mice, the next aim was to investigate the effect 
of cardiac NNCS in preventing diabetes-induced vascular dysfunction. This aim was tested by 
imaging the coronary circulation by Synchrotron radiation microangiography. The total number 




However, as the fourth-order coronary vessels were only visualized in a small number of mice 
(in particular only in the db/db-ChAT-tg mice), the number of fourth-order coronary vessels 
was combined with the number of third-order coronary vessels for analysis. The results showed 
that the difference in the total number of coronary vessels was not statistically significant in the 
db/db-ChAT-tg mice in comparison to the db/db mice at 12-weeks of age (Figure 4.10). 
However, at 24-weeks of age, the number of second-order coronary vessels was significantly 






Figure 4.10 Effect of cardiac NNCS activation in maintaining vasculature.  
Representative microangiogram images and bar graphs with scatter plots showing the number of first, 
second, third and fourth-order coronary vessels in the db/db and db/db-ChAT-tg mice at 12- and 24-
weeks of age. The 50 μm diameter tungsten wire in the bottom left corner of all angiogram frames serves 
as a reference. Data are presented as mean ± SEM. A non-parametric Mann-Whitney U test was 
performed. **p<0.01 VS age-matched db/db mice. The number of samples per group is indicated in the 
figure. 
 
The diameter of the coronary vessels was measured by using 50 μm tungsten wire as a reference. 




order vessels) in the db/db-ChAT-tg mice in comparison to the db/db mice at 12- and 24-weeks 
of age, however, this was not statistically significant (Figure 4.11 A&B). 
 
           
Figure 4.11 The range of vessel size in db/db and db/db-ChAT-tg mice. 
Box and whisker plots showing the internal diameter of first, second, and third coronary vessels in the 
(A) 12-weeks and (B) 24-weeks old db/db and db/db-ChAT-tg mice. Data are presented as a range. A 
non-parametric Mann-Whitney U test was performed. The number of samples per group is indicated in 
the figure. 
 
Next, to determine the endothelial function of the coronary vasculature, the mice were infused 
with ACh (10 µg/kg/min) and SNP (10 µg/kg/min) to examine the endothelial-dependent and -
independent vasodilation, respectively. Measurement of diameter of first to third-order 
coronary vessels was performed. The diameter of coronary vessels was measured and further 
sorted according to vessel size of 0-100, 100-150, 150-200, 200-350 μm. After ACh infusion, 
the percentage change in diameter of the db/db-ChAT-tg mice was comparable to that of db/db 
mice at 12- and 24-weeks of age (Figure 4.12 A&B). Similarly, the percentage change in 
diameter after SNP infusion was similar between db/db-ChAT-tg and db/db mice at 12- and 24-
weeks of age (Figure 4.12 C&D). Thus, there was no change in the diameter of coronary vessels 
in response to ACh and SNP in the db/db-ChAT-tg mice compared to the db/db mice at 12- and 
24-weeks of age. These results suggest that endothelial-dependent and -independent 






Figure 4.12 The effect of ACh and SNP on the diameter of coronary vessels in db/db and db/db-
ChAT-tg mice. 
The line graphs showing (A&B) Acetylcholine (ACh; 10 µg/kg/min) and (C&D) Sodium nitroprusside 
(SNP; 10 µg/kg/min) in changing the diameter of coronary vessels. The percentage changes were sorted 
according to the coronary vessel size in the db/db and db/db-ChAT-tg mice at 12- and 24-weeks of age, 
respectively. Data are presented as mean ± SEM. A non-parametric Mann-Whitney U test was 
performed. The number of samples per group is indicated in the figure. 
 
The final measurement was performed to determine if ACh and SNP exerted its effect by 
recruiting small coronary vessels (i.e., third and fourth-order measured together). This 
measurement was only performed on the mice at 24-weeks of age as the decline in the number 
of coronary vessels was evident in the db/db mice at 24-weeks of age compared to the db/db 
mice at 12-weeks of age (Figure 4.10). The analysis revealed that the number of third and 
fourth-order coronary vessels of db/db-ChAT-tg mice was significantly increased after ACh 
(Figure 4.13B) and SNP infusion (Figure 4.13C) compared to that of the age-matched db/db 
mice. Thus, an increase in the number of third and fourth-order coronary vessels indicates 






Figure 4.13 The effect of ACh and SNP on recruiting the small coronary vessels in db/db and db/db-
ChAT-tg mice at 24-weeks of age. 
Representative microangiogram images and bar graphs with scatter plots showing the number of third 
and fourth-order coronary vessels in the db/db and db/db-ChAT-tg mice at 24-weeks of age (A) under 
baseline condition, (B) after ACh infusion (10 µg/kg/min) and (C) after SNP infusion (10 µg/kg/min). 
Red arrows indicate third-order coronary vessels, while yellow arrows indicate fourth-order coronary 
vessels. Data are presented as mean ± SEM. A non-parametric Mann-Whitney U test was performed. 
*p<0.05; **p<0.01 VS aged-matched db/db mice after ACh or SNP infusion. The number of samples 
per group is indicated in the figure. 
 
4.4.3.2 Coronary microvasculature  
To further support the observation of an increased number of coronary vessels in the db/db-
ChAT-tg mice, the microvascular density (i.e., the number of capillaries and arterioles) was 
examined by immunofluorescence analysis. This method was performed to accurately detect 
endothelial cells (Isolectin) as well as the smooth muscle cells (anti-αSMA antibody). Arterioles 
were identified by positive staining for Isolectin and αSMA, whereas capillaries were positive 




The diameter of arterioles was measured and sorted into two groups – large arterioles (>50 μm) 
and small arterioles (<50 μm). The analysis revealed that the number of large arterioles was 
comparable between the db/db and db/db-ChAT-tg mice at 12- and 24-weeks of age (Figure 
4.14). The number of small arterioles in the db/db-ChAT-tg mice was not different from the 
db/db mice at 12-weeks of age (Figure 4.14). There was an increasing trend in the number of 
small arterioles of the db/db-ChAT-tg mice compared to that of the db/db mice at 24-weeks of 
age. However, this was not statistically significant. The image of the secondary antibody-only 





Figure 4.14 The effect of cardiac NNCS on the density of large and small arterioles.  
Representative fluorescent images and bar graphs with scatter plots showing the density of large and 
small arterioles as indicated by the number of αSMA- and Isolectin-stained smooth muscle cells in the 
ventricular tissue of db/db and db/db-ChAT-tg mice at 12- and 24-weeks of age. Data are presented as 
mean ± SEM. A non-parametric Mann-Whitney U test was performed. Yellow arrows indicate large 
arterioles (>50 µm) while white arrows indicate small arterioles (<50 µm). The number of samples per 
group is indicated in the figure. 
 
While the number of capillaries was comparable between the db/db and db/db-ChAT-tg mice at 








Figure 4.15 The effect of cardiac NNCS on the density of capillaries. 
Representative fluorescent images and bar graphs with scatter plots showing the density of capillaries 
which indicated by the number of Isolectin-stained endothelial cells in the ventricular tissues of db/db 
and db/db-ChAT-tg mice at 12- and 24-weeks of age. Data are presented as mean ± SEM. A non-
parametric Mann-Whitney U test was performed. *p<0.05 VS aged-matched db/db mice. The number 





4.4.3.3 Molecular alterations associated with improved vascular function 
Having demonstrated that increased number of coronary vessels and microvessels in the db/db-
ChAT-tg mice, the next aim was to identify if VEGF-A contributed to the enhanced angiogenic 
effect since VEGF-A is a direct downstream target of a HIF1 transcription factor.  
The anti-VEGF-A antibody used in my study is polyclonal and resulted in multiple bands on 
blot (Appendix 2, Figure S2.7). However, there was only a band with strong intensity detected 
in between 20 kDa and 25 kDa. Thus, I identified this band as VEGF-A positive. Data analysis 
revealed that VEGF-A protein expression was significantly increased by 0.1-fold in the db/db-
ChAT-tg mice in comparison to the db/db mice at 12-weeks of age (Figure 4.16). The protein 
expression of VEGF-A in the ventricles of db/db-ChAT-tg mice was comparable to that of db/db 
mice at 24-weeks of age. 
 
 
Figure 4.16 Activation of cardiac NNCS induced increased VEGF-A protein expression in 12-
weeks old db/db-ChAT-tg mice. 
Representative blots and bar graphs with scatter plots showing the protein expression of VEGF-A in the 
db/db and db/db-ChAT-tg mice at 12- and 24-weeks of age. Data are presented as mean ± SEM. A non-
parametric Mann-Whitney U test was performed. *p<0.05 VS age-matched db/db mice. The number of 
samples per group is indicated in the figure. 
 
4.5 Discussion 
In this chapter, the db/db-ChAT-tg mouse model was used to examine the effect of 
overexpressing ChAT gene in the diabetic heart. The metabolic profile, such as body weight 
and blood glucose level of the db/db-ChAT-tg mice, was recorded. The LV function, vascular 




(ChAT and M2AChR), pro-survival signaling pathway (Akt, HIF1α, and GLUT-4), energy 
homeostasis (AMPKα) and angiogenesis (VEGF-A) were examined. I hypothesized that 
ventricular-specific overexpression of ChAT gene would lead to activation of 
PI3K/Akt/HIF1α/GLUT-4 signaling pathway to promote glucose metabolism, thus improving 
cardiac function of the diabetic heart. Also, I hypothesized that ventricular-specific 
overexpression of ChAT gene would lead to an increase in VEGF-A expression and promote 
angiogenesis, thus improving vascular function and in turn, enhancing the cardiac function of 
the diabetic heart. The main findings of this study can be summarized as follows: 
 
1. Metabolic profiles: 
• The body weight was significantly decreased in the db/db-ChAT-tg mice at 12-weeks of 
age. 
• The blood glucose level was significantly decreased in the db/db-ChAT-tg mice at 8- to 
16-weeks of age. 
 
2. Cardiac function: 
• LV systolic function (i.e., ESV and ESP) and contractility (i.e., SV, CO, and EF) were 
improved in the db/db-ChAT-tg mice at 8- to 20-weeks of age. 
• Molecular alterations associated with improved LV function in the db/db-ChAT-tg mice: 
o Activation of cardiac NNCS and ACh-M2AChR mediated signaling: 
▪ Increased ChAT protein expression at 8- to 20-weeks of age  
▪ Prevention of decreased M2AChR protein expression at 16- to 20-weeks 
of age 
o Activation of cardiac NNCS-mediated pro-survival PI3K/Akt/HIFIα/GLUT-4 
signaling cascade: 




▪ Increased HIF1α protein expression at 8- and 20-weeks of age 
▪ Increased GLUT-4 protein expression at 8- to 20-weeks of age 
o Energy homeostasis in the ventricles: 
▪ Decreased phosphorylation level of AMPKα at 8- to 16-weeks of age 
 
3. Vascular function:  
• The number of coronary vessels was increased in the db/db-ChAT-tg mice  
• No significant increase in the diameter of coronary vessels in the db/db-ChAT-tg mice  
• ACh and SNP did not change the diameter of coronary vessels in the db/db-ChAT-tg 
mice  
• ACh and SNP-induced vasodilation revealed an increase in the number of third and 
fourth-order of coronary vessels in the db/db-ChAT-tg mice at 24-weeks of age. 
• Increased number of capillaries in the db/db-ChAT-tg mice was observed at 24-weeks 
of age.  
• This improved vascular function in the db/db-ChAT-tg mice was associated with 
increased VEGF-A protein expression at 12-weeks of age. 
 
4.5.1 Activation of cardiac NNCS improved LV function of db/db mice 
Kakinuma et al. [100] showed that ventricular-overexpression of ChAT gene in a normal heart  
did not alter the LV diastolic, systolic function, and contractility of ChAT-tg mice. While in my 
study, the ChAT transgene in the diabetic heart augmented the cardiac function (Figure 4.2 & 
4.3). One possible reason for this could be because the db/db mice spontaneously developed 
cardiac dysfunction and hence the effect of ChAT transgene on cardiac function was evident in 
the db/db-ChAT-tg mice. Conversely, the effect of ChAT transgene was not evident in the mice 




The clinical assessment of diastolic function relies on a few variables such as early and late 
mitral flow velocity (E’ and A’), mitral annular early diastolic velocity (e’), E/A ratio, E/e’ ratio 
as well as the deceleration time of E’ [245-248], while the clinical assessment of systolic 
function is assessed by the measurement of EF, FS, CO and SV [249-251]. In my study, the 
measurement of diastolic function was based on EDV and EDP and there were not evident 
changes in these indices in the db/db-ChAT-tg mice (Figure 4.2A&B). However, the limitation 
of pressure-volume loop method is that it only measures the pressure and volume, and hence, 
these results may not be conclusive enough to determine the diastolic function of the db/db-
ChAT-tg mice. Therefore, it would be crucial to perform echocardiography to assess the E/A 
ratio and deceleration time of E’ on the db/db-ChAT-tg mice in future study. Apart from this, 
the LV systolic function (indicated by ESP and ESV; Figure 4.2C&D), as well as contractility 
(indicated by CO, SV, and EF; Figure 4.3B-D), were significantly enhanced in the db/db-ChAT-
tg mice. Taken together, the overall findings suggest that activation of cardiac NNCS enhances 
the LV systolic function and contractility of the diabetic heart. The underlying mechanism for 
this beneficial effect is contributed by enhanced GLUT-4 and VEGF-A expression as induced 
by pro-survival PI3K/Akt/ HIF1α signaling pathway [100]. This is discussed in the following 
sections.  
On a side note, the measurement of cardiac function was performed under 1% - 2% isoflurane 
via inhalation (Appendix 4). Isoflurane and other common inhalational anesthesia such as 
desflurane as well as intravenous anesthetics such as barbiturates are known to influence cardiac 
function and hemodynamics [252-255]. However, the influence of isoflurane to the cardiac 
function of mice used in this study should be minimal as previous studies showed that isoflurane 
concentration titrated between 0.5% - 2% did not induce significant effect on cardiac function 





4.5.1.1 Cardiac NNCS activated PI3K/Akt/HIF1α/GLUT-4 signaling pathway  
As discussed in Chapter 1 and 3, ACh-initiated mAChR signaling leads to the activation of pro-
survival PI3K/Akt/HIF1α signaling pathway [100, 120, 125]. Although it is still not known 
which subtype of mAChR is responsible for initiating this signaling pathway, M2AChR may 
involve in this as this subtype is the most abundant mAChR in the heart [111, 179, 186, 187]. 
Further, the non-neuronal effect of ACh-mAChR mediated signaling includes an increase in 
GLUT-4 expression via activation of PI3K/Akt/HIF1α signaling cascade [96, 100].  
In the db/db-ChAT-tg mice, decreased M2AChR expression was prevented at 16- and 20-weeks 
of age (Figure 4.5). Such prevention indicates that the non-neuronal effects mediated through 
ACh-M2AChR interaction were possibly restored after activation of cardiac NNCS. Of note, 
normalization of M2AChR expression was also observed in the db/db mice at 16-weeks. This 
finding contrasts with the outcome from Chapter 3 that showed a persistent reduction of 
M2AChR expression in the db/db mice (Figure 3.7B). Although the reason for this is not known, 
this could be caused by the composition of food pellet used in the animal facility of University 
of Otago (6.2% fat, 3.5% fiber and 18.6% protein) that is different from the food pellet used in 
the Japanese animal facility (4.5% fat, 5.05% fiber and 25.1% protein). Thus, it is logical to 
postulate that the db/db mice that fed with lower fat content (in Japan) would develop diabetes-
induced complications at a slower rate, and the molecular alteration may be different [256-258]. 
One possible future experiment could be performed is to feed the db/db mice originated from 
New Zealand and Japan with the food pellets used in New Zealand and Japanese animal facility, 
respectively. The outcome of this experiment could provide insight whether the composition of 
diet does influence the expression changes in M2AChR. 
Kakinuma et al. [100] showed that ventricular-specific overexpression of ChAT gene resulted 
in increased cardiac ACh content, the phosphorylation level of Akt (threonine 308), HIF1α and 
GLUT-4 expression in the ChAT-tg mice, indicating activation of PI3K/Akt/HIF1α/GLUT-4 




showed an increase in the phosphorylation level of Akt (serine 473; Figure 4.6), HIF1α (Figure 
4.7) and GLUT-4 expression (Figure 4.8) in the db/db-ChAT-tg mice compared to that of the 
age-matched WT and db/db mice. These findings support that the pro-survival 
PI3K/Akt/HIF1α/GLUT-4 signaling cascade was activated in the db/db-ChAT-tg mice.  
On a side note, normalizing the phosphorylated protein expression to its respective total protein 
expression is generally a well-accepted approach. However, the outcome derives from this 
approach may not necessarily reflect the actual phosphorylated protein expression when the 
expression of total protein expression changes. In particular, the blot shows that the 
phosphorylation level of Akt was unchanged while total Akt expression was decreased in the 
db/db and db/db-ChAT-tg mice at 8-weeks of age (Figure 4.6 and additional image in Appendix 
4, Figure S4.2). This suggests that T2DM decreases total Akt expression without affecting the 
phosphorylation capacity in the diabetic cardiomyocytes. To further confirm this, future study 
can consider performing enzyme-linked immunosorbent assay (ELISA) to detect the 
phosphorylated Akt or biochemical assay to detect the activity of Akt.  
Besides, the phosphorylation level of Akt was increased in the db/db mice in comparison to the 
ND mice (Figure 4.6). In line with this, Cook et al. [61] showed that the basal phosphorylation 
level of Akt was increased in the ob/ob mouse model. Further, they demonstrated that GLUT-
4 vesicle dysfunction contributed to the decreased sarcolemmal GLUT-4 expression in the 
T2DM patients and ob/ob mouse model, while the proximal insulin signaling was activated (i.e., 
IRS1 and PI3K) and functional in the diabetic heart [61]. However, the findings from my study 
and Cook et al. [61] are in contrast to other studies [259-261] that reported impaired insulin 
signaling cascade in the diabetic mouse model. The reason for this discrepancy is unknown, but 





4.5.1.2 Normalization of GLUT-4 expression to restore glucose metabolism and 
energy level   
Reduction in GLUT-4 expression decrease glucose uptake and oxidation in the diabetic heart 
[56-63, 79]. Previous studies showed that global overexpression of GLUT-4 gene effectively 
decreased blood glucose level and alleviated insulin resistance in the db/db mice [20, 262] and 
diet-induced insulin resistance mice [263]. Further, increased GLUT-4 expression enhanced 
glycolysis and glucose oxidation as well as suppressed palmitate oxidation in the diabetic heart, 
and thereby preventing diabetes-induced cardiac dysfunction [20, 69]. Thus, this suggests that 
targeting GLUT-4 to rectify cardiac metabolism and prevent cardiac dysfunction can be a 
therapeutic option. In my study, GLUT-4 expression was significantly increased in the db/db-
ChAT-tg mice (Figure 4.8) together with improved LV systolic function and contractility 
(Figure 4.2 & 4.3). Although cardiac glucose content, rate of glycolysis and glucose oxidation 
were not measured in the study, it is possible that increased GLUT-4 expression enhanced 
glucose metabolism and thus improving LV function in the db/db-ChAT-tg mice.  
Besides, glucose metabolism augments ATP production in comparison to FFA metabolism, 
thus allowing the heart to cope with increased cardiac workload efficiently [264]. Although the 
cardiac ATP content was not measured in the present study, the phosphorylation level of 
AMPKα could provide a link to the energy status. The decreased phosphorylation level of 
AMPKα in the db/db and db/db-ChAT-tg mice (8- to 16-weeks of age) indicated that AMPK 
was inactivated possibly due to low AMP/ATP ratio (Figure 4.9) [222]. Notably, the 
phosphorylation level of AMPKα in db/db-ChAT-tg mice was further decreased in comparison 
to the age-matched db/db mice, suggesting that the AMP/ATP ratio was lower (i.e., energy 
preservation) and this could be associated with increased GLUT-4 expression. At 20-weeks of 
age when cardiac dysfunction began to develop in the db/db mice [1], the phosphorylation level 
of AMPKα in db/db-ChAT-tg mice was similar to that of the WT heart, and this again could be 




production could be augmented due to increased glucose uptake in the db/db-ChAT-tg mice. 
However, the measurement of cardiac ATP and glucose content is undoubtedly required to 
support this postulation.  
Besides, previous studies reported that defective AMPK activation contributes to impaired 
glucose utilization in the diabetic heart [226, 227, 265, 266]. However, the phosphorylation of 
AMPKα in db/db mice at 20-week of age is not clear as two normalization approaches resulted 
in contradictory result. Whether T2DM induces an increase (in the case of normalizing to 
Ponceau S stained blot), or, a decrease in the phosphorylation of AMPKα (in the case of 
normalizing to total AMPKα expression), this need to be clearly examined in future. An ELISA 
assay to detect phosphorylated AMPKα or biochemical assay to detect the activity of AMPK 
can be considered. 
 
4.5.2 Activation of cardiac NNCS preserved coronary vasculature and 
improved vascular function of db/db mice 
The angiogram showed that the heart of db/db-ChAT-tg mice generally exhibited an increased 
number of coronary vessels as compared to the db/db mice at both 12- and 24-weeks of age 
(Figure 4.10). Importantly, there was a decreasing trend in the number of second, third and 
fourth-order coronary vessels in the 24-weeks old db/db mice compared to that of the 12-weeks 
old db/db mice. This observation was consistent with the study performed by Katare et al. [16] 
who showed a decreasing trend in the number of coronary vessels in the db/db mice with the 
progression of age. Conversely, the number of second, third, and fourth-order coronary vessels 
remained similar in the 24-weeks old db/db-ChAT-tg mice as compared to that of the 12-weeks 
old db/db-ChAT-tg mice. These results suggest that in-vivo activation of cardiac NNCS 
prevented a decline in the number of coronary vessels. Importantly, these findings also indicate 
that the blood and oxygen delivery to the myocardium was improved in the db/db-ChAT-tg 




Apart from this, the diameter of coronary vessels in the db/db-ChAT-tg mice was increased in 
the baseline condition, although the changes were not statistically significant (Figure 4.11A&B). 
While the reason for this is not known, Oikawa et al. [267] showed that the cardiac ACh and 
nitric oxide (NO) were significantly increased after overexpression of the ChAT gene. An 
increase in NO production was resulted from the ACh-muscarinic receptor stimulation [99, 268, 
269]. Although cardiac NO and ACh content were not measured in the present study, the effect 
of increased vascular diameter may indicate a possibility that endogenous ACh- and NO-
induced vasodilation in the db/db-ChAT-tg mice under baseline condition [270, 271].  
Previous studies demonstrated coronary endothelial dysfunction as indicated by blunted ACh-
induced change in the diameter of coronary vessels in the db/db mice [16, 272, 273]. While in 
my study, the findings showed that exogenous addition of ACh- and SNP-induced diameter 
changes were comparable between the db/db and db/db-ChAT-tg at 12- and 24-weeks of age 
respectively (Figure 4.12). This result could again indicate that the diameter of coronary vessels 
in db/db-ChAT-tg mice may have already been increased under baseline condition, and thus, 
the changes induced by ACh and SNP were not evident. Therefore, future study should consider 
using vasoconstrictor such as phenylephrine to examine the magnitude of the diameter’s 
changes, which in return will provide information on whether the coronary vessels are partially, 
or entirely wider in the db/db-ChAT-tg mice under baseline condition. Nonetheless, the 
exogenous addition of ACh and SNP did further increase the number of third and fourth-order 
coronary vessels in the db/db and db/db-ChAT-tg mice (Figure 4.13A&B). Notably, the increase 
in the number was minimal in the db/db mice after ACh infusion (Figure 4.13A), comparing to 
the increase in number after SNP infusion (Figure 4.13B). This result suggests endothelial 
dysfunction in the db/db mice. Conversely, the db/db-ChAT-tg mice exhibited a significant 
increase in the number of third and fourth-order coronary vessels after ACh and SNP infusion, 




Hinkel et al. [274] reported the density of capillary was significantly reduced in the diabetic 
swine model and diabetic human with HF. In line with this, Teng et al. [275] reported that 
capillary rarefaction was observed in the pre-diabetic, T1DM, and T2DM mouse model. These 
findings indicate that microvascular rarefaction plays a role in the pathogenesis of DHD. While 
in my study, the density of capillaries was significantly increased in the db/db-ChAT-tg mice at 
24-weeks of age in comparison to the db/db mice (Figure 4.15). This result suggests that the 
microvascular rarefaction was attenuated in the db/db-ChAT-tg mice. This result is also in 
agreement with Kakinuma et al. [100], who showed that activation of cardiac NNCS increased 
the number of endothelial cells in the ventricles, indicating enhanced microvasculature. Thus, 
my findings demonstrate that in-vivo activation of cardiac NNCS via overexpression of ChAT 
gene preserved endothelial function and maintained coronary macro- and microvasculature in 
the db/db-ChAT-tg mice. 
 
4.5.2.1 Increased VEGF-A expression to maintain coronary vasculature 
Coronary vascular rarefaction is associated with decreased proangiogenic factor VEGF 
expression in the diabetic animal model as well as diabetic human [137, 276, 277]. In particular, 
Rawal et al. [137] demonstrated that reduced VEGF-A protein expression (at 12-weeks of age) 
preceded the reduction in capillaries and small arterioles (<50 µm; at 20-weeks of age) in the 
db/db mice. In my study, the findings showed that the VEGF-A expression was significantly 
increased in the db/db-ChAT-tg mice at 12-weeks of age (Figure 4.16). As the improvements in 
coronary vasculature (Figure 4.10), endothelial function (Figure 4.12) and microvasculature 
(Figure 4.14 & 4.15) were only evident in the db/db-ChAT-tg mice at 24-weeks of age, but not 
the 12-weeks of age, these results suggest that early restoration of VEGF-A could prevent the 
development of vascular dysfunction and rarefaction in the diabetic heart.  
The increase in VEGF-A expression was likely initiated by activation of PI3K/Akt/HIF1α 




target of HIF transcription factor [100, 215, 269, 278]. In line with this, Xue et al. [215] 
demonstrated that cardiac-specific overexpression of HIF1α gene increased VEGF expression 
and the number of capillaries in the T1DM mice. Therefore, this supports that cardiac NNCS 
activation increased VEGF-A expression, which in turn mediates paracrine signaling in the 
endothelial cells and leads to angiogenesis in the db/db-ChAT-tg mice. Further, this molecular 
alteration may contribute to the improved LV function in the db/db-ChAT-tg mice by improving 
blood and oxygen delivery to the myocardium to sustain the myocardial perfusion.  
 
4.5.3 Activation of cardiac NNCS reduced body weight and blood glucose 
level in the db/db mice 
Another observation from my study was the reduction of bodyweight and blood glucose level 
in the db/db-ChAT-tg mice. In generally, the blood glucose level of a normal healthy mouse is 
typically 100 to 200 mg/dL [279]. In my study, the blood glucose level ranged from 353.8 to 
449.9 mg/dL in db/db mice and 269.5 to 319.4 mg/dL in db/db-ChAT-tg mice at the age of 8- 
to 20-weeks old (Figure 4.1B).  
The underlying mechanism of these extra-cardiac effects are not clear. Oikawa et al. [267, 280] 
reported that ventricular-specific overexpression of ChAT gene resulted in an activation of CNS 
via afferent vagus nerve. Such heart-brain crosstalk was evident by increased c-Fos signal in 
the medulla and increased norepinephrine (NE) level in the hypothalamus [267]. Previous 
studies showed that hypothalamic NE plays a role in suppressing food intake [281, 282]. 
Therefore, it may be logical to postulate that weight loss and decreased blood glucose level 
observed in the db/db-ChAT-tg mice could be due to suppressed food intake as a result of 
increased hypothalamic NE. Besides, recent report from Oikawa et al. [280] proposed that 
ventricular-specific overexpression of ChAT gene led to anti-inflammatory response by Kupffer 
cells in the liver through hepatic vagus nerve (i.e. heart-brain-liver crosstalk). Thus, I speculate 




glucose uptake, thereby reducing the blood glucose level. However, as this is out of the scope 
of the present study, more in-depth investigation is required to elucidate the underlying 
mechanism for these effects. 
 
4.6 Limitations 
4.6.1 Assessing the cardiac ACh, glucose and ATP content 
The myocardial tissues from db/db and db/db-ChAT-tg mice were prioritized for western blot 
analysis instead of other analyses such as measurement of cardiac ACh, glucose, and ATP 
content. Thus, this study was not able to provide functional evidence that in-vivo activation of 
cardiac NNCS increases cardiac glucose content and preserves ATP in the diabetic heart.  
 
4.6.2 Aging effect in the db/db and db/db-ChAT-tg mice 
As explained in Chapter 3 (section 3.6.4), comparison of expression changes of the same protein 
target between different age groups had to be omitted as the experimental condition could vary 
from time to time. However, it is undeniable that aging is one of the factors that could alter the 
expression changes. Thus, the experimental setup of the future study should consider this factor.  
 
4.6.3 Assessing the role of GLUT-1 
It is well established that GLUT-1 gene is the direct downstream target of HIF1 transcription 
factor [130] and Kakinuma et al. [100] has also reported that GLUT-1 protein expression was 
increased in the ChAT-tg mice via western blot analysis. Further, it has also been shown that 
cardiac-specific overexpression of GLUT-1 prevented the development of HF in the animal 
model, suggesting an essential role of GLUT-1 in cardiovascular disease [283]. However, as 
the present study only focused on the functional role of GLUT-4, the future study may consider 




4.6.4 Assessing membrane GLUT-4 expression 
As explained in Chapter 3 (section 3.6.5), the measurement of membrane GLUT-4 expression 
could have provided further insight on the function of GLUT-4 in transporting glucose in the 
cardiomyocytes. However, the separation of cytosolic and membrane protein was not initially 
planned. Thus, this is one of the limitations of the study. Future study should carefully design 
the experimental layout and consider this factor.   
 
4.6.5 Specificity of antibodies 
For immunofluorescence analysis, anti-αSMA antibody conjugated with Cy3™ was used as a 
marker for smooth muscle cells. However, the specificity of this antibody was not tested as this 
antibody is no longer available in the laboratory. Thus, this is one of the limitations of the study.   
For western blot analysis, the identification/quantification of the ChAT-, M2AChR- and GLUT-
4-positive band was consistent as described in Chapter 3. However, due to limited resources 
and time, there was no additional control experiment to test the specificity of anti-GLUT-4 
antibody as well as anti-pAKT, anti-AKT, anti-pAMPKα, anti-AMPKα, anti-HIF1α and anti-
VEGF-A antibodies used in this study. This is one of the limitations of the study. Future study 
should consider testing the antibody on purified antigen, overexpressing or knockout 
tissue/cells.  
 
4.6.6 Sample size 
As specified in Chapter 3, power analysis was not performed prior to the experiments. This may 
explain why I often observed an increasing or decreasing trend in protein expression, the 
number of coronary vessels, diameter changes and density of arterioles, and yet, these changes 
were not statistically significant. For example, to effectively detect the significant changes in 
M2AChR expression in the db/db-ChAT-tg mice in comparison to the ND mice at 8-weeks of 




Also, to effectively detect the significant changes in the number of second order coronary 
vessels in db/db mice at 12- and 24-weeks of age (Figure 4.10), power analysis revealed that 
nine mice per group are required (80% power; https://clincalc.com/stats/samplesize.aspx).  
Future study should consider performing power analysis to determine the sample size required 
to detect significant expression changes. 
 
4.7 Conclusion 
Based on the overall findings from this study, I confirm the hypothesis that ventricular-specific 
overexpression of ChAT gene would in turn mediates PI3K/Akt/HIF1α/GLUT-4 signaling 
pathway to promote glucose metabolism, thus improving cardiac function of the diabetic heart 
(Figure 4.17). In addition to this, I also confirm the hypothesis that ventricular-specific 
overexpression of ChAT gene would lead to an increase in VEGF-A expression and promote 
angiogenesis, thus improving vascular function and in turn enhancing the cardiac function of 
the diabetic heart (Figure 4.17). The use of this unique transgenic model confirms the potential 
for modulating cardiac NNCS to improve cardiovascular capacity and prevent the development 
of DHD. However, as the current study only focused on db/db-ChAT-tg mice at 8- to 24-weeks 
of age, further work is certainly required to examine how activation of cardiac NNCS could 
involve in the late progression of diabetes mellitus (or geriatric diabetic mice – 18 to 24 months 





Figure 4.17 The beneficial effect of increased ACh bioavailability in the diabetic heart. 
Activation of cardiac NNCS via overexpression of the ChAT gene in the ventricles increases ACh bioavailability, which in-return releases and binds to M2AChR to 
mediate PI3K/Akt/HIF1α signaling cascade in an auto/paracrine manner. Initiation of this signaling cascade leads to increased GLUT-4 protein expression, which is 
responsible for glucose uptake in the heart. Such alteration restores the metabolic flexibility and rectifies the cardiac metabolism of diabetic cardiomyocytes, thus 
normalizing ATP production and maintaining the contractile function efficiently. Besides, the initiation of PI3K/Akt/HIF1α signaling cascade leads to increased 
VEGF-A protein expression, which is a paracrine mediator responsible for angiogenesis. Such alteration maintains vasculature and increases the number of macro- 
and micro-coronary vessels in the diabetic heart, thus improving coronary circulation and myocardial perfusion.  The improved vascular function in-return improves 




Chapter 5 : The effect of cardiac NNCS activation in the 
diabetic AC16 cells in hypoxia 
 
5.1 Introduction 
The findings from Chapter 4 showed that activation of cardiac NNCS via overexpression of the 
ChAT gene enhanced the cardiovascular function of the diabetic mouse heart. However, it is 
not known if cardiac NNCS-induced upregulation of GLUT-4 could alleviate the damage in the 
diabetic heart in the event of myocardial ischemia. Therefore, in this chapter, the in-vitro study 
was designed to investigate the protective effect of cardiac NNCS activation in diabetic 
cardiomyocytes under the hypoxic condition to mimic ischemic insult.  
 
5.1.1 Myocardial Insulin signaling pathway in the normal and diabetic heart  
In the adult heart, GLUT-4 is the key glucose transporter for glucose uptake [285]. Under the 
basal condition, GLUT-4 resides in the intracellular vesicles, and it can be translocated to the 
membrane by insulin. As shown in Figure 5.1, insulin binds to the insulin receptor (IR) and 
leads to autophosphorylation of the receptor’s β subunit (IRβ). The activated IR binds to and 
phosphorylates insulin receptor substrate family proteins (IRS1-3), which in turn binds and 
recruits PI3K to the cellular membrane. PI3K phosphorylates phosphatidylinositol 4,5-
biphosphate (PIP2) to phosphatidylinositol-3, 4,5-triphosphate (PIP3), which in turn activates 
phosphoinositide-dependent protein kinase 1 (PDK1). PDK1 phosphorylates Akt and activated 
Akt subsequently phosphorylates Rab GTPase-activating protein AS160, causing dissociation 
of AS160 from GLUT-4 containing vesicles. This dissociation initiates GLUT-4 containing 
vesicles to translocate and fuse with the plasma membrane, thus promoting glucose uptake 





Figure 5.1 Insulin-mediated glucose uptake signaling pathway  
Insulin binds to the IR and activates IRS1/PI3K/Akt signaling cascade. Activated Akt phosphorylates 
AS160, and thus dissociating AS160 from the GLUT-4 containing vesicles. This dissociation allows the 
vesicles to be translocated and fused with the plasma membrane to promote glucose uptake.  
 
Myocardial insulin resistance is characterized by the impaired biologic response to insulin 
stimulation, thus decreasing insulin-stimulated glucose uptake in the diabetic heart [287]. This 
defect can be caused by decreased protein expression of IRβ and IRS1 [288],  increased 
inhibitory phosphorylation of IRS1 [289], thereby reducing AKT activation [290] and blunting 
insulin-mediated signaling. Further, diabetes leads to a reduction in GLUT-4 expression and 
defective GLUT-4 translocation to the plasma membrane [58, 291, 292]. Collectively, impaired 
insulin signaling, as well as reduced GLUT-4 expression and activity, adversely affect glucose 
metabolism in the diabetic heart. In support of this, Belke et al. [20] showed that the 
overexpression of GLUT-4 improved glycolysis and cardiac contractile function in the diabetic 





5.1.2 Diabetic heart in ischemia  
Metabolic derangement impairs vascular function and accelerates the formation of 
atherosclerotic plaques in the epicardial coronary arteries, thus causing CAD in diabetic 
individuals [7, 68, 293-296]. Additionally, endothelial dysfunction in the coronary microvessels 
impairs myocardial perfusion and results in chest pain syndromes similar to CAD in the absence 
of atherosclerotic plaques [297-299]. Both CAD and CMVD cause myocardial ischemia in the 
diabetic heart, thus limiting coronary blood flow and oxygen perfusion. 
A healthy heart can switch to glucose metabolism for efficient ATP production during 
myocardial ischemia [42-45]. The glucose uptake is facilitated by GLUT-4 [300], and the 
mediator for ischemia-induced GLUT-4 membrane translocation is AMPK, which is activated 
by energy depletion (i.e., high AMP/ATP ratio) [44, 224, 228, 301-303]. However, the diabetic 
heart is unable to induce GLUT-4 membrane translocation due to insulin resistance and 
metabolic derangement [47-51, 55, 304]. On top of this, defective AMPK activation impairs 
glucose utilization in the diabetic heart [226, 227, 265, 266]. In this case, myocardial ischemia 
reduces oxygen availability to oxidize FFA in diabetic heart, thus halting ATP production and 
decreasing contractile function [21, 45, 80, 81].  
 
5.1.3 Cardiac NNCS-induced glucose metabolism to protect the heart 
against ischemia 
As outlined in the previous chapter, activation of cardiac NNCS promotes glucose metabolism 
through increasing GLUT-4 expression to transport glucose [100]. Further, Kakinuma et al. 
[100] showed that ChAT-tg mice had a higher survival rate after chronic ischemia induced by 
left artery descending (LAD) ligation. In addition to this, the ChAT-tg heart was resistant to 
ischemia-reperfusion injury induced using ex-vivo Langerdorff perfusion [100]. Kakinuma et 
al. [100] further showed that the intracellular ATP content was increased and accompanied by 




tg mice [100]. Notably, glucose metabolism requires approximately 15% lesser oxygen 
molecules for oxidation to produce the same amount of ATP from FFA metabolism (reviewed 
in [305]). Thus, these results demonstrate the activation of cardiac NNCS promotes glucose 
metabolism, which in turn reduce oxygen demand and enhance ATP production during 
ischemia, thereby protecting the heart against ischemia-reperfusion injury.   
 
5.2 Study aim 
The aims of this chapter are to (1) establish an in-vitro diabetic cardiomyocytes model using 
AC16 cells (human ventricular cardiomyocytes), and (2) to investigate whether overexpression 
of ChAT gene has beneficial effects by preventing hypoxia-induced cell death. I hypothesized 
that palmitate and glucose treatment would impair insulin signaling cascade and induce insulin 
resistance in the AC16 cells. Further, I hypothesized that overexpression of ChAT gene in the 
diabetic AC16 cells would lead to an increase GLUT-4 expression, thus sustaining energy 
production and reducing apoptosis under hypoxic condition. 
 
5.3 Materials and methods 
This section only outlines the specific reagents, concentration, and conditions used for each 
general method. Detailed experimental procedures for general methods are described in 
‘Chapter 2: General materials and methods’. 
 
5.3.1 Human ventricular cardiomyocyte cell line – AC16 cells 
AC16 cells were maintained and grown in cell culture media composed of DMEM (Gibco, 
31600034) with 5% FBS (Hyclone, SH30406.02) and 1X antibiotic-antimycotic solution 
(Gibco, 15240062), under 37⁰C and 5% CO2. The complete DMEM medium was changed every 





5.3.2 Overexpression of human ChAT gene in AC16 cells 
The AC16 cells were seeded at a density of 0.75x105 cells/cm2, which resulted in approximately 
90% confluency after overnight attachment. Then, the cells were transfected with pReceiver-
M83 expression plasmid with the human ChAT gene (M83-hChAT) or without an open reading 
frame (M83-neg) as a negative control for 24 hours. The expression plasmid allows 
simultaneous expression of mCherry fluorescent protein to determine the transfection 
efficiency (Chapter 2, Section 2.6.3).  
 
5.3.3 Induction of insulin resistance in AC16 cells 
The AC16 cells were seeded at a density of 0.6x105 cells/cm2, which resulted in approximately 
70% confluency after overnight attachment. The cells were incubated in DMEM serum-free 
medium containing 400 μM palmitate/4% BSA complex, 30.5 mM glucose, and 1X antibiotic-
antimycotic solution for 48 hours (addressed as diabetic cells) to induce insulin resistance [306]. 
The AC16 cells which served as a vehicle control were incubated in DMEM serum-free medium 
containing 5.5 mM glucose, 25 mM mannitol (osmotic control), non-conjugated 4% BSA 
solution and 1X antibiotic-antimycotic solution for the same duration (addressed as control cells; 
Chapter 2, Section 2.7).  
 
5.3.4 Hypoxic condition 
The cells were cultured in basal DMEM serum-free medium with 1X antibiotic-antimycotic 
solution under 37⁰C, 5% CO2 and 1% O2 (nitrogen level was approximately 94%) or 24 hours 
to induce hypoxic injury.  
 
5.3.5 Combined experimental protocol 
The ultimate aim of this study was to investigate the protective effect of cardiac NNCS 




were first subjected to 24 hours of transfection (Section 5.3.2), followed by 48 hours of 
palmitate and glucose treatment (Section 5.3.3) and finally exposing the cells to 24 hours of 
hypoxic condition (Section 5.3.4). The purpose of this combined experimental setup was to (1) 
activate cardiac NNCS via overexpression of ChAT gene first, then (2) induce insulin resistance, 
and finally (3) subjected the treated and transfected cells to the low oxygen environment.  
 
5.3.6 Oil Red O (ORO) staining of AC16 cells 
ORO staining was performed as described in Chapter 2 (Section 2.8) to visualize the palmitate 
deposition in the AC16 cells after 48 hours of vehicle or palmitate and glucose treatment. 
 
5.3.7 Staining of IRX4, CTNI, ChAT, and GLUT-4 in AC16 cells 
The staining of Iroquois homeobox 4 (IRX4; ventricular marker) and CTNI (cardiac marker) 
were performed to demonstrate AC16 cells are the cardiac-ventricular origin (Chapter 2, 
Section 2.4). Besides, to confirm that AC16 endogenously expression the key components of 
cardiac NNCS as well as the key glucose transporter, cells were immunostained for ChAT and 
GLUT-4 (along with DAPI at 1:1,000 for nuclei staining). The specificity of anti-ChAT and 
anti-CTNI antibodies were tested on ventricular tissue of db/db-ChAT-tg mouse (positive 
control; Appendix 3, Figure S3.1) and skeletal muscle tissue of ND mouse (negative control; 
Appendix 3, Figure S3.2). The specificity of anti-IRX4 antibody was tested by one of the Ph.D. 
students from Katare lab on undifferentiated iPSC and iPSC-induced ventricular cells. However, 
the specificity of anti-GLUT-4 antibody was not tested as explained in previous chapter, thus, 
this is one of the limitations of the study. Table 5.1 summarizes the information of each 







Table 5.1 Information on antibodies/label for immunofluorescence  




IRX4 Rabbit 1:100 Abcam, AB123542 
CTNI (antibody is biotinylated) Mouse 1:100 NovusBio, NB110-2546B 
ChAT Rabbit 1:100 Abcam, AB181023 






AlexaFluor® 488 conjugated anti-rabbit IgG Goat 1:200 Invitrogen, A32731 
Streptavidin-AlexaFluor® 568 - 1:200 Invitrogen, S11226 
AlexaFluor® 633 conjugated anti-rabbit IgG Goat 1:100 Invitrogen, A21070 
 
5.3.8 Western blot analysis 
Total protein (Section 2.3.2.1), or cytosolic and membrane protein extraction (Section 2.3.2.2) 
from AC16 cells was performed. The cytosolic and membrane fraction of protein were 
separated as part of the experiments required to detect membrane-specific proteins. An equal 
amount of protein was loaded and electrophoresed and blotted for following protein targets, 
processed as described in Section 2.3.2.4. The protein expression of pan-cadherin (membrane 
protein) was detected via western blot analysis to confirm the successful separation of cytosolic 
and membrane protein (Appendix 5, Figure S5.1). The band intensity of the target protein was 
normalized to a prominent band between 37 kDa and 50 kDa on the Ponceau S stained blot as 
described in Chapter 2 (section 2.3.2.5) [143, 144] and expressed as fold changes towards the 
control group [145]. As explained in Chapter 4 (Section 4.3.3), the quantification of the 
phosphorylation of Akt and AMPKα was done by normalizing to its respective total protein as 
well as to a prominent band between 37 kDa and 50 kDa on the Ponceau S stained blot. The 




















pAkt (Ser473) Rabbit/polyclonal 1:1,000 60 
Cell Signaling, 
9272 
Akt Rabbit/polyclonal 1:1,000 60 
Cell Signaling, 
9271 
pAMPKα (Thr172) Rabbit/polyclonal 1:1,000 62 
Cell 
Signalling,2531 
AMPKα Rabbit/polyclonal 1:1,000 62 
Cell Signaling, 
2532 
ChAT Goat/polyclonal 1:1,000 70/74 Chemicon, AB144P 
Cleaved caspase-3 (Asp175) Rabbit/polyclonal 1:500 17/19 
Cell Signaling, 
9661 
GLUT-4 Rabbit/polyclonal 1:2,500 55 
NovusBio, NBP1-
49533 
Pan-cadherin  Mouse/monoclonal 1:1,000 125-140 Abcam, Ab6528 
Secondary antibodies 
Anti-goat IgG, HRP 
conjugated 
Mouse 1:3,000 - 
Santa Cruz, 
SC2354 
Anti-rabbit IgG, HRP 
conjugated 
Goat 1:5,000 - 
Sigma-Aldrich, 
A6154 
Recombinant mouse IgGҡ 
light chain binding protein, 
HRP conjugated 
- 1:3,000 - 
Santa Cruz, 
SC516102 
Note: the predicted molecular weight of protein is recommended by the manufacturer 
 
5.3.9 Statistical analyses 
All statistical analyses were performed using GraphPad Prism (version 7) in consultation with 
biostatistician Mr. Andrew Grey and Dr. Claire Cameron (Centre for Biostatistics, University 
of Otago). Data are expressed as the mean ± SEM. Two-way ANOVA followed Tukey’s test 
for multiple comparison test was performed to analyze the protein expression of all target. 
However, the total sample number in Figure 5.7 is too small for a normality test (n=4). Thus 
the protein expressions of ChAT, cytosolic, and membrane GLUT-4 protein expression were 







5.4.1 ChAT and GLUT-4 are endogenously expressed in the human 
ventricular AC16 cells 
AC16 cell line is a fusion of non-proliferating primary cultures of human adult ventricular heart 
tissues with SV40 transformed human fibroblasts [141]. The immunofluorescence analysis was 
performed to demonstrate the cardiac-ventricular origin of AC16 cells by detecting IRX4 
(ventricular marker) and CTNI (cardiac marker). The results showed the expression of CTNI 
was localized in the cytoplasm (Figure 5.2A), and IRX4 was localized in the perinuclear region 
(Figure 5.2B) of the AC16 cells. Next, immunofluorescence analysis was performed to 
demonstrate if AC16 cells endogenously express ChAT to synthesize ACh and GLUT-4 to 
transport glucose. The findings showed perinuclear localization of ChAT (Figure 5.2C) and 
both cytoplasmic and perinuclear localization of GLUT-4 in the AC16 cells (Figure 5.2D). The 
immunofluorescent images for secondary antibody-only control for staining of CTNI, IRX4, 
ChAT, and GLUT-4 are in Appendix 5 (Figure S5.2). The overall findings indicate that the 
ventricular AC16 cells are a suitable model to study cardiac NNCS as these cells endogenously 
express ChAT and GLUT-4 expression that was required to serve as a control to compare with 







Figure 5.2 Immunostaining of CTNI, IRX4, ChAT, and GLUT-4 in AC16 cells.  
Representative fluorescent images showing the staining of (A) cardiac marker, CTNI; (B) ventricular 
marker, IRX4; (C) cardiac NNCS marker, ChAT; and (D) GLUT-4 in AC16 cells.  
 
5.4.2 Establishment and validation of the in-vitro diabetic model 
An in-vitro diabetic model was established to study the role of cardiac NNCS in diabetic 
condition. AC16 cells were either treated with 400 μM palmitate and 30.5 mM glucose (diabetic) 
or vehicle treatment (no palmitate and 5.5 mM glucose; control) for 48 hours. Forty-eight hours 
was chosen as there was no significant decrease in insulin-stimulated membrane GLUT-4 
translocation after 24 hours of treatment (Appendix 5, Figure S5.3). ORO staining was 
performed to visualize the intracellular deposition of palmitate in the AC16 cell to confirm 
palmitate uptake in the AC16 cells (Figure 5.3A). The analysis showed that incubation with 




of viable cells remained compared to the control cells without palmitate treatment (Appendix 
5, Figure S5.4). 
As palmitate is known to impair insulin signaling cascade by inhibiting Akt phosphorylation 
[306, 307], the next experiment was to measure the phosphorylated and total expression of Akt 
in the cytosolic fraction. Also, as explained in Chapter 4, two approaches of normalization were 
performed to examine the phosphorylation level of Akt. In generally, these two approaches 
showed identical results. The basal phosphorylation level of Akt was significantly decreased in 
the diabetic cells compared to that of the control cells (Figure 5.3B). The control and diabetic 
cells were stimulated with 500 nM insulin for 30- and 60-mins to examine the insulin 
responsiveness after palmitate and glucose treatment. Five hundred nanomolar of insulin was 
chosen based on the optimization experiment to induce membrane GLUT-4 translocation 
(Appendix 5, Figure S5.5). The findings revealed that the phosphorylation level of Akt was 
significantly increased after stimulating the control and diabetic cells with insulin (Figure 5.3B). 
However, the phosphorylation level of Akt was lower in the diabetic AC16 cells in comparison 
to the control AC16 cells after 60-mins of insulin stimulation (Figure 5.3B), suggesting reduced 
insulin responsiveness after palmitate and glucose treatment. The total Akt protein expression 
was not altered in control AC16 cells. However, after 60-mins of insulin stimulation, the total 
Akt protein expression was significantly decreased in the diabetic AC16 cells. Thus, this could 
indicate that palmitate and glucose treatment reduced the availability of Akt for phosphorylation, 






Figure 5.3 Decreased insulin responsiveness in the diabetic AC16 cells. 
(A) Representative images showing the ORO staining of control and diabetic AC16 cells after 48 hours 
of treatment. The hematoxylin-stained nuclei are in blue while the ORO-stained palmitate appears in 
red. Yellow arrows indicate ORO-positive cells. The diabetic cells showed palmitate deposition, while 
the control cells did not show palmitate deposition after treatment. (B) Representative blots and bar 
graphs with scatter plots showing the phosphorylated (Ser473) and total Akt protein expression in AC16 
cells after 48 hours of vehicle or palmitate and glucose treatment. After treatment, the cells were 
stimulated with 500 nM of insulin for 30- and 60-mins to test the insulin responsiveness. Data are 
expressed as mean ± SEM. Two-way ANOVA with Tukey’s multiple comparisons test was performed. 
***p<0.001, ****p<0.0001 VS respective control or diabetic AC16 cells treated with 0 nM insulin; 
##p<0.01, ###p<0.001, ####p<0.0001 VS respective control AC16 cells with same insulin stimulation 
duration. The number of samples per group is indicated in the figure. The total number of samples was 
derived from three independent experiments. 
 
The protein expression of membrane GLUT-4 was measured to examine if impaired Akt 
activation correlates with insulin-stimulated GLUT-4 membrane translocation. Thirty and sixty 
minutes (mins) of insulin stimulation gradually increased the membrane GLUT-4 expression in 
control AC16 cells; however, the increase in expression was not statistically significant (Figure 




after 30-mins of insulin stimulation. After 60-mins of stimulation, membrane GLUT-4 protein 
expression was significantly decreased (Figure 5.4A). This observation suggests decreased 
GLUT-4 membrane translocation in diabetic AC16 cells, which is in agreement with reduced 
insulin responsiveness. The cytosolic GLUT-4 expression in the control and diabetic cells did 
not change after 30- and 60-mins of insulin stimulation (Figure 5.4B). These findings suggest 
that decreased membrane GLUT-4 protein expression in the diabetic cells could possibly due 
to a retention of GLUT-4 in the intracellular vesicles after palmitate and glucose treatment. 
 
     
Figure 5.4 Decreased membrane GLUT-4 protein expression in the diabetic AC16 cells. 
Representative blots and bar graphs with scatter plots showing the (A) membrane GLUT-4 protein 
expression and (B) cytosolic GLUT-4 protein expression in AC16 cells after 48 hours of vehicle or 
palmitate and glucose treatment. After treatment, the cells were stimulated with 500 nM of insulin for 
30- and 60-mins to test the insulin responsiveness in translocating GLUT-4 to the plasma membrane. 
Data are expressed as mean ± SEM. Two-way ANOVA with Tukey’s multiple comparisons test was 
performed. *p<0.05 VS diabetic AC16 cells treated with 0 nM insulin; ##p<0.01 VS control AC16 cells 
with same insulin stimulation duration. The number of samples per group is indicated in the figure. The 
total number of samples was derived from three independent experiments. 
 
ChAT protein expression was measured to examine the effect of palmitate and glucose 
treatment on ACh synthesis. The basal ChAT protein expression was unaltered in both the 
control and diabetic AC16 cells (Figure 5.5). In response to 30- and 60-mins of insulin 
stimulation, the control AC16 cells showed an increasing trend in the ChAT protein expression, 




increasing trend in ChAT expression, this was absent after 60-mins of insulin stimulation 
(Figure 5.5).  
Taken together, the overall findings from this section indicate that palmitate and glucose 
treatment significantly decreased Akt phosphorylation, insulin-stimulated GLUT-4 membrane 
translocation in the diabetic AC16 cells. Therefore, this model can be used to investigate the 
effect of activation of cardiac NNCS via overexpression of the ChAT gene in regulating GLUT-
4 expression.   
 
 
Figure 5.5 Insulin stimulation modulated ChAT expression in AC16 cells. 
Representative blots and bar graphs with scatter plots showing the ChAT protein expression in AC16 
cells after 48 hours of vehicle or palmitate and glucose treatment. Data are expressed as mean ± SEM. 
Two-way ANOVA with Tukey’s multiple comparisons test was performed. The number of samples per 
group is indicated in the figure. The total number of samples was derived from three independent 
experiments. 
 
5.4.3 Overexpression of ChAT gene in the AC16 cells 
AC16 cells were transfected with M83-hChAT plasmid to overexpress human ChAT gene 
(hChAT) while the cells transfected with M83-neg plasmid served as a negative control (WT). 
Both expression plasmids allowed simultaneous expression of mCherry fluorescent protein to 
determine the transfection efficiency. The transfection efficiency was approximately 40% 




GLUT-4 fluorescent intensity in the hChAT transfected cells compared to that of the WT cells 
(Figure 5.6 A). The immunofluorescent images of secondary antibody-only control for ChAT 
and GLUT-4 staining are in Appendix 5 (Figure S5.7). Further, western blot analysis revealed 
that overexpression of the ChAT gene resulted in an approximately 10.2±2.8-fold increase in 
the ChAT protein expression in the hChAT transfected cells (Figure 5.6B). Also, the total 
GLUT-4 protein expression was significantly increased in the hChAT cells. The increase in 
GLUT-4 protein expression is likely to be mediated by PI3K/Akt/HIF1α/GLUT-4 signaling 
pathway via cardiac NNCS as a result of overexpression of ChAT gene, as discussed in Chapter 
4 and by Kakinuma et al. [100]. 
 
 
Figure 5.6 ChAT and GLUT-4 protein expression in the transfected AC16 cells. 
(A) Representative confocal images showing the expression of mCherry fluorescent proteins and 
staining of ChAT and GLUT-4 proteins in the WT and hChAT transfected cells. (B) Representative blots 
and bar graphs with scatter plots showing the protein expression of ChAT and total GLUT-4 protein 
expression in the WT and hChAT transfected AC16 cells. Data are expressed as mean ± SEM. Unpaired 
T-test was performed. *p<0.05, ****p<0.0001 VS WT AC16 cells. White arrows indicated transfected 
AC16 cells. The number of samples per group is indicated in the figure. The total number of samples 





To further investigate if the hChAT transfected cells express increased GLUT-4 protein 
expression in the plasma membrane, the cytosolic and membrane fraction of protein lysates 
were separated and analyzed. Western blot analysis revealed that membrane GLUT-4 protein 
expression was significantly increased in the hChAT transfected cells (Figure 5.7). The 
decrease in cytosolic GLUT-4 protein expression in hChAT transfected cells was not 
statistically significant. However, the decreasing trend supports that GLUT-4 proteins in the 
intracellular vesicles have translocated to the plasma membrane.    
 
 
Figure 5.7 ChAT, membrane and cytosolic GLUT-4 protein expression in the hChAT transfected 
AC16 cells. 
Representative blots and bar graphs with scatter plots showing the protein expression of ChAT, cytosolic, 
and membrane GLUT-4 protein expression in the M83-neg and M83-hChAT transfected cells. Data are 
expressed as mean ± SEM. A non-parametric Mann-Whitney test was performed. *p<0.05 VS WT AC16 
cells. The number of samples per group is indicated in the figure. The total number of samples was 
derived from two independent experiments. 
 
5.4.4. The role of cardiac NNCS in diabetic AC16 cells under hypoxic 
condition 
The protein expression of ChAT was measured to examine whether the palmitate and glucose 
treatment, as well as hypoxic condition, affects the cardiac NNCS. Western blot analysis 
showed no difference in the endogenous ChAT expression between the control and diabetic 




respectively. However, diabetic WT cells showed a significant decrease in the endogenous 
ChAT expression following hypoxia (Appendix 5, Figure S5.8). Similarly, the control and 
diabetic hChAT transfected cells showed a substantial decrease in the ChAT expression 
following hypoxia (Appendix 5, Figure S5.8). Thus, these results suggest that hypoxia 
decreased ChAT expression. Further, diabetic hChAT transfected cells showed an only 2.2±0.3-
fold increase in the ChAT expression in hypoxic condition. The decrease in ChAT expression 
was caused by the combinational effect of palmitate and glucose treatment, as well as hypoxia 
(Figure 5.8; Appendix 5, Figure S5.8). Therefore, the overall findings suggest that ACh 
synthesis was reduced in the diabetic cells in hypoxic condition, which may reduce the 
activation of ACh-mediated pro-survival signaling cascade. 
 
 
Figure 5.8 Palmitate and glucose treatment decreased ChAT protein expression in the hChAT 
transfected AC16 cells under hypoxic condition. 
Representative blots and bar graphs with scatter plots showing the protein expression of ChAT in the 
control/diabetic and WT/hChAT AC16 transfected cells after 24 hours of 1% O2 hypoxic condition.  Data 
are expressed as mean ± SEM. Two-way ANOVA with Tukey’s multiple comparisons test was performed. 
****p<0.0001 VS control WT cells; ####p<0.0001 VS control hChAT transfected cells. The number of 
samples per group is indicated in the figure. The total number of samples was derived from three 
independent experiments. 
 
To examine if GLUT-4 expression was also decreased due to reduced ChAT expression in the 




and cytosolic GLUT-4 protein expression were examined. Western blot analysis revealed that 
there were no significant changes in the membrane and cytosolic GLUT-4 expression in the 
control hChAT transfected AC16 cells (Figure 5.9A&B). However, there was a substantial 
decrease in the membrane GLUT-4 protein expression in the diabetic WT cells (Figure 5.9A), 
suggesting reduced translocation of GLUT-4 to the membrane and possibly decreased glucose 
uptake. There was no significant change in the cytosolic GLUT-4 expression in the diabetic 
WT cells (Figure 5.9B). In contrast, the membrane GLUT-4 expression was unaltered while the 
cytosolic GLUT-4 expression was significantly reduced in the diabetic hChAT transfected cells 
(Figure 5.9A&B). This result suggests that diabetic hChAT transfected cells prevented the 
decrease in membrane GLUT-4 possibly by translocating the cytosolic GLUT-4 to plasma 
membrane under hypoxic condition. Thus, the overall findings suggest that cardiac NNCS was 
still activated in the diabetic cells, and activation of cardiac NNCS preserved membrane GLUT-
4 expression when exposed to hypoxia.  
 
 
Figure 5.9 Normalized membrane GLUT-4 protein expression in the diabetic hChAT transfected 
AC16 cells under hypoxic condition. 
Representative blots and bar graphs with scatter plots showing the (A) membrane GLUT-4 protein 
expression and (B) cytosolic GLUT-4 protein expression in the control/diabetic and WT/hChAT 
transfected AC16 cells after 24 hours of 1% O2 hypoxic condition. Data are expressed as mean ± SEM. 
Two-way ANOVA with Tukey’s multiple comparisons test was performed. *p<0.05 VS diabetic WT cells; 
#p<0.05, ####p<0.0001 VS respective control WT or hChAT transfected cells. The number of samples per 






Previous studies showed that improved glucose transport under ischemic condition alleviates 
ischemic damage and prevents cell death [224, 308]. Since diabetic hChAT transfected cells 
preserved membrane translocation of GLUT-4 under hypoxic condition, the next aim was to 
determine if hypoxia-induced apoptosis could be alleviated. Western blot analysis was 
performed to measure the protein expression of pro-apoptotic marker cleaved caspase-3. The 
anti-cleaved caspase 3 antibody is polyclonal and resulted in multiple bands. However, based 
on the predicted molecular weight recommended by the manufacturer, I identified the two bands 
at/above molecular weight of 17 kDa as cleaved-caspase 3 positive (17/19 kDa; Appendix 2, 
Figure S2.8). The analysis showed that palmitate and glucose treatment significantly increased 
the protein expression of cleaved caspase-3 in both the diabetic WT and hChAT transfected 
cells in comparison to that of the control WT and hChAT transfected cells respectively (Figure 
5.10).  There was no difference between the diabetic WT and diabetic hChAT transfected cells 
after palmitate and glucose treatment. This result suggests that the extent of the hypoxic injury 
was not altered by overexpression of the ChAT gene in the AC16 cells. (Note: Figure 5.10 
shows a total of 12 samples per group derived from four independent experiments. However, 
three protein samples isolated from one of the independent experiments had low protein amount, 
and hence I was only able to perform western blot analysis for cleaved caspase-3 protein, but 






Figure 5.10 Increased cleaved caspase-3 protein expression in the diabetic cells under hypoxic 
condition. 
Representative blots and bar graphs with scatter plots showing the cleaved caspase-3 protein expression 
in the control/diabetic and WT/hChAT transfected AC16 transfected cells after 24 hours of 1% O2 
hypoxic condition.  Data are expressed as mean ± SEM. Two-way ANOVA with Tukey’s multiple 
comparisons test was performed. ##p<0.01 VS respective control WT or hChAT transfected AC16 cells. 
The number of samples per group is indicated in the figure. The total number of samples was derived 
from four independent experiments. 
 
One reason for the failure to reduce the hypoxia-induced apoptosis by activation of cardiac 
NNCS in the diabetic cells could be due to impaired ATP production under hypoxic condition. 
Thus, the next aim was to examine if the ATP homeostasis regulated by AMPK was affected 
by palmitate and glucose in the hypoxic condition. As explained in Chapter 4, two approaches 
of normalization were taken to examine the phosphorylation level of AMPKα. However, such 
normalizations resulted in two different sets of result. By normalizing to the selected band 
between 37 kDa and 50 kDa on the Ponceau S stained blot, the phosphorylation level of 
AMPKα was significantly decreased in the diabetic WT and hChAT transfected cells under 
hypoxic condition (Figure 5.11). Conversely, by normalizing to total AMPKα expression, the 
phosphorylation level of AMPKα was unchanged in diabetic WT and hChAT transfected cells 








Figure 5.11 Decreased AMPK activation in the diabetic cells under hypoxic condition. 
Representative blots and bar graphs with scatter plots showing the phosphorylated (Thr172) and total 
AMPKα protein expression in control/diabetic and WT/hChAT transfected AC16 cells after 24 hours of 
1% O2 hypoxic condition. Data are expressed as mean ± SEM. Two-way ANOVA with Tukey’s multiple 
comparisons test was performed. *p<0.05 VS control WT cells; ##p<0.01, ####p<0.0001 VS respective 
control WT or hChAT transfected AC16 cells. The number of samples per group is indicated in the figure. 







In this chapter, the in-vitro diabetic AC16 cell model was first established. This purpose of 
developing this model was to investigate the role of cardiac NNCS under “diabetic” condition. 
Human ventricular-origin AC16 cell line is a suitable model to study the role of cardiac NNCS 
in regulating glucose metabolism as it expresses ChAT and GLUT-4 endogenously. To 
investigate the effect of cardiac NNCS in protecting the diabetic AC16 cells in hypoxic 
condition, the experiments were carried out in three steps: (1) 24 hours of transfection to 
overexpress human ChAT gene in AC16 cells, then (2) 48 hours of palmitate and glucose 
treatment to induce diabetic effect, and finally (3) 24 hours of incubation in 1% O2 hypoxic 
condition. I hypothesized that palmitate and glucose treatment would impair insulin signaling 
cascade and induce insulin resistance in the AC16 cells. Further, I hypothesized that 
overexpression of ChAT gene in the diabetic AC16 cells would lead to an increase GLUT-4 
expression, thus sustaining energy production and reducing apoptosis under hypoxic condition. 
The main findings of this study can be summarized as follows: 
 
1. Diabetic AC16 cells: 
• Palmitate and glucose treatment impaired insulin signaling cascade as evidenced by 
decreased basal and the insulin-stimulated phosphorylation level of Akt expression 
and insulin-stimulated membrane GLUT-4 protein expression. 
• The basal ChAT protein expression was unaffected. However, the insulin-induced 
increased ChAT protein expression was abolished in the diabetic AC16 cells.  
 
2. hChAT transfected AC16 cells: 






3. Diabetic hChAT transfected AC16 cells in hypoxic condition: 
• The decrease in membrane GLUT-4 protein expression was prevented in 
comparison to diabetic WT AC16 cells. 
• The hypoxic injury was not alleviated as cleaved caspase-3 protein expression was 
similar to the diabetic WT cells. 
• The phosphorylation level of AMPKα is not clear. Thus, it is not clear if AMPK 
inactivation contributes to the hypoxic injury. 
 
5.5.1 In-vitro diabetic AC16 cells 
In cardiovascular research, the establishment of the in-vitro diabetic model mainly involves the 
use of high glucose [1, 137, 309], palmitate [306, 307], insulin [310] or a combination of 
palmitate and insulin [311] to mimic the in-vivo insulin resistance. Particularly, palmitate 
desensitizes the insulin-mediated glucose uptake by inhibiting Akt phosphorylation [306, 311]. 
In the study performed by Chokshi et al. [312], the diabetic AC16 cells exhibited decreased 
basal and insulin-stimulated Akt phosphorylation after 16 hours of palmitate treatment. 
However, Chokshi et al. [312] did not examine the GLUT-4 membrane translocation in the 
diabetic model. My study showed similar results with a reduction in both basal and insulin-
stimulated Akt phosphorylation in the diabetic cells (Figure 5.3B). Also, my study further 
demonstrated a reduction in insulin-stimulated GLUT-4 membrane translocation in diabetic 
AC16 cells, supporting that the insulin signaling cascade was impaired in the model (Figure 
5.4A).  
The use of diabetic AC16 cells can provide mechanistic insight on how cardiac NNCS is 
specifically altered in the condition of insulin resistance. This is one of the advantages of using 
an in-vitro model over the in-vivo models that typically display a complex pathophysiology 
when different systems and cell types interact with each other. In my study, palmitate and 




5.5 & Appendix 5, Figure S5.8). However, insulin stimulation increased ChAT expression (not 
statistically significant) in control AC16 cells while this effect was abolished in the diabetic 
cells (Figure 5.5). To the best of my knowledge, this is the first study observed the effect of 
insulin in regulating ChAT expression specifically in the ventricular cardiomyocytes. This 
particular effect of insulin was previously demonstrated in neuronal cell lines and the frontal 
lobe and cerebellum of animal model [313-315]. Further, the streptozotocin-induced diabetic 
rats showed decreased ChAT expression in the hippocampus [316]. Taking all these 
information and my results into consideration,  metabolic derangements and insulin resistance 
may suppress ChAT expression in the ventricular cardiomyocytes, and hence preventing the 
activation of cardiac NNCS in T2DM.  
  
5.5.2 Activation of cardiac NNCS did not alleviate hypoxia-induced 
apoptosis in the diabetic AC16 cells  
The previous study showed that glucose oxidation plays a vital role to maintain contractile 
function in mild-to-moderate ischemia (i.e., 60% reduction in LAD coronary blood flow) [45]. 
Tian et al. [300] showed that GLUT-4 is essential to transport glucose into the cardiomyocytes 
for ATP generation in ischemic condition. Notably, Kakinuma et al. [100] showed that 
activation of cardiac NNCS increased GLUT-4 expression, cardiac glucose, and ATP content, 
thereby reducing ischemia-reperfusion injury to the WT ChAT-tg heart. In my study, I 
questioned whether activation of cardiac NNCS could increase the membrane translocation of 
GLUT-4, which in turn could allow efficient ATP production and prevent hypoxia-induced 
apoptosis in the diabetic AC16 cells.  
The overexpression of the ChAT gene did not increase the membrane GLUT-4 translocation in 
the control and diabetic hChAT transfected cells in hypoxia. This outcome could be due to the 
reduction of ChAT expression by palmitate and glucose treatment as well as hypoxia (Appendix 




in membrane GLUT-4 translocation in the diabetic cells (Figure 5.9 A&B). In spite of this, 
hypoxia-induced apoptosis was similar between the diabetic WT and hChAT transfected cells 
(Figure 5.10). Vanoverschelde et al. [317] showed that the rate of glycolysis is invesely 
proportional to ischemic damage in the heart, suggesting that a high rate of glycolysis is 
undoubtedly needed to protect the cardiomyocytes against hypoxia-induced apoptosis.  
Besides, previous studies showed that ischemia-induced activation of AMPK protects the heart 
against ischemia-reperfusion injury [44, 224, 228, 301-303]. Notably, activation of AMPK 
signaling cascade enhanced glucose uptake and oxidation, thus reducing apoptosis in the heart 
[224, 303]. In my study, I was unable to conclude the phosphorylation level of AMPKα as the 
outcome of the result was different depending on the way the data were analyzed (Figure 5.11). 
Whether the phosphorylation level of AMPKα is decreased or unaltered after palmitate and 
hypoxic treatment, this requires further investigation. An ELISA assay to detect phosphorylated 
AMPKα or biochemical assay to detect the activity of AMPK could also be considered in the 
future. However, previous studied showed that palmitate treatment impaired AMPK activation 
in the cardiomyocytes [318] and endothelial cells [319, 320]. Thus, based on these information, 
it may be considered that AMPK-mediated glucose uptake could be prevented by palmitate 
treatment, thus increasing apoptosis following hypoxia. On a side note, the mechanism of 
cardiac NNCS-induced GLUT-4 membrane translocation is likely to be independent on AMPK 
activation in hypoxia, as preserved GLUT-4 membrane translocation was observed in the 
diabetic cells (Figure 5.9A). 
Besides, my results showed that the ChAT expression has to be at least a 10-fold increase to 
enhance membrane GLUT-4 expression in an in-vitro setting (Figure 5.6&5.7). Considering 
that the transfection efficiency was approximately 40% (Appendix 5, Figure S5.6), and due to 
the fact that palmitate and glucose treatment as well as hypoxia decrease ChAT expression 
(Figure 5.8, Appendix 5, Figure S5.8), this suggests that the number of hChAT transfected cells 




treatments. Thus, a longer transfection duration to increase transfection efficiency could be 
considered in the future study. However, this was not performed in the present study due to 
time constraint. Additionally, as the current study performed transient overexpression of the 
ChAT gene in AC16 cells, the future study could consider generating AC16 cells that are stably 
overexpressing ChAT gene as an alternative. Having the ChAT-overexpressing stable cell line 
would omit the lipofectamine transfection step that could also induce cell loss during the 
experimental process.  
 
5.6 Limitations 
5.6.1 The use of the in-vitro diabetic model 
The in-vitro diabetic AC16 established in my study exhibited impaired insulin signaling cascade. 
This allows one to examine how cardiac NNCS is specifically altered under the condition of 
insulin resistance. However, the impaired insulin signaling cascade only represents a subset of 
the pathophysiology of T2DM. Thus, this indicates the limitation of the in-vitro diabetic model 
as it cannot completely mimic the in-vivo insulin resistance in T2DM. 
 
5.6.2 Assessing intracellular ACh, glucose and ATP content 
Due to time constraint, the measurement of intracellular ACh, glucose content, and ATP content 
were not performed. Measurement of these functional parameters would support the findings 
derived from western blot analysis.   
 
5.6.3 Transfection efficiency   
In the present study, lipofectamine-mediated transfection was optimized in the AC16 cells in 
normoxic condition, and this resulted in approximately 40% transfection efficiency. As both 




transfection efficiency is needed to account for the reduction in ChAT expression due to cell 
loss. However, this was not done due to time constraints.  
 
5.6.4 Specificity of antibodies 
As specified in previous chapter, due to limited resources and time, additional control 
experiments were not performed to test the specificity of anti-GLUT-4, anti-pAKT, anti-AKT, 
anti-pAMPKα, anti-AMPKα and anti-cleaved caspase 3 antibodies used in this study. This is 
one of the limitations of the study. Future study should consider testing the antibody on purified 
antigen, overexpressing or knockout tissue/cells. 
 
5.6.5 Sample size 
The present study only collected nine samples from three independent experiments due to time 
constraints. Thus, future study should consider increasing the number of samples to confidently 
detect the expression changes.  
 
5.7 Conclusion 
In summary, I confirm the hypothesis that palmitate and glucose treatment would impair insulin 
signaling cascade and induce insulin resistance in the AC16 cells. However, I do not confirm 
the hypothesis that overexpression of ChAT gene in the diabetic AC16 cells would lead to an 
increase in GLUT-4 expression, thus sustaining energy production and reducing apoptosis 
under hypoxic condition. The reason is that membrane GLUT-4 expression was not increased, 
and hypoxia-induced apoptosis was not alleviated in the diabetic hChAT transfected cells. One 
possible reason could be the ChAT expression was not durable enough to increase the 
membrane GLUT-4 expression in the diabetic hChAT transfected cells in hypoxic condition. 
This is because the results from optimization showed at least a 10-fold increase in ChAT 




transfection duration may be required to increase the transfection efficiency or generation of 
stable ChAT-overexpressing cell line may be favorable in the future study. Apart from this, my 
results also suggest that insulin resistance prevents an insulin-stimulated upregulation of ChAT. 
This result further supports that findings from Chapter 3 that dysregulation of cardiac NNCS is 
caused by metabolic derangement and insulin resistance before the onset of DHD. Nevertheless, 
more in-depth studies are needed to elucidate the underlying mechanism of how metabolic 





Chapter 6 : General discussion 
6.1 Overview of key findings 
The main findings of my thesis are: 
1. Chapter 3: Changes in cardiac NNCS is associated with the development of DHD  
• Time-dependent increase or decrease in the expression of the components of 
cardiac NNCS (i.e., ChAT, CHT1, VAChT, AChE, and M2AChR) in the diabetic 
heart. In the db/db mice, increased AChE and decreased M2AChR expression was 
observed in the early stage of T2DM (8-, 12- and 16-weeks of age), followed by 
increased VAChT and CHT1 expression as well as decreased AChE and M2AChR 
expression at 20- and 24-weeks of age. Subsequently, decreased ChAT, AChE, and 
M2AChR expression as well as increased VAChT expression at 28- and 32-weeks of 
age (Figure 3.18). Further, decreased CHT1 expression was observed in the diabetic 
human heart. These novel findings provide evidence that cardiac NNCS is dysregulated 
in T2DM, and the changes in the components of cardiac NNCS may play a role in the 
diabetic heart.  
 
• Decreased GLUT-1 and GLUT-4 expression in the diabetic heart. Previous studies 
showed that GLUT-1 and GLUT-4 expression were decreased in the diabetic heart [20, 
58, 61, 63, 153, 215]. In line with this, my study showed that GLUT-1 and GLUT-4 
expression was decreased in the db/db mice at 16- and 20-weeks of age, respectively. 
The GLUT-1 expression remained decreased till 32-weeks of age. On the other hand, 
GLUT-4 expression was normalized at 24-weeks of age, and the expression was 
subsequently decreased in the db/db mice at 28- and 32-weeks of age. Also, the GLUT-
4 expression, but not GLUT-1 expression, was reduced in the diabetic human heart. The 
findings from my study support that T2DM decreases GLUT-1 and GLUT-4 expression 




diabetic heart. Further, to the best of my knowledge, this is the first study to demonstrate 
the time-dependent expression changes in GLUT-1 and GLUT-4.  
 
• Changes in cardiac NNCS is associated with a decrease in GLUT-4 expression and 
diastolic dysfunction in the diabetic heart. Kakinuma et al. [100] showed that cardiac 
NNCS plays a role in glucose metabolism by regulating GLUT-4 expression. Further, 
previous studies showed that decreased glucose metabolism and basal myocardial 
energy status contributed to cardiac dysfunction in the diabetic heart [19-21, 65-68, 70-
72]. In my study, diabetes increased AChE expression and decreased M2AChR 
expression in the db/db mice at 8- to 16-weeks of age, while GLUT-4 expression and 
diastolic function were decreased at 20-weeks of age [1]. This suggests that altered 
cardiac NNCS could contribute to decreased GLUT-4 expression and cardiac 
dysfunction in diabetes. 
 
• Changes in cardiac NNCS is associated with cardiac hypertrophy and remodeling 
in the diabetic heart. Previous studies reported that cardiac NNCS prevents cardiac 
hypertrophy and remodeling [97, 99, 101, 124]. In my study, altered cardiac NNCS 
preceded the cardiac hypertrophy and remodeling [1], suggesting cardiac NNCS plays 
a role in offsetting hypertrophic signals in the diabetic heart. 
 
2. Chapter 4: Activation of cardiac NNCS is beneficial to the diabetic heart 
• Activation of cardiac NNCS increased GLUT-4 expression and enhanced LV 
systolic function and contractility of the diabetic heart. Belke et al. [20] showed that 
global overexpression of GLUT-4 gene increased glycolysis and glucose oxidation in 
the diabetic heart, and ultimately attenuated diabetes-induced cardiac dysfunction. My 




activation of cardiac NNCS in the ventricles. Further, my study showed that the 
improved LV functions were associated with increased GLUT-4 expression initiated by 
pro-survival PI3K/Akt/HIF1α/GLUT-4 signaling cascade through cardiac NNCS 
(Figure 4.17). Taken together, the findings from my study support the essential role of 
cardiac NNCS in enhancing GLUT-4 expression to regulate cardiac glucose metabolism 
and prevent deterioration of cardiac function in diabetes. 
 
• Activation of cardiac NNCS increased VEGF-A expression and preserved 
coronary vasculature and enhanced the vascular function of the diabetic heart. 
Rawal et al. [137] demonstrated that decreased VEGF-A expression preceded the 
microvascular rarefaction in the db/db mice. Further, Hinkel et al. [322] showed that 
treatment with VEGF-A stimulated angiogenesis and restored capillary density as well 
as cardiac function in the diabetic swine model. Thus, the findings from these studies 
[241, 322] and my study support that cardiac-derived VEGF-A is essential to prevent 
vasculature rarefaction in the diabetic heart (Figure 4.17). My results also underscore 
the critical role of cardiac NNCS in angiogenesis.  
 
3. Chapter 5: Transient activation of cardiac NNCS is not effective to protect diabetic 
cardiomyocytes in hypoxia 
• Preservation of membrane GLUT-4 expression was insufficient to alleviate 
hypoxia-induced apoptosis in diabetic AC16  cardiomyocytes model overexpressed 
with ChAT gene. My findings showed that preservation of membrane GLUT-4 
expression alone was not sufficient to protect the diabetic cells from hypoxic injury. 
Vanoverschelde et al. [317] demonstrated that a high rate of glycolysis is necessarily 





• Insulin resistance prevented the activation of cardiac NNCS. Previous studies 
showed that insulin stimulation increased ChAT and CHT1 expression in the neuronal 
cell lines and rodent’s brain [313, 314]. Further, ChAT expression was decreased in the 
hippocampus of T1DM rat model [316]. In line with this, insulin stimulation increased 
ChAT expression in control AC16 cells. However, this was abolished in the diabetic 
AC16 cells. The result suggests that insulin resistance possibly prevents activation of 
cardiac NNCS, thereby contributing to reduced GLUT-4 expression.  
  
In summary, this thesis provides evidence that changes in cardiac NNCS may contribute to the 
development of DHD. Also, activation of cardiac NNCS by increasing ACh bioavailability is 
beneficial to the cardiovascular function of the diabetic heart (Figure 6.1). Further, a transient 
activation of cardiac NNCS is not adequate to reduce hypoxic injury in the diabetic 






Figure 6.1 The role of cardiac NNCS in the diabetic heart. 
(A) Cardiac NNCS expression is decreased in the diabetic heart. (B) Activation of cardiac NNCS via 
overexpression of the ChAT gene increases ACh synthesis in the diabetic heart. The ACh is released 
and bound to M2AChR, and thus activating PI3K/Akt/HIF1α signaling cascade (C) Initiation of this 
pathway leads to increased GLUT-4 expression, and thereby increasing glucose uptake and normalizing 
cardiac metabolism and cardiac efficiency in the diabetic heart. Hence, this could prevent the 
development of cardiac dysfunction. (D) Initiation of PI3K/Akt/HIF1α signaling pathway leads to an 
increase in VEGF-A expression, and thereby promoting angiogenesis in the diabetic heart. Hence, this 
could prevent diabetes-induced vascular rarefaction. (E) However, the combination of hypoxia as well 
as palmitate and glucose treatment decreased ChAT expression in the in-vitro diabetic cardiomyocytes 
that overexpressing ChAT gene. Thus, the membrane GLUT-4 expression was not increased, but it was 
preserved in hypoxia. In this case, the hypoxia-induced apoptosis was not alleviated.  
 
6.2 Can cardiac NNCS be a therapeutic target?   
As outlined in Chapter 1, glucose metabolism is suppressed due to reduced GLUT-4 expression 
in the diabetic heart [58, 63, 153, 321]. This was consistently observed in the diabetic mouse 
and human heart samples used in my study (Chapter 3). Besides, previous studies showed that 
cardiac NNCS regulates glucose metabolism by modulating GLUT-4 expression, thereby 
enhancing glucose uptake and ATP production in the heart [122, 323]. In line with this, my 




suggesting dysregulation of cardiac NNCS, which together with insulin resistance, contributes 
to decreased GLUT-4 expression in diabetes (Chapter 3). Further, GLUT-4 expression, as well 
as LV function, was enhanced after activating cardiac NNCS via overexpression of the ChAT 
gene in the diabetic heart (Chapter 4). These findings are in agreement with Belke et al. [20] 
that global overexpression of GLUT-4 gene prevents cardiac dysfunction by increasing glucose 
uptake and oxidation in the diabetic heart.  These findings strongly support the notion for 
therapeutically targeting cardiac NNCS as a metabolic intervention to restore glucose 
metabolism in the diabetic heart.  
Although this thesis was initially set to investigate the role of cardiac NNCS in regulating 
glucose metabolism in the diabetic heart, my findings newly revealed that cardiac NNCS plays 
a role in angiogenesis in the diabetic heart (Chapter 4). In T2DM, endothelial dysfunction is 
associated with decreased NO bioavailability [237-240]. Previous studies reported that 
cardiomyocytes produce NO via ACh-muscarinic receptor stimulation [99, 268, 269]. 
Therefore, targeting cardiac NNCS to increase ACh production could be an attractive approach 
to restore NO bioavailability. This notion was evident in the previous study by Oikawa et al. 
[267], using WT ChAT-tg mice, where overexpression of ChAT gene resulted in increased NO 
bioavailability in the heart. Although cardiac NO content was not measured in my study, the 
enhanced vascular function observed in the diabetic heart may indicate the possibility that NO 
bioavailability was either preserved or increased. In addition to NO availability, reduction of 
proangiogenic factor VEGF-A contributes to coronary vascular rarefaction in diabetes, thus 
impairing vascular function [137]. Previous studies showed that VEGF-A treatment stimulated 
angiogenesis in the diabetic swine heart [322] as well as infarcted myocardium [324]. My 
findings are in agreement with these studies that increased VEGF-A preserved coronary 
vasculature in the diabetic heart (Chapter 4). Therefore, these findings further strengthen the 




Cardiac autonomic neuropathy (CAN) is a severe complication of diabetes [325]. It is caused 
by damage to the nerve fibers that innervate the heart and blood vessels, thus increasing the risk 
of developing cardiovascular disease in the diabetic population (reviewed in [326]). The early 
development of CAN is characterized by increased sympathetic and decreased parasympathetic 
tone on the cardiac function such as HR and contraction (reviewed in [327]). Further, the 
decreased parasympathetic tone is associated with decreased ACh secretion [328]. At present, 
no clinically available therapy aims to deliver ACh to the heart directly. Therefore, targeting 
cardiac NNCS via overexpression of the ChAT gene could be an attractive approach to restore 
the ACh bioavailability in the diabetic heart, thereby normalizing parasympathetic control of 
cardiac functions. 
In summary, the overall findings position cardiac NNCS as a therapeutic target to normalize 
GLUT-4 expression (metabolic effect), VEGF-A expression (angiogenic effect), and neuronal 
cholinergic effects (parasympathetic effect).  
 
6.3 Strategies to target cardiac NNCS   
In this section, I propose strategies such as gene therapy, pharmacological therapy, microRNA 
therapy, stem cell therapy, and vagal nerve stimulation to target cardiac NNCS to enrich the 
heart with ACh. (The content presented in this section has been modified from the published 
literature review in the Journal of Molecular and Cellular Cardiology [102]). 
 
6.3.1 Gene therapy 
My study utilized a genetic approach to overexpress ChAT gene to activate cardiac NNCS, 
however, targeting other components such as CHT1 and VAChT can be equally useful to enable 
cardiac NNCS (Figure 6.2). This notion is because CHT1 is involved in reuptake of choline for 
ACh synthesis, and VAChT is involved in the release of ACh [101]. While my study used 




the suitable vector (i.e., non-viral and viral vector) for efficient delivery of a gene to the heart.  
This  is because a different type of vector would result in different duration of transgene 
expression and transfection efficiency (reviewed in [329]). For instance, Rengo et al. [330] 
reported that the cardiac expression of transgene lasted for up to 12-weeks via adeno-associated 
viral vector and such long duration of transgene expression was able to prevent MI-induced HF 
and normalized the neurohormonal axis. In contrast, Giordano et al. [331] demonstrated 
transient transgene expression with an adenoviral vector was sufficient to promote angiogenesis 
and therefore ameliorating the myocardial contractile dysfunction by improving blood flow. 
Due to the chronic nature of diabetes, a vector that can induce long term gene expression may 
be required. On the other hand, viral vectors have been demonstrated to induce inflammatory 
responses (reviewed in [329]). Therefore, future studies should be carefully designed to identify 





Figure 6.2 The proposed therapeutic strategies to target cardiac NNCS to elevate ACh production to protect the heart against cardiovascular disease.   
(A) Gene therapy where cholinergic genes such as ChAT, CHT1, and VAChT can be delivered to the cardiomyocytes and therefore increasing the expression of these 
markers that are responsible for ACh synthesis and secretion. (B) The pharmacological approach by using AChE inhibitors can prolong the ACh effect in the 
extracellular space. Notably, donepezil and SNPiP can increase ChAT transcriptional activity and protein expression. (C) Inhibiting the cardiac miRNAs that promotes 
degradation of the cholinergic mRNAs. (D) Stem cells therapy to repopulate the cholinergic neurons or to replace the damaged cardiomyocytes with differentiated 
cholinergic neurons and cardiomyocytes, respectively. (E) Vagal nerve stimulation to electrically activate the vagal nerve to produce and release ACh, and these ACh 




6.3.2 Pharmacological therapy 
The abundant presence of AChE in the extracellular space rapidly hydrolyze ACh and therefore 
terminating its effect. Previous studies demonstrated the use of AChE inhibitors such as 
donepezil, physostigmine, and pyridostigmine as effective agents in improving cardiac function 
in animal models [332-336] as well as HF patients [337-344]. Inhibition of AChE increases the 
availability of extracellular ACh which in turn acts as an activator to stimulate the 
cardiomyocytes to synthesize and release ACh in a positive feedback manner [96, 99, 123] 
(Figure 6.2). Further, donepezil can directly increase the cardiac ChAT gene and protein 
expression [96]. Increased ChAT expression was also observed in donepezil-treated neuronal 
cells in-vitro [345] and in-vivo [346] as well as human umbilical vein endothelial cells 
(HUVECs; [123]), suggesting that donepezil functions as an AChE inhibitor as well as NNCS 
inducer. Although the exact molecular mechanism of donepezil in upregulating ChAT 
expression is unknown, Kakinuma et al. [96] showed that muscarinic ACh receptor is required 
for donepezil’s action as atropine reduced the ChAT expression and intracellular ACh 
concentration. However, whether donepezil would be effective for the diabetic heart is not 
known as my findings showed decreased M2AChR expression in the db/db mice (Chapter 3 and 
4). Besides, a recent report showed that novel nitric oxide donor S-Nitroso-NPivaloyl-D-
Penicillamine (SNPiP) activated cardiac NNCS by increasing ChAT expression [347]. 
However, the underlying mechanism of how SNPiP leads to an increased ChAT expression is 
not clear. Although donepezil and SNPiP seem to be a promising agent to induce cardiac NNCS, 
further investigations are needed to determine the short- and long-term efficacy in the diabetic 
heart as well as the safety of these drugs. 
 
6.3.3 MicroRNA therapy 
MicroRNAs (miRNAs) have been recognized as an essential regulator of gene expression in 




untranslated region of targeted mRNA to inhibit translation and to induce degradation of mRNA 
(reviewed in [348]). Oikawa et al. [349] reported that miR-345 as the regulator for ChAT 
mRNA in the murine heart. They demonstrated that the expression pattern of miR-345 was 
reciprocal to the expression pattern of ChAT mRNA (i.e., high miR-345 expression and low 
ChAT mRNA expression) in the murine heart as well as in the miR-345 transfected cell lines. 
However, previous studies showed that dysregulation of microRNA contributed to the 
pathophysiology of the diabetic heart [1, 137, 350, 351]. Thus, it is not known whether diabetes 
would affect the expression of miR-345. Nevertheless, a synthetic inhibitor (also known as anti-
miR) that has the reverse complement to the miR-345 can be designed to bind to miR-345 and 
deplete its abundance to prevent degradation of ChAT mRNA and eventually increase the 
ChAT protein expression and ACh synthesis (Figure 6.2).  
 
6.3.4 Stem cell therapy  
Chronic exposure to metabolic derangement induces apoptosis of cardiomyocytes [352, 353]. 
Thus, the population of cardiomyocytes that remains healthy and able to produce and release 
ACh is lesser as diabetes progresses. In this case, stem cell therapy is an attractive option, as 
stem cells can either differentiate into or activate the regeneration of new functional 
cardiomyocytes to compensate those lost due to diabetes. In particular, an attempt to use 
resident cardiac stem cells to regenerate the cardiomyocytes has increasingly received great 
attention along with controversies [354-356]. Regeneration of lost cardiomyocytes will restore 
their numbers, and this will indirectly increase the population of cells able to produce and 
release ACh. (Figure 6.2)  
Withdrawal of parasympathetic cholinergic tone as a result of CAN is commonly seen in the 
diabetic population (reviewed in [326]). In this case, stem cell therapy can be used to repopulate 
the cholinergic neurons, specifically in the medulla oblongata where all the preganglionic 




autonomic system in diabetes. While this therapeutic option has not been explored and tested 
in the cardiovascular disease model, it has been demonstrated to be beneficial in an Alzheimer’s 
disease mouse model [357]. The mice received stem cells therapy showed increased mature 
cholinergic neurons that functionally integrated into the endogenous basal forebrain cholinergic 
projection system and eventually improved learning and memory performance. Thus, stem cell 
therapy to repopulate the cardiomyocytes or cholinergic neurons would be worthwhile to 
explore in the future as a successful outcome could also be a significant breakthrough in 
cardiovascular disease. 
 
6.3.5 Autonomic regulation therapy via vagal nerve stimulation 
Vagal nerve stimulation has been proposed as an adjunctive treatment to stimulate the neuronal 
cholinergic nerves to produce ACh. This treatment is achieved by surgically implanting a 
stimulator that connects to the cervical vagal nerve [358-360]. Since the cardiac NNCS activity 
can be directly influenced by the neuronal cholinergic system (Chapter 1, Section 1.2.4), 
electrical stimulation of the vagal nerves to produce and release ACh would in return activate 
the cardiac NNCS in the cardiomyocytes (Figure 6.2). However, the long-term efficacy of vagal 
nerve stimulation has been controversial, as NECTAR-HF [361, 362] and INOVATE-HF [363] 
clinical trials reported no improvement up to 18-month of therapy while ANTHEM-HF clinical 
trial [364-367] reported an increase in LVEF after 42-month of treatment. Although Malbert et 
al. [368] showed that vagal nerve stimulation improved skeletal glucose uptake, it is not known 
if this therapy would be beneficial to the diabetic heart. Nevertheless, the risks and post-surgery 
side effects associated with this procedure have to be considered as it may not be favorable in 





6.4 Future directions 
The overall findings from this thesis extend the knowledge of cardiac NNCS in regulating 
glucose metabolism and vasculature in the diabetic heart. The study’s limitations stated in 
Chapter 3 to 5 provide suggestions to improve the present study. Apart from this, the following 
future experiments could further strengthen and support the role of cardiac NNCS as a 
therapeutic target in diabetes.  
 
I. Donepezil [96] and SNPiP [347] enhance ChAT expression in the heart. In a future 
study, it would be interesting to treat the db/db mice with donepezil or SNPiP to assess 
whether this strategy improves cardiovascular functions in comparison to the non-
treated db/db mice. The use of db/db mice with different age groups could provide 
valuable insight into the treatment. For example, treating the db/db mice before 
established cardiac dysfunction would demonstrate whether the donepezil or SNPiP 
could prevent the manifestation of DHD. Treating the db/db mice after established 
cardiac function would confirm whether donepezil or SNPiP are effective in 
ameliorating the effect of DHD. The outcome would further position the role of 
donepezil or SNPiP as a prophylactic or therapeutic treatment when translating to the 
clinics.  
 
II. Reduction of ChAT expression by loss-of-function through knocking out the ChAT gene. 
The experiment could be performed in in-vitro and in-vivo diabetic models where 
deterioration of LV and vascular function, severe impairment in glucose utilization and 
metabolism as well as increased apoptosis might be observed. The outcome from the 
experiments will complement the findings derived from the present study and further 






An early rectification of cardiac metabolism prevents the development of DHD in the diabetic 
heart. In this thesis, I demonstrated that dysregulation of cardiac NNCS is associated with 
altered cardiac metabolism in diabetic heart and hence, the development of DHD. Further, I 
showed that the activation of cardiac NNCS prevents the development of DHD. However, 
transient activation of cardiac NNCS is not adequate to alleviate hypoxic injury in diabetic 
cardiomyocytes. Last but not least, this thesis provides a strong foundation that targeting cardiac 
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Appendix 1  
 
Figure S1.1 Optimization and controls for RT-qPCR analysis. 
(A) Gradient PCR was performed to optimize the annealing temperature (50°C, 54°C, 58.4°C or 55°C, 60°C and 65°C) of each primers ; (B) PCR was performed 
with (+) and without (-; serving as negative control) reverse transcription of rDNase treated RNA. (C) Melting curve analysis showed the melting temperature of each 
PCR amplicon which was also serve as a quality control for specific amplification. The PCR amplicon of RN18S shows two melting temperatures which is likely due 
to the GC rich region in the amplicon. This was confirmed by using Umelt software (https://www.dna.utah.edu/umelt/umelt.html) to predict the melt curve profile 






Figure S2.1 The protein expression of α-tubulin, β-actin and total protein from Ponceau S staining 
of the mouse ventricular tissues. 
Representative blots showing (A) a decreasing trend in α-tubulin expression in the db/db mice at 8-
weeks of age while β-actin expression and total protein as well as the selected band (red arrow) from 
Ponceau S staining showed consistent expression in all samples; (B & C) a decreasing trend in β-actin 
expression in the db/db mice at 16- and 20-weeks of age while total protein as well as selected band 
(red arrow) from Ponceau S staining showed relatively consistent expression in all samples. 
 
 
Figure S2.2 Examination of the specificity of anti-ChAT and anti-M2AChR antibodies 
Representative full blots showing the specificity of anti-ChAT and anti-M2AChR antibodies tested on 
protein lysates from mouse brain tissue (positive control), AC16 cells, HL1 cells (mouse atrial 






Figure S2.3 Examination of the specificity of anti-CHT1 and anti-VAChT antibodies 
Representative full blots showing the specificity of anti-CHT1 and anti-VAChT antibodies tested on 
protein lysates from mouse brain tissue (positive control), AC16 cells, HL1 cells (mouse atrial 
cardiomyocytes cells), mouse ventricular tissues, human LV and right atrial appendage (RAA).  
 
               
Figure S2.4 Examination of the specificity of anti-AChE antibody 
Representative full blots showing the specificity of anti-AChE antibody tested on protein lysates from 
mouse brain tissue (positive control), AC16 cells, HL1 cells (mouse atrial cardiomyocytes cells), mouse 






Figure S2.5 Examination of the specificity of anti-GLUT-1 and anti-GLUT-4 antibodies 
Representative full blots showing the specificity of anti-GLUT-1 and anti-GLUT-4 antibodies tested on 
protein lysates from mouse ventricular tissues, human LV and right atrial appendage (RAA).  
 
 
Figure S2.6 Examination of the specificity of anti-pAkt, anti-Akt and anti-HIF1α antibodies 
Representative full blots showing the specificity of anti-pAkt (serine 473), anti-Akt and anti-HIF1α 
antibodies tested on protein lysates from mouse ventricular tissues of ND, db/db and db/db-ChAT-tg 
mouse. There are three isoforms of HIF1α. Isoform 2 that has approximately 83 kDa was identified as 
HIF1α-positive as the band intensity appeared to be more prominent that other isoforms in the 






Figure S2.7 Examination of the specificity of anti-pAMPkα, anti-AMPKα and anti-VEGF-A 
antibodies 
Representative blots showing the specificity of anti-pAMPKα (threonine 172), anti-AMPKα and anti-
VEGF-A antibodies tested on protein lysates from mouse ventricular tissues of ND at 8-, 36-weeks of 




Figure S2.8 Examination of the specificity of anti-VEGF-A and anti-cleaved caspase 3 antibodies 
Representative blots showing the specificity of anti-VEGF-A and anti-cleaved caspase 3 antibodies 








Figure S3.1 Examination of the specificity of anti-ChAT antibody 
Representative confocal images showing positive ChAT staining in the ventricular tissue from (A) db/db 
mouse and (B) db/db-ChAT-tg mouse. The intensity of ChAT is stronger in the db/db-ChAT-tg mice due 
to overexpression of ChAT gene. (C) No staining in the secondary antibody only control performed on 





Figure S3.2 Examination of the specificity of anti-CTNI antibody 
Representative confocal images showing (A) positive CTNI staining in the ventricular tissue from ND 
mouse and (B) negatvie CTNI staining in the secondary antibody only control performed on the 
ventricular tissues from ND mouse. (C) No staining detected in the skeletal muscle tissues from ND 






Figure S3.3 The co-staining of ChAT and GLUT-4 on the same ventricular tissue in the absence 
and presence of AffiniPure anti-rabbit Fab fragments 
Representative fluorescent images showing co-staining of ChAT and GLUT-4 (A) in the absence and 
(B) in the presence of AffiniPure anti-rabbit Fab fragments. The anti-rabbit Fab fragments successfully 
blocked the crossreactivity as ChAT and intracellular GLUT-4 vesicles (white arrows) can be clearly 
differentiated in the cardiomyocytes.   
 
 
Figure S3.4 Single and triplet staining of ChAT, GLUT-4 and CTNI on mouse ventricular tissues 
Representative confocal images showing (A) single staining on different mouse ventricular tissue and 
(B) triplet staining of ChAT, GLUT-4 and CTNI in the same mouse ventricular tissue. This images from 






Figure S3.5 The secondary-antibody only control for CTNI, ChAT, GLUT-4 in mouse ventricular 
tissue 
Representative confocal images showing secondary-antibody only control of (A) CTNI and (B) ChAT, 






Measurement of blood glucose level 
Accu-Chek Performa blood glucose device kit (Roche) was used to measure the blood glucose 
level of the db/db and db/db-ChAT-tg mice. The measurement was taken between 9 am to 10 
am to minimize fluctuation of blood glucose level due to the mice’s activity at different time. 
A lancing device was used to prick the tail of the mice to obtain blood. The blood drop was 
touched on the end of the test strip that has been inserted into the blood glucose meter. The 
results were expressed as mg/dL.  
 
Measurement of LV function using pressure-volume (PV) catheter  
LV function was measured as described by Oikawa et al. [267]. Briefly, the mice were 
anesthetized with 1% - 2% isoflurane at a flow rate of 0.5-1.0 L/min. The incision was made 
into the abdominal cavity to allow the PV catheter to be inserted into the apex of the heart via 
the diaphragm. The catheter was connected to an ADVantage PV system control box (Transonic 
Systems) and a data acquisition system (iWorx System). Hemodynamic parameters were 






Figure S4.1 The secondary antibody-only control for staining of endothelial cells and smooth 
muscle cells.  
Representative fluorescent images showing secondary antibody-only control for Isolectin B4 and anti-
αSMA antibody staining as well as staining of nuclei in the ventricular tissue.  
 
 
Figure S4.2 The protein expression of pAkt and total Akt in ND, db/db and db/db-ChAT-tg mice at 
8-weeks of age.  
Representative blots showing the protein expression of pAkt (serine 473), total Akt as well as total 










Figure S5.1 Fraction of cytosolic and membrane protein from AC16 cells. 
Representative blots showing the protein expression of Pan-Cad (membrane protein) in cytosolic and 
membrane fraction. Low protein expression of Pan-Cad in cytosolic fraction indicates the successful 




Figure S5.2 Secondary antibody-only control for CTNI, IRX4, ChAT, and GLUT-4 staining.  
Representative fluorescent images showing the secondary antibody-only control for (A) CTNI, (B) IRX4, 






Figure S5.3 24-hours of palmitate and glucose treatment did not impair insulin-stimulated GLUT-
4 membrane translocation 
Representative blots and bar graphs with scatter blots showing the membrane GLUT-4 protein 
expression in AC16 cells after 24 hours of vehicle or palmitate and glucose treatment. After treatment, 
the cells were stimulated with 500nM of insulin for 30-mins to test the insulin responsiveness. Data are 
expressed as mean ± SEM. A non-parametric Mann-Whitney test was performed. #p<0.05 VS control 
AC16 cells with the same insulin treatment. The number of samples per group is indicated in the figure. 
The total number of samples was derived from two independent experiments. 
 
 




(A) Representative images showing the ORO staining of AC16 cells treated with 100, 200, 300, 400 and 
500µM of palmitate for 48 hours. The hematoxylin-stained nuclei are in blue while the ORO-stained 
palmitate appears in red. Yellow arrows indicate ORO-positive cells. Bar graphs with scatter plots 
showing the (B) total number of viable cells/mm2 remained and (C) percentage of ORO-positive cells 
per total cells after 48 hours of treatment. A non-parametric Kruskal-Wallis test with Dunn’s multiple 
comparison test was performed. For figure B: *p<0.05 VS AC16 cells treated with 0µM of palmitate; 
For figure C: *p<0.05; ***p<0.001 VS AC16 cells treated with 100µM of palmitate. The number of 





Figure S5.5 Stimulation of AC16 cells with various concentration of insulin to mediate GLUT-4 
membrane translocation. 
Representative blots and bar graphs with scatter blots showing the protein expression of GLUT-4 at the 
plasma membrane in response to stimulation with 0, 500, 750 and 1,000 nM of insulin concentration 
for 60-mins. Data are expressed as mean ± SEM. One-way ANOVA with Dunnett’s multiple comparisons 
test was performed. **p<0.01 VS AC16 cells treated with 0nM insulin. The number of samples per group 






Figure S5.6 Optimization of cell seeding density for lipofectamine transfection 
(A) Representative fluorescent images showing the expression of mCherry fluorescent proteins and 
staining of nuclei by DAPI in the AC16 cells after 24 hours of transfection. Bar graphs with scatter plots 
showing the (B) transfection efficiency determined by the percentage of mCherry-positive cells per total 
cells and (C) total number of viable cells remained after 24 hours of transfection. A non-parametric 
Mann-Whitney test was performed. *p<0.05 VS AC16 cells seeded in density of 0.5x105 cell/cm2. The 
number of samples per group is indicated in the figure. The total number of samples was derived from 
two independent experiments. 
  
 
Figure S5.7 Secondary antibody-only control for ChAT and GLUT-4 in the transfected AC16 cells  
Representative confocal images showing the endogenous mCherry fluorescent protein as well as 





In order to compare (1) the expression changes in endogenous ChAT in the control or diabetic 
WT cells in normoxic and hypoxic condition OR (2) the expression changes in ChAT in the 
control or diabetic hChAT transfected cells in normoxic and hypoxic condition (Appendix 3, 
S5.8), the protein samples from these cells should have grouped and processed in one PAGE 
gel for western blot analysis. However, as the protein amount from the diabetic cells were 
insufficient, I was not able to handle these samples together. Thus, the comparison of ChAT 
expression changes was made in separate blots. For this reason, I expressed the data as a ratio 
between ChAT and total protein (relative expression) rather than fold change.  
 
 
Figure S5.8 ChAT expression in control and diabetic transfected AC16 cells in normoxic and 
hypoxic condition.  
Representative blots and bar graphs with scatter plots showing (A) the endogenous ChAT expression 
from control and diabetic AC16 cells and (B) the ChAT expression after overexpression of ChAT gene 
from control and diabetic in normoxic and hypoxic condition. Data are expressed as mean ± SEM. One-
way ANOVA test with Tukey’s comparison test was performed. ****p<0.0001 VS control hChAT 
transfected cells AC16 cells; #p<0.05, ####p<0.0001 VS respective control or diabetic AC16 cells in 
normoxic condition. The number of samples per group is indicated in the figure. The total number of 
samples in the normoxic condition was derived from two independent experiments, while the total 
number of samples in the hypoxic condition was derived from three independent experiments. 
 
 
